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ABSTRACT 
Obesity and Type 2 diabetes are associated with high fat diet (HFD), reduced 
mitochondrial mass and function and insulin resistance as characterized by glucose 
disposal and relative to body fatness.   
We hypothesized that (a) HFD affects expression of genes involved in 
mitochondrial biogenesis and function, (b) carbohydrate metabolism and storage is under 
transcriptional control and (c) both overall fatness and characteristics of adipose tissue 
influence the interplay between free fatty acids (FFAs) and insulin-stimulated glucose 
disposal.  To test hypotheses “a” and “b”, we fed 10 insulin-sensitive males an 
isoenergetic HFD for 3 days with muscle biopsies before and after intervention.  
Oligonucleotide microarrays revealed 370 genes differentially regulated in response to 
HFD (Bonferonni adjusted p < 0.001).  Expression of six genes involved in oxidative 
phosphorylation decreased.  PGC1α and PGC1ß mRNAs decreased by ~22%.  Seven 
genes in the carbohydrate metabolism pathway changed in response to HFD, and three 
genes confirmed by qRT-PCR: PFKFB3, PDK4 and GYS1.  In a separate experiment, 
C57Bl/6J mice were fed HFD for three weeks and the same OXPHOS and PGC1 mRNAs 
decreased by ~90%, Cytochrome C and PGC1α protein by ~40%, while the same glucose 
metabolism genes changed by ~70%.  These results suggest a mechanism whereby HFD 
downregulates genes necessary for oxidative phosphorylation and mitochondrial 
biogenesis, as well as glucose utilization and storage.  These changes mimic those 
observed in diabetes and insulin resistance. 
 To test hypothesis “c”, we measured changes in respiratory quotient (∆RQ; 
metabolic flexibility) before and during euglycemic-hyperinsulinemic clamps in healthy 
 viii
young males.  Anthropometric, laboratory measurements, fat biopsies and fat cell size 
(FCS) were measured after overnight fast.  Adipose tissue gene expression (qRT-PCR) 
was measured.  Metabolic inflexibility (lower ∆RQ) was associated with higher body fat, 
larger FCS and higher insulin-suppressed FFAs.   ∆RQ was not related to fasting FFAs, 
but lower ∆RQ was associated with lower serum adiponectin levels.  Higher adipose 
tissue inflammatory gene expression was associated with higher insulin-suppressed FFAs 
and lower ∆RQ.  These results indicate fatness, adipocyte hypertrophy, blunted insulin 
suppression of FFAs, decreased adiponectin levels and inflammation, are associated with 
decreased insulin-stimulated glucose uptake and oxidation, an important component of 
metabolic inflexibility. 
 ix
 CHAPTER 1:  INTRODUCTION 
 
1.1 Obesity and Diabetes:  A Pandemic 
An obesity pandemic threatens to overwhelm health systems around the globe with 
illnesses such as diabetes and heart disease, and this pandemic of obesity is as big of a threat to 
the world’s population as global warming and bird flu.  The World Health Organization (WHO) 
says more than 1 billion adults are overweight and 300 million of them are obese; furthermore, to 
date more overweight people exist in the world than the undernourished, who number about 600 
million (1). 
Obesity is a major cause of premature mortality with severe economic consequences.  A 
recent study estimated the annual cost of obesity in the United States to be $93 billion per year, 
or 9.1% of all healthcare dollars (2).  A recent survey by the United States Centers for Disease 
Control indicates that 66% of the U.S. population are overweight, with 32.3% having a body 
mass index (BMI) of more than 30 kg/m2 (3). 
The current worldwide pandemic of obesity and its major complications, namely Type 2 
diabetes and cardiovascular disease (CVD), is well documented.  “Thrifty” metabolic traits have 
evolved in the setting of decreased famine to give rise to the obesity pandemic.  These thrifty 
traits, specifically a decreased capacity for dietary thermogenesis and an increased resistance to 
insulin-mediated glucose uptake in skeletal muscle, would historically prolong survival during 
famine but now predispose individuals to obesity and diabetes in the face of abundance (4-6).   
Body-fat distribution is an important factor in determining high-risk obesity.  People with 
abdominal obesity are at greater risk for heart disease, diabetes, hypertension and hyperlipidemia 
compared to people with a more gluteal fat distribution (7).  The reason for the association 
between central abdominal obesity and metabolic syndrome is not clear, but one leading concept 
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 maintains that visceral adipose tissue has a higher rate of lipolysis, resulting in elevated portal 
non-esterified fatty acids (NEFAs) increasing hepatic very-low-density lipoprotein (VLDL) 
production, hepatic glucose output (HGO) and impairing peripheral insulin sensitivity (8). 
Considerable evidence exists in the literature for increased inflammation preceding the 
onset of obesity-related metabolic disorders.  Many studies have described correlations between 
vascular disease and elevated levels of interleukin-6, C-reactive protein and chemokines such as 
macrophage chemoattractant protein-1 (MCP-1) all of which promote a proinflammatory state 
(9).  Although the origin of this proinflammatory state is not clear, it is important to note the 
commonalities among the development of obesity and certain features of the metabolic 
syndrome, such as insulin resistance and vascular disease.  All of these suggest that adipose 
tissue itself may be an important source of proinflammatory cytokines. 
The role of adipose tissue in metabolic syndrome and inflammation has continued to 
evolve with the discoveries of numerous secretory proteins from adipocytes, commonly referred 
to as adipokines.  These adipokines are important determinants of insulin resistance, either 
through a hormonal effect in the circulation, or through local effects on the adipocytes 
themselves.  Tumor necrosis factor-α (TNFα) expression by adipose tissue of obese rodents and 
humans was discovered in the mid-1990s (10; 11).  Numerous other proteins are secreted by 
adipocytes, showing adipose tissue is an active metabolic and endocrine tissue.  Many of the 
numerous adipokines expressed by adipose tissue have been implicated in the pathogenesis of 
metabolic syndrome.  For example, plasma levels of interleukin-6 and adipose-secreted TNFα 
are associated with obesity, as well as with insulin resistance not related to obesity (12).  Several 
mechanisms exist for the actions of TNFα on insulin resistance, including an inhibition of 
insulin-receptor signaling (13), along with an autocrine effect on adipose tissue causing a 
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 stimulation of lipolysis and elevation of plasma NEFAs (14).  Consistent with this model, TNFα-
knockout mice do not become insulin resistant with diet-induced obesity (15). 
Another important secretory protein of the adipocytes is adiponectin.  Unlike other 
adipokines, adiponectin acts as an anti-diabetic hormone (16).  Adiponectin circulates as 
complex multimeric forms (17), and two receptors for adiponectin have been described (18).  
Adiponectin-knockout mice develop marked insulin resistance while consuming high-fat diets, 
and this insulin resistance is improved following adiponectin supplementation (19).  In humans, 
blood levels of adiponectin are decreased under conditions of obesity, insulin resistance, Type 2 
diabetes and coronary disease (20; 21). 
Recent studies, however, have suggested that the cell producing many of the adipose 
tissue cytokines is not the adipocyte, but instead is the macrophage that infiltrates adipose tissue 
during obesity (22; 23).  Once activated, macrophages secrete a plethora of cytokines such as 
TNFα, interleukin-6 and interleukin-1 (24), and the adipose tissue resident macrophages were 
found to be responsible for the expression of most of the tissue TNFα and interleukin-6 (25; 26).  
In human studies, there is a correlation between adipose macrophage markers and BMI (22), and 
an even stronger relationship with insulin resistance.  The expression of TNFα and interleukin-6 
correlate strongly with the expression of macrophage markers from adipose tissue (27).  These 
adipose-tissue macrophages elucidate our understanding of inflammation, obesity and the 
metabolic syndrome.  Recent data suggest that progressive obesity leads to adipose-tissue 
macrophage infiltration, at least in some subjects, with consequent over-expression of 
inflammatory cytokines, metabolic syndrome and a state of heightened inflammation (24; 28). 
The prevalence of obesity is increasing at an alarming rate, and the obesity pandemic is 
driving the pandemic of Type 2 diabetes.  High-risk obesity is characterized by abdominal 
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 obesity with abnormal glucose and lipid metabolism, and a state of increased inflammation.  As 
body weight increases, lipid accumulation occurs in adipose tissue, as well as in other organs, the 
latter effect commonly referred to as ‘lipotoxicity’.  Lipotoxicity in liver, muscle and the 
pancreatic islets may account for many of the features of the metabolic syndrome.  
Consequently, it may be a culmination of the effects of all four tissues (pancreatic β-cells, liver, 
adipose tissue and skeletal muscle) that leads to the state of insulin resistance and ultimately 
overt Type 2 diabetes. 
Adipose tissue is the primary organ of lipid storage; however, in the case of obesity, lipid 
is deposited into other non-adipose organs, including liver, skeletal muscle, β-cells and cardiac 
tissue, leading to ‘ectopic fat’.  The ectopic fat deposited in the liver leads to the commonly 
observed hepatic steatosis, also known as non-alcoholic steatohepatitis or “fatty liver”.  
Together, the lipotoxicity in these organs leads to insulin resistance, impaired insulin secretion 
and eventually Type 2 diabetes.  Because the majority of glucose disposal occurs in muscle (29), 
this tissue is extremely important in understanding the mechanisms underlying peripheral insulin 
resistance.  Insulin-resistant subjects demonstrate increased intramyocellular lipid, a decreased 
proportion of the oxidative type I and type IIA muscle fibers, decreased oxidative capacity of 
each class of muscle fiber and decreased capillary density (30; 31). Recent studies that compared 
insulin-resistant and insulin-sensitive subjects have suggested the presence of a reduced 
mitochondrial lipid oxidation as an early defect (32; 33).  Improvement in the intramyocellular 
lipid and muscle lipid oxidative capacity accompanies improvement in insulin resistance 
following weight loss (34), and in response to treatment of insulin-resistant subjects with 
pioglitazone, which causes a shift in lipid from ectopic sites to subcutaneous adipose tissue (35). 
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 A reduction, therefore, in intramyocellular lipid flux or an increased sequestation of lipid in 
adipose tissue may be an attractive target for future drug therapies. 
Indeed, muscle impairments in insulin-mediated glucose transport, glycogen synthesis 
and glucose oxidative pathways are the central features of individuals at high risk for Type 2 
diabetes, such as the offspring of Type 2 diabetics (36; 37).  As these population groups also 
present with elevated plasma concentrations of fatty acids and amino acids, these substrates (by 
interfering with the uptake and metabolism of glucose in skeletal muscle) are thought to play a 
central role in the onset of insulin resistance (36; 38-40).  Furthermore, there is also evidence that 
as chronic hyperglycemia develops, the oversupply of glucose could also, by inhibiting fatty acid 
oxidation, lead to the accumulation of intramyocellular lipid that further inhibits glucose uptake 
and subsequent metabolism and hence exacerbates the state of insulin resistance (e.g. the 
‘reverse Randle Cycle’) (41-43). 
The complications of obesity affect all specialties of medicine, and the effective 
treatment of obesity will be one of the major challenges for the 21st century.  Until effective 
medical therapy becomes available, it is important to identify patients with evidence of the 
metabolic syndrome and other features of high-risk obesity and to treat the diabetes, 
hyperlipidemia, inflammation and other associated co-morbidities effectively.  
The treatment of obesity requires the identification of the high-risk patient, the institution 
of lifestyle measures with a long-term outlook and an avoidance of extreme fad diets.  Current 
research will likely lead to improved medications in the future. 
1.2 Substrate Utilization 
Substrates compete for respiration.  Beginning in the 1930s Krebs (44) showed 
competition between amino acids and glucose in kidney slices.  Subsequent to Krebs, Waters et 
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 al demonstrated a competition between 3-hydroxybutyrate and glucose in dog heart lung 
preparations (45).  However, general acceptance of the concept came in 1963 with Sir Randle’s 
demonstration that lipid fuels inhibit glucose oxidation in rat diaphragm and perfused heart (46; 
47).  This lead to Randle et al (48; 49) proposing a ‘glucose-fatty acid cycle’ as an important set 
of mechanisms by which carbohydrate and fat metabolism interact.  As recently as 1998, Randle 
revisited the essential components of this cycle (50):  (1) the relationship between glucose and 
fatty acid oxidation is reciprocal and not dependent, (2) in vivo, the oxidation of lipid fuels (fatty 
acids and ketone bodies) released into the circulation (e.g., in starvation or diabetes) may inhibit 
the catabolism of glucose in muscle and (3) in vitro, the oxidation of fatty acids released from 
muscle triacylglycerol or intramyocellular triglycerides also inhibits intracellular glucose 
metabolism. 
Frayn reevaluated the ‘glucose-fatty acid cycle’ from a physiological perspective and 
pointed out that it is appropriately termed a ‘cycle’ because it describes a series of events that 
interlink carbohydrate and fat metabolism (51).  Elevated glucose concentrations (as in the post-
prandial state after a meal) stimulate insulin secretion, which then suppresses free fatty acid 
(FFA) release from adipose tissue.  This eliminates competition for substrate utilization in 
skeletal muscle, so that glucose utilization may be stimulated by insulin, unaffected by high 
concentrations of fatty acids.  Conversely, when plasma FFAs are high, which is usually because 
glucose and insulin concentrations are low (as in the post-absorptive state), fatty acids then 
become the major fuel for skeletal muscle.  According to Frayn, “This makes perfect 
physiological sense in terms of blood glucose homeostasis.  The ‘coarse’ control of the 
reciprocal utilization of glucose and FFA in the body is brought about through insulin secretion: 
fine-tuning is provided in skeletal muscle” (51). 
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 The Randle (glucose-fatty acid) Cycle embodies the concept of direct competition 
between substrates for mitochondrial oxidation.  A plethora of mechanisms have been put 
forward concerning the biochemical regulation of fuel homeostasis in skeletal muscle (40; 41).  
Interestingly, the oversupply of each of the three main fuel substrates (fatty acids, amino acids, 
glucose) converges towards the accumulation of triglycerides.  This can occur when circulating 
free fatty acids (FFAs) exceed FFA oxidation, as well as when amino acids from protein or 
glucose from carbohydrate exceed their oxidation; malonyl-CoA is formed in each case driving 
lipid synthesis (52).  Malonyl-CoA inhibits carnitine palmitoyltransferase-1 (CPT-1), which 
reduces entry of long-chain fatty acyl-CoAs into mitochondrial fatty acid oxidation.  The 
consequence of this excess unoxidized lipid leads to an effect known as ‘lipotoxicity’, which can 
lead to the development of intramuscular lipid droplets.  Intramuscular lipid impairs insulin 
signaling, which is necessary for insulin-stimulated glucose uptake and consequently glucose 
metabolism.  Lipotoxicity can also lead to ceramide synthesis and lipid peroxidation via 
nonoxidative metabolic pathways, leading to cell dysfunction and death through apoptosis (53). 
The term ‘lipotoxicity’ indicates toxicity that may result from lipid overloading induced 
by delivery exceeding oxidation of circulating FFA and local release of FFAs from triglyceride 
stores by lipoprotein lipase (LPL), but also from that induced by glucose overloading (gluco-
lipotoxicity) and protein overloading (or proteo-lipotoxicity).  These models of lipotoxicity 
explain how nutrient supply exceeding oxidation may lead to insulin resistance in skeletal 
muscle.  In addition, fuel oxidation matches increased fuel supply vis-à-vis cellular nutrient 
sensors and signaling systems, and contributes to blood glucose homeostasis and protection 
against muscle lipotoxicity.  Tthe interactions between glucose and lipid metabolism in skeletal 
muscle in relation to blood glucose homeostasis, and subsequently these interactions with respect 
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 to thermogenic mechanism of substrate cycling could offer protection against skeletal muscle 
lipotoxicity. 
The inhibitory effect of elevated lipid fuels (fatty acids and ketone bodies) on glucose 
disposal in skeletal muscle has been established by numerous studies conducted both in vivo and 
in vitro.  In humans, it has been shown that under in vivo conditions when fatty acid 
concentrations are elevated (e.g., in response to lipid infusion) whole body, as well as skeletal 
muscle glucose utilization, is impaired (54-56).  The plethora of mechanisms put forward to 
explain how fatty acids limit insulin-stimulated glucose utilization fall into two main categories.  
Both categories were first proposed by Randle following the original studies which formed the 
basis of the ‘glucose-fatty acid cycle’: (1) fatty acid-induced desensitization of insulin-mediated 
glucose transport and (2) inhibitory effects of fatty acid oxidation (46-49).  According to Randle, 
an increase in lipid oxidation will decrease glucose oxidation by suppression of the 
mitochondrial pyruvate dehydrogenase (PDH) complex, with the subsequent reduction of 
glycolytic flux, which results in an increase in glucose-6-phosphate, inhibition of hexokinase 
activity and ultimately decreased glucose uptake.  As a result of this, nonoxidative metabolism 
(storage) of glucose should decrease.  A variety of model systems have largely confirmed the 
validity of Randle’s mechanism, at least in terms of the acute effects of fatty acids on muscle 
glucose metabolism and storage (50; 57). 
In the late 1970s McGarry et al elucidated the reciprocal nature of interactions between 
glucose and lipid metabolism by demonstrating that high glucose (and insulin) concentrations 
can suppress hepatic fatty acid oxidation through malonyl-CoA inhibition of CPT-1, a key rate-
limiting enzyme that controls the entry of fatty acids into the mitochondrial fatty acid oxidation 
system (58; 59).  This mechanism by which glucose regulates fatty acid oxidation is 
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 complementary to the mechanism described by Randle et al and is often referred to as the 
‘reverse glucose-fatty acid cycle’.  Malonyl-CoA inhibition of fatty acid oxidation contributes to 
the switch to pyruvate oxidation; however, inhibition of acetyl-CoA carboxylase (ACC), which 
produces malonyl-CoA from acetyl-CoA, enables fatty acid oxidation at the expense of glucose 
oxidation.  This ‘reverse glucose-fatty acid cycle’ can be viewed as further ‘fine-tuning’ of the 
balance between glucose and fatty acid metabolism, and it adds weight to the bi-directionality of 
the cycle.   
Recently, a new twist and important question was posed regarding glucose inhibition of 
fatty acid oxidation, namely:  “How can one substrate have opposing roles?”  Mitochondrial fatty 
acid oxidation is inhibited by an elevation in malonyl-CoA, an intermediate substrate (formed 
from acetyl-CoA by ACC) that is also a precursor for de novo fatty acid synthesis--hence, the 
paradox (60).  The role of malonyl-CoA as a precursor of lipid synthesis and as an inhibitor of 
lipid oxidation was eventually reconciled with the discovery of two isoforms of ACC (61; 62).  
ACC1 is expressed predominantly in lipogenic tissues that synthesize large amounts of fatty 
acids (liver and adipose tissue) and ACC2 is expressed in non-lipogenic tissues such as skeletal 
muscle and cardiac muscle.  ACC1 is thought to reside in the cytoplasm, where it synthesizes the 
pool of malonyl-CoA that is used for de novo lipogenesis; whereas, ACC2 is thought to control 
the pool of malonyl-CoA that regulates fatty acid oxidation.   
In skeletal muscle, the suppressive effect of elevated glucose on fatty acid oxidation 
occurs via malonyl-CoA (synthesized by ACC2) inhibition of CPT-1, but the question of 
whether a cytoplasmic pool of malonyl-CoA might be used for fatty acid synthesis has not been 
raised.  Historically, skeletal muscle is not an organ where de novo lipogenesis occurs.  
Whenever the expression or activity of a rate-limiting enzyme for de novo lipogenesis (e.g., fatty 
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 acid synthase) was reported in skeletal muscle, this was just thought to be adipocyte 
contamination rather than de novo lipogenesis occurring in myocytes (52; 63).  As a 
consequence, the role of skeletal muscle substrate metabolism in blood glucose homeostasis has 
been viewed from the relationship between glucose and lipid metabolism.  Recent evidence, 
however, suggests that skeletal muscle has a more active role.  De novo lipogenesis can occur in 
muscle cells and be modulated by factors that influence the body’s nutritional state; therefore, 
glucose and lipid metabolism may actually depend on, rather than respond to, each other for 
these two fuel substrates in skeletal muscle.  This is in contrast to Randle’s revisit of the 
‘glucose-fatty acid cycle’ in 1998 (50). 
It has been proposed that there is an interdependency between glucose, lipids and 
thermogenesis.  Acetyl-CoA produced from glucose and fatty acid oxidation may overload the 
Krebs cycle.  This, in turn, results in excess mitochondrial citrate, which activates ACC2 and 
also provides substrate (in the form of acetyl-CoA) to ACC2 for the synthesis of malonyl-CoA.  
Malonyl-CoA serves as the main substrate for fatty acid synthase (FAS), which produces a new 
pool of fatty acids.  On the other side of the equation, glucose plays a central role in this cycle as 
a source of acetyl-CoA, Krebs cycle intermediates and NADPH molecules, which are required 
for fatty acid synthesis.  Glucose might also function as a stimulator of de novo lipogenesis, 
based on recent evidence in rat muscle satellite cells that glucose stimulates expression of genes 
encoding glycolytic and lipogenic enzymes, leading to an increased lipogenic flux (64). 
Skeletal muscle adapts to three different physiological conditions by increasing fat 
oxidation:  (1) reduced energy intake during fasting, (2) increased energy expenditure during 
exercise (65) and (3) in obesity (66-68).  The transition to fat oxidation for energy spares glucose 
metabolism during fasting and delays muscle glycogen metabolism during exercise.  Almost 50 
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 years ago, it was reported that even in lean, healthy volunteers after just an overnight fast, 
skeletal muscle chiefly relies upon fat oxidation for fuel supply (69).  Recently, it has been 
proposed that inability to increase reliance upon fat oxidation is related to the pathogenesis of 
insulin resistance in skeletal muscle and perhaps to the pathogenesis of obesity (70; 71).  To this 
end, Ukropcova et al examined the capacity for fat oxidation in skeletal muscle by using primary 
human skeletal muscle cells obtained from biopsy of the vastus lateralis.  They found that fatty 
acid oxidation was increased in cells from subjects with higher insulin sensitivity, leanness and 
aerobic fitness (72). 
The physiologic purpose of alterations in fuel selection is to channel energy to and from 
the appropriate storage compartments under all circumstances that may confront the organism.  
An obligate need exists to regulate glycogen within a relatively narrow window.  Studies 
conducted in subjects with Type 2 diabetes and in healthy subjects to determine the fate of 
glucose after it is taken up by muscle cells demonstrate that muscle glycogen synthesis, along 
with glycolysis, is an important pathway in overall skeletal muscle glucose metabolism (76).  
Muscle cells adjust the fuels they oxidize in order to match substrate supply, signals from the 
endocrine and neural systems and the ATP required for contraction.  The supply of substrate to 
muscle tissue depends upon several factors including the dietary macronutrient content, the 
storage of nutrients in liver and fat, capillary recruitment and transport, and in the case of 
triglycerides, the release of free fatty acids by the enzymatic activity of lipoprotein lipase (LPL) at 
the surface of the cell.  The adjustment of substrate oxidation to the local nutrient concentrations 
occurs through at least three mechanisms: minute-to-minute changes in the activity of enzymes 
that direct carbohydrate and fat into oxidation or storage (86), the activation of signaling 
pathways such as PKC (98) and NFκB (190) and through long-term regulatory systems that 
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 involve changes in gene transcription and hence the cellular machinery driving the first two 
processes.  The ability of insulin to regulate glucose homeostasis, i.e. insulin sensitivity, is 
closely related to these regulatory pathways, justifying further attempts to unravel the details of 
these regulatory systems.  Strong experimental evidence exists for each of these pathways, 
particularly for the regulation of substrate utilization and insulin sensitivity through enzyme 
activity (87) and signaling pathways (98).   
Skeletal muscle plays a key role in determining systemic insulin sensitivity.  Upon insulin 
stimulation the majority of glucose metabolism occurs in the skeletal muscle.  Impaired glucose 
metabolism in muscle constitutes peripheral insulin resistance and is seen in Type 2 diabetes and 
obesity.  Is the impairment of skeletal muscle to increase fat oxidation under appropriate 
conditions also related to insulin resistance?  Insulin resistance in muscle can be induced by 
elevated plasma fatty acids levels.  High FFAs are also associated with increased fat oxidation 
(54; 57).  Maintenance of fasting levels of plasma fatty acids through lipid infusions significantly 
lowers insulin-stimulated glucose uptake by skeletal muscle, impairs insulin suppression of lipid 
oxidation and blunts stimulation of glucose oxidation in muscle (56).  These experimental 
conditions, which induce insulin resistance in skeletal muscle by elevating circulating free fatty 
acids, mimic those found in obesity and Type 2 diabetes (73; 74).  These observations 
complicate the evidence that insulin-resistant skeletal muscle can also demonstrate reduced 
efficiency of fat oxidation during fasting despite high levels of plasma free fatty acids, which are 
almost invariably present in obesity and Type 2 diabetes, as well as high very low density 
lipoprotein (VLDL) triglycerides and intermediate density lipoprotein (IDL) triglycerides. 
Kelley et al showed a high reliance of leg muscle on fat oxidation (lower RQ) during 
fasting conditions.  In these same individuals, insulin infusion suppressed fat oxidation and 
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 shifted to a high reliance on glucose oxidation (higher RQ) (75); therefore, metabolically healthy 
skeletal muscle is characterized by the ability to switch easily between glucose and fat oxidation 
in response to homeostatic signals and substrate availability.  The skeletal muscle of individuals 
with Type 2 diabetes (T2D) and obesity demonstrates decreased metabolic flexibility.  Even 
though RQ values during fasting are higher in T2D and obesity, stimulation of glucose oxidation 
in response to insulin is blunted (76; 77).  This phenomenon of responding inefficiently both to 
the fasting stimulus to enhance fat oxidation and to the insulin stimulus to turn on glucose 
oxidation has been termed “metabolic inflexibility”.  Ukropcova et al examined metabolic 
flexibility in their cultured myocytes (72) and found a match between the cellular characteristics 
and the whole body “metabolic flexibility” of the cellular donor.  Furthermore, Goodpaster et al 
found that moderate weight loss, combined with an improvement in aerobic capacity, can restore 
metabolic flexibility and improve insulin-stimulated glucose disposal in overweight and obese 
insulin-resistant individuals (78).  Interestingly, however, moderate weight loss without a change 
in aerobic capacity does not improve fat oxidation under fasting conditions, rather it improves 
suppression of fat oxidation during insulin-stimulated conditions (79; 80). 
Metabolic flexibility involves:  (1) insulin suppression of fat oxidation with stimulation 
of glucose oxidation, and (2) stimulation of fat oxidation during fasting.  In the study by 
Ukropcova et al, glucose had a varying effect on the suppression of fat oxidation in the primary 
human myocytes.  Resistance to suppression of fat oxidation by hyperglycemia was inversely 
related to insulin sensitivity, percent body fat and aerobic capacity (72). 
Another study by Henry et al found that characteristics of insulin resistance in skeletal 
muscle are retained in myocyte culture (81), and it has been reported that muscle obtained from 
Type 2 diabetics has reduced capacity for fat oxidation in culture (82).  Additionally, the results 
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 reported by Ukropcova et al demonstrate metabolic flexibility (the transition between fat and 
glucose oxidation) is a cellular characteristic that is retained in vitro.  It is not clear what the 
cellular characteristics of myocytes determine metabolic flexibility, but Ukropcova et al did show 
that mitochondria play a critical role.  Competition between glucose and fat oxidation can occur 
at several locations in the mitochondria.  One location is the mitochondrial outer membrane 
where pyruvate dehydrogenase and carnitine palmitoyl transferase complexes compete for 
acetyl-CoA.  Competition may also occur in the mitochondrial matrix between β-oxidation (fatty 
acid oxidation) and the tricarboxylic acid (TCA) cycle, as well as in the delivery of FADH2 and 
NADH molecules to the electron transport chain (ETC) for oxidative phosphorylation in the 
inner mitochondrial membrane.   
Recently, mitochondria have become a hot topic in the investigation of the pathogenesis 
of muscle insulin resistance (83-87).  In addition to clinical investigations, suitable animal 
models for further study are also being developed.  For example, rats selectively bred for low 
oxidative enzyme activity in skeletal muscle develop a metabolic syndrome phenotype (88).  
Also, in studies that examined the physiological phenotype of metabolic flexibility, muscle 
biopsy samples have shown reduced oxidative enzyme activity (33; 80; 89).   
In the future it will be important to examine the links between substrate utilization and 
mitochondrial metabolism and incorporate the findings into the broader spectrum of metabolic 
pathways within insulin-sensitive tissues, such as liver, adipose tissue and skeletal muscle.  
Understanding metabolic adaptation to our nutritional environment is important to the future of 
obesity and diabetes research. 
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 1.3 The ADAPT Study Design 
The ADAPT study began in 2000 and completed in 2003.  In the past several years a 
“thrifty phenotype” has been identified and characterized in lean men by Smith et al as an 
inability to adapt rapidly to a high fat diet by increasing fatty acid oxidation.  It is associated with 
a low maximal VO2 during exercise and a high fasting insulin.  We hypothesized that individuals 
with the “thrifty phenotype” are at higher risk for becoming obese, and that exercise may be 
effective in overcoming this problem.  The latter hypothesis was supported as treadmill exercise 
increased the rate of adaptation to a high fat diet (90). 
Several questions remained to be answered regarding this “thrifty phenotype”.  First, 
given the large interindividual differences in fatty acid oxidation, how could we identify those 
individuals at the highest risk?  What would be the distinguishing biochemical, endocrine and 
environmental characteristics of individuals that store fat when exposed to high fat diets?  This 
was important because if these individuals could be easily identified, then dietary and other 
interventions could be targeted to this “at-risk” population. 
Second, what would be different about the individual with the “thrifty phenotype”?  What 
would be the cellular pathways dysregulated in the skeletal muscle of these individuals?  If the 
defect was intrinsic, i.e. a diminished ability to conserve glucose and oxidize fat in skeletal 
muscle or alternately, was the phenotype due to environmental, and dietary factors such as 
inactivity and energy excess? 
To answer these questions we planned a three-year project that aimed to:  (1) characterize 
the biochemical, endocrine, anthropometric and environmental characteristics of individuals with 
the “thrifty phenotype”, (2) identify the signaling pathways in skeletal muscle that are 
dysregulated in individuals with the “thrifty phenotype” through mRNA expression profiling and 
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 (3) determine the role of environmental factors such as inactivity and caloric intake versus 
intrinsic (genetic) factors in the “thrifty phenotype”.   
The first component of the proposed experiment was to compare adaptation to high fat, 
versus low carbohydrate diets in men versus women, particularly comparing women with a 
central versus peripheral fat distribution pattern.  Capacity to adapt to high fat diets was 
measured at energy balance in a whole room calorimeter after feeding a high-fat diet on the 
preceding three days (see experimental schedule below).  In an attempt to sort out the relative 
role of these factors in the “thrifty phenotype” we measured:  socioeconomic status, body 
composition, family history of diabetes and obesity, fat preference, restraint/disinhibition, core 
body temperature, habitual physical activity, aerobic capacity, insulin sensitivity, energy related 
hormones and sympathetic nervous system (SNS) activity (as measured by heart rate variability 
+ plasma and urinary catecholamines).  We measured food intake after three days of a high fat 
diet to determine if the decrease in carbohydrate stores in “thrifty” individuals would increase 
subsequent food intake. 
The second component of the proposed experiment was to compare the biochemical and 
signaling pathways dysregulated in skeletal muscle and adipose tissue of the individual with the 
“thrifty phenotype” compared to “fat-burning individuals”.  Before and after the measurement of 
their capacity to adapt to high fat diets as described above, individuals with high and low fat 
oxidative capacity underwent an adipose tissue and skeletal muscle biopsy.  These samples were 
examined for gene expression for several candidate genes from pathways involved in substrate 
utilization and energy/nutrient sensing 
In addition to the candidate gene approach, these samples were analyzed using 
microarray resources at Pennington Biomedical Research Center.  The expression data was 
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 analyzed using cluster analysis, gene shaving and other advanced bioinformatics techniques (91-
102).  We confirmed differentially expressed mRNAs and proteins using Western blotting and/or 
enzyme assays. 
The third component was to determine if the phenotype of impaired fat oxidation was 
preserved in vitro.  In this study, skeletal muscle from “thrifty” and “non-thrifty” individuals was 
cultured in vitro and fat versus carbohydrate oxidation was determined at various concentrations 
of insulin.  We then compared the phenotype in vitro with the phenotype in vivo.  If the 
phenotype was retained, then we concluded that the defect was genetic.  If the phenotype was not 
retained, then we concluded that the defect lie in the neural or endocrine systems or was 
environmental.  Studies of this type were critical in understanding the role of genetics in the 
metabolic disorder of insulin resistance syndrome (81).   
All volunteers had to complete a two-stage screening study.  Screening visit one was for 
blood sampling (chem 16 with lipids, CBC, UA).  Screening visit two was for physical 
examination and familiarization with the metabolic chamber. 
Eligible volunteers were screened and signed a consent document.  After enrolling into 
the study, the volunteers completed the baseline measures.  After consuming the control diet for 
one day, they were admitted to the metabolic unit for testing at 6pm.  On the next day, baseline 
blood samples (GLP-1, leptin, ghrelin, resistin, insulin, C-reactive protein (CRP), C-peptide, 
glucose, NEFA, lipids, study archives) were drawn.  After local anesthesia, a muscle and a fat 
biopsy were performed.  The next test was an insulin-glucose clamp to measure insulin 
sensitivity and metabolic flexibility. 
The next four days were spent in the metabolic chamber:  one day with the standard diet 
and three days with the high fat diet.  Each day, the volunteers exited the chamber, a butterfly IV 
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 was inserted, they rested in a recumbent condition for 30 minutes and a basal blood sample was 
collected.  After exiting the chamber on the fourth day, volunteers had the last morning blood 
sample drawn and then consumed the test meal. 
Both genders and all races were invited to participate.  Women were asked to participate 
in the follicular phase of the menstrual cycle as determined by menstrual history, and a negative 
pregnancy test was also recorded prior to participation.  Body mass index (BMI) range was > 19 
and < 30.  Age range was 18 to 30 years. 
 
Table 1.1 Clinical procedures for the ADAPT study.  
 
procedure baseline run-in diet high-fat diet 
  Su M Tu W Th F Sat 
   inpatient metabolic chamber  
body composition X        
exercise test X        
activity monitor X        
metabolic cart   X X X X X  
questionnaires   X      
insulin clamp   X      
blood draw    X X X X  
metabolic chamber    X X X X  
core temperature    X X X X  
fasting blood sample    X X X X X 
heart rate variability    X    X 
urine collection   X X X X X  
biopsy   X     X 
 
Smokers were excluded from the study.  Volunteers who were unwilling or unable to 
abstain from alcohol consumption and caffeine consumption prior to testing and laboratory were 
excluded.  Significant renal, hepatic, endocrine, pulmonary, cardiac or hematological diseases 
were also exclusionary.  Women who were pregnant, post-menopausal or taking oral 
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 contraceptives or estrogen replacement therapy were excluded.  Other exclusion criteria 
included:  (1) corticosteroid use in the previous two months, (2) chronic use of anti-diabetic, 
anti-hypertensive or other medications known to affect fat metabolism and (3) weight gain or 
loss > 3kg in the previous six months. 
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 CHAPTER 2:  EXPERIMENTAL PROCEDURES 
 
2.1 Euglycemic-hyperinsulinemic Clamp (EHC) 
Insulin sensitivity and metabolic flexibility (change in respiratory quotient (∆RQ) from 
fasting to insulin-stimulated) was measured by euglycemic-hyperinsulinemic clamp (103) prior 
to HFD. After an overnight fast, insulin [80mIU/m2BSA] was administered intraveneously and 
glucose infused to maintain plasma glucose at 90mg/dl for 2 hours.  The glucose disposal rate 
(GDR; mg/kgFFM/min), was adjusted for kg of lean body mass.  
2.2 Maximal Aerobic Capacity (VO2 Max) 
Maximal oxygen uptake was determined by a progressive treadmill test to exhaustion 
(104).  The volumes of O2 (VO2) and CO2 (VCO2) were measured continuously using a metabolic 
cart (V-Max29 Series, SensorMedics, Yorba Linda, California). 
2.3 Body Composition (DEXA) 
Body fat mass and lean body mass were measured on a Hologic Dual Energy X-Ray 
Absorptiometer (QDR 2000, Hologic, Inc. Waltham, MA).  Visceral fat was measured by CT 
scanning using a High SpeedTM CT scanner under an established protocol (105). 
2.4 Indirect Calorimetry 
24-hour energy expenditure and respiratory quotient (RQ) were determined in the whole 
room respiratory calorimeter, prior and during 3 days of isocaloric high fat diet.  Energy 
expenditure was set at 1.4 times the resting metabolic rate and clamped across the 4-day chamber 
stay.  After an overnight fast, fasting and steady state (insulin infusion) respiratory quotient (RQ) 
were measured for 20 minutes by indirect calorimetry during the EHC using a Deltratrac II 
indirect calorimeter (DATEX-Ohmeda, Helsinki, Finland).  Oxidative and non-oxidative glucose 
disposal was calculated as described by Livesy (106). 
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 2.5 Laboratory Measures 
Baseline serum glucose and free fatty acids were assayed by established enzymatic 
procedures (Beckman Synchron CX7 or CX5; Beckman Coulter, Brea, CA) using the Wako FFA 
reagents (Richmond, VA).  Baseline plasma insulin and C-peptide were measured on an 
Immulite autoanalyzer (DPC, Los Angeles, CA).  Steady state (insulin infusion) serum glucose 
and insulin were assayed during the euglycemic-hyperinsulinemic clamp in the same manner as 
the baseline samples.  The enzymatic assay was not sensitive enough to reliably measure insulin-
suppressed free fatty acids (FFAs), so steady state (insulin infusion) FFAs were measured in 
triplicate by high performance liquid chromatography (HPLC) as previously described (107) by 
Dr. John Miles, Mayo Clinic, Rochester, MN. 
2.6 Fat Cell Size 
Fat cell size was determined as previously described (108).  Briefly, adipose tissue was 
fixed in osmium tetrachloride/collidine-HCl followed by disassociation by urea digestion.  Cells 
were sized and counted on a Multisizer-3 (Beckman Coulter, Fullerton, CA) using a 400-µm 
aperture (dynamic linear range, 12–320 µm) and reported as the mean of all adipocytes 
>22.5µm. 
2.7 Animal Study 
Male C57BL/6J mice were housed at room temperature with a 12h light-12h dark cycle 
for five weeks.  Six mice ate the control diet 10% fat diet  (Research Diets, Inc., D12450B, New 
Brunswick, NJ: 10% of energy from fat, 20% of energy from protein, 70% of energy from 
carbohydrate) and seven mice ate the 45% high fat diet (HFD) (Research Diets, Inc., D12451, 
New Brunswick, NJ: 45% of energy from fat, 20% of energy from protein, 35% of energy from 
carbohydrate).  All animals ate the control diet ad lib for two weeks and then seven were 
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 switched to the HFD for three additional weeks.  The gastrocnemius muscles were dissected and 
snap-frozen in liquid nitrogen. 
2.8 Preparation of RNA and DNA 
Human and mouse total RNA from 50-100 mg vastus lateralis and gastrocnemius muscle, 
respectively, was isolated with Trizol reagent (Invitrogen, Carlsbad, CA).  Mouse muscle from 
20-30 mg gastrocnemius was digested overnight in proteinase K (FisherBiotech, Houston, TX) at 
55oC.  DNA was extracted the following day with phenol-chloroform.  The quantity and the 
integrity of the RNA and DNA were confirmed by Agilent 2100 Bioanalyzer according to 
manufacturer’s procedure (Agilent Technologies, Palo Alto, CA). 
2.9 Preparation of Whole Cell Extracts 
Murine muscle tissues were homogenized in buffer (50mM HEPES, pH 7.4, 2mM 
EDTA, 150mM NaCl, 30mM NaPPO4, 10mM NaF, 1% Triton X-100, 10µL/mL protease 
inhibitor, 10µL/mL phosphatase I inhibitor, 10µL/mL phosphatase II inhibitor, and 1.5mg/mL 
benzamidine HCl).  The whole homogenates were centrifuged for 25 minutes at 15,000g, and 
supernatants were stored at -80 °C prior to Western immunoblotting. 
2.10 Oligonucleotide Microarrays 
RNA sample pairs (2µg) from the ten subjects were labeled by reverse transcriptase with 
dCTP-Cy3 and dCTP-Cy5, respectively, and in the inverse order (dye swap) using MICROMAX 
TSA Labeling & Detection kit (Perkin-Elmer, Wellesley, MA).  Equal amounts of labeled cDNA 
probes were hybridized in duplicate to oligonucleotide slides containing 18,861 spots 
corresponding to 17,260 unique oligonucleotides (Compugen, NJ) in hybridization chambers 
(GenomicSolutions, Ann Arbor, MI) for up to 72 hours at 42°C.  Detection and washing were 
performed at room temperature according to manufacturer’s protocol (Perkin-Elmer, Wellesley, 
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 MA).  Oligonucleotide chips were spotted on to poly-L-lysine slides using a GeneMachine 
OmniGrid microarrayer (GenomicSolutions, Ann Arbor, MI) equipped with a Stealth SPH32 
printhead and Stealth SMP4 Micro Spotting Pins (Telechem Internation, Inc., Sunnyvale, CA).  
Oligonucleotides were stored in 384-well plates in 45% DMSO.  Microarray slides were scanned 
using a GSI Lumonics ScanArray 5000 scanner (Perkin-Elmer, Wellesley, MA) at high 
intensities (~95% for Cy3, ~75% for Cy5) and low intensities (~55% for Cy3, ~35% for Cy5) 
applying ScanArray Express software and quantified using QuantArray (GenomicSolutions, Ann 
Arbor, MI).  All subsequent microarray analyses were performed using SAS version 8.2 (SAS, 
Cary, NC).  A robust local regression procedure (LOWESS) was performed to remove the 
systematic variations in the measured gene expression levels so that differences in expression 
across the samples could be distinguished accurately and precisely (109).  After normalization, 
gene shaving (110) and bootstrapping (111), cluster analysis was performed (112), and the slide 
effect, dye effect and variety effect, as well as the duplicate design, were taken into account in an 
ANOVA model (113).  Resampling-based multiple pairwise comparison was used to identify the 
differentially expressed genes before versus after the high fat diet.  Differentially expressed 
genes were identified based on a Bonferroni  
adjusted p-value < 0.001. 
2.11 Real Time qRT-PCR for RNA 
RNA sample pairs (1µg) were reverse transcribed using iScript cDNA synthesis kit 
(BioRad, Hercules, CA) and SYBR Green I qRT-PCR (Applied Biosystems, Roche, Branchburg, 
NJ).  All primers and probes were designed using Primer Express version 2.1 (Applied 
Biosystems, Roche, Branchburg, NJ).  The sequences of primers and probes and accession 
numbers for each gene are shown in Appendix A.1 and Appendix A.3.  Real time RT-PCR 
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 reactions (114) for tested genes were performed using the Taqman technique (Applied 
Biosystems, Roche, Branchburg, NJ).  Real-time RT-PCRs were performed as one-step reactions 
in an ABI PRISM 7900 (Applied, Biosystems, Branchburg, NJ) using the following parameters: 
one cycle of 48oC for 30 min, then 95o C for 10 min, followed by 40 cycles at 95oC for 15 sec 
and 60oC for 1 min.  For all assays performed using SYBR Green I, 18S was used as the internal 
control, and for all assays performed using Taqman primers and probe, RPLP0, which is the 
human equivalent of the murine 36B4 (115), was used as the internal control.  Cyclophilin B was 
used for all murine assays.  All expression data were normalized by dividing the amount of target 
gene by the amount housekeeping gene used as an internal control.  
2.12 Real Time qPCR for mtDNA and Genomic DNA Copy Number 
Taqman primers and probes were designed using Primer Express version 2.1 (Applied 
Biosystems, Roche, Branchburg, NJ).  The sequences of primers and probes and accession 
numbers for each gene are shown in Appendix A.1.  Real-time PCR was carried out in an ABI 
PRISM 7900 sequence detector (Applied, Biosystems, Branchburg, NJ) using the following 
parameters: one cycle of 50oC for 2 min, then 95o C for 10 min, followed by 40 cycles at 95oC 
for 15 sec and 60oC for 1 min.  Murine skeletal muscle genomic DNA copy number was 
measured at the UCP2 gene using a primer-probe set that amplifies genomic DNA.  
Mitochondrial DNA copy number was measured from the COXII mtDNA gene.  Mitochondrial 
DNA copy number was calculated by first taking the absolute value of the delta Ct values 
between groups (control vs. HFD).  Because amplification occurs exponentially (increasing two-
fold with each cycle of PCR), log base 2 of delta Ct as the copy number for each sample (116).  
 
 
 24  
 2.13 Western Immunoblotting 
Homogenates were run on a 10% PAGE, transferred to PDVF membranes, incubated 
with the primary antibodies PGC1α (#P3363, US Biological, Swampscott, MA) and Cytochrome 
C (#556433, BD Biosciences, San Jose, CA) and signal detected using the ECL detection system 
(Pierce, Rockford, IL).  GAPDH (#4699-9555, Biogenesis, Kingston, NH) was used as an 
internal control and brown adipose tissue as positive control. 
2.14 Skeletal Muscle Enzyme Activities 
Skeletal muscle samples were diluted 20-fold and homogenized in extraction buffer (0.1 
M KH2PO4/Na2PHO4, 2 mM EDTA, pH = 7.2).  Citrate synthase (CS), Cytochrome C oxidase 
(COX) and beta-hydroxyacyl-CoA dehydrogenase (BHAD) activities were determined 
spectrophotometrically as previously described (117; 118). DNA was extracted from the same 
homogenate (total nucleic acid extraction, Epicentre, Madison, WI) and mtDNA measured to 
correct for differences in the content of mitochondria (119). 
2.15 Statistical Analysis 
Statistical analysis for all real time qRT-PCR and qPCR data in skeletal muscle was 
performed using two-tailed paired Student’s t-test for before versus after HFD (human) and 
unpaired Student’s t-test for low fat versus high fat diet (mouse) to establish main effects of the 
high fat diet intervention.  Adipose tissue gene expression and clinical data were correlated using 
regressions.  The change in respiratory quotient (∆RQ) was divided into quartiles (quartile 1 = 
∆RQ < 0.06; quartile 2 = 0.06 < ∆RQ < 0.08; quartile 3 = 0.08 < ∆RQ < 0.11; quartile 4 = ∆RQ 
> 0.11) to illustrate the range in metabolic flexibility within the cohort.  ANOVA was used to 
test for differences in biopsy and blood parameters across quartiles of metabolic flexibility 
(∆RQ), with post-hoc testing by mean equality contrast between different groups using the 
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 Tukey-Kramer HSD; alpha = 0.05.  Type I error rate was set a priori at p < 0.05.Analysis was 
performed using GraphPad Prism version 4.0 (GraphPad Software Inc., San Diego, CA) and 
JMP version 5.0 (SAS, Cary, NC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26  
 CHAPTER 3:  HIGH-FAT DIET DOWNREGULATES OXPHOS GENES* 
 
3.1 Introduction 
Type 2 diabetes affects over 110 million people worldwide, and Type 2 diabetes 
associated with obesity is reaching epidemic proportions (120; 121).  Many pathophysiological 
processes have been implicated in diabetes, such as pancreatic β cell dysfunction and defects in 
insulin signaling, carbohydrate utilization and mitochondrial metabolism (83; 122).  At the 
molecular and structural level, mitochondrial biogenesis and mitochondrial function are altered 
in diabetes, as well as in insulin-resistant relatives of Type 2 diabetics (86; 123).  At the ultra-
structural level, a reduction in the number, location and morphology of mitochondria is strongly 
associated with insulin resistance (123).  Two recent microarray studies have shown that genes 
involved in oxidative phosphorylation (OXPHOS) exhibit reduced expression levels in the 
skeletal muscle of Type 2 diabetics and prediabetics.  These changes may be mediated by the 
peroxisome proliferator-activated receptor γ coactivator-1 (PGC1) pathway.  PGC1α- and 
PGC1β-responsive OXPHOS genes show reduced expression in the muscle of patients with 
Type 2 diabetes (83; 84).  In addition to the cellular energy sensor AMPK, the peroxisome 
proliferator-activated receptor (PPAR) cofactors PGC1α (124-126) and possibly PGC1ß (127) 
activate mitochondrial biogenesis and increase OXPHOS gene expression by increasing the 
transcription, translation and activation of the transcription factors necessary for mitochondrial 
DNA (mtDNA) replication.  Similarly, PGC1α increases the transcription of enzymes necessary 
for substrate oxidation, electron transport and ATP synthesis.  Morphological and functional 
 
* published as Diabetes 54: 1926-1933, 2005, with permission from Diabetes. 
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  studies (85; 123; 128), combined with the recent microarray data, indicate that PGC1 is 
important in the development of Type 2 diabetes.   
Rates of ATP synthesis, measured in situ with magnetic resonance spectroscopy, are 
decreased in subjects with a family history of diabetes before the onset of impaired glucose 
tolerance (85; 86).  Based on these results, the prevailing view is that these defects have a genetic 
origin (86).  One common feature of diverse insulin resistant states is an elevation in non-
esterified fatty acids (129).  This gave rise to the concept of ‘lipotoxicity’ and ‘ectopic fat’ (130) 
and shifted attention toward the adipose tissue and increased free fatty acid concentrations as a 
potential foundation for insulin resistance (129).   
Excess dietary fat has been implicated in the development of obesity and diabetes (131).  
Even at energy balance high fat diets will increase the flux of fatty acids through skeletal muscle 
for oxidation.  The purpose of these experiments was to identify the transcriptional responses in 
skeletal muscle to an in vivo isoenergetic high fat diet (HFD) in healthy young men using 
oligonucleotide microarrays.  We found downregulation of genes encoding proteins in complex I 
and complex II of the electron transport chain after an acute isoenergetic high fat diet.  Similarly, 
Cytochrome C (complex III protein) and Surfeit 1 (complex IV protein), PGC1α and PGC1β 
mRNA were also downregulated by the HFD.  These changes were recapitulated and amplified 
in a murine model after a three-week HFD.  These studies implicate increased fatty acid flux in 
the defects in OXPHOS genes observed in diabetes and the prediabetic/insulin-resistant state. 
3.2 Results 
The characteristics of the study population are presented in Table 3.1.  Fasting  
glucose, insulin and free fatty acids were unchanged as the diet was switched from a  
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 ‘standard’ fat content (35%) to a high fat diet (50%) (Table 3.2).  Intra-subject changes in 
skeletal muscle gene expression before vs. after three days eating a 50% high fat diet were 
 
Table 3.1 Characteristics of the study population before the high-fat diet. Ten male subjects 
were chosen from the larger study population based on a high aerobic capacity and insulin 
sensitivity. BMI, body mass index; GDR, glucose disposal rate; FFA, free fatty acids; FCS, fat 
cell size. 
 
Subject Characteristics Mean ± SD
Age (y)   23.0 ± 3.1
Height (cm) 179.7 ± 6.3
Weight (kg)   78.9 ± 13.2
BMI (kg/m²)   24.3 ± 3.0
VO2max (ml/kg/min)   48.8 ± 3.3
WHR (au)   0.88 ± 0.1
RQ (au)   0.87 ± 0.1
Fasting Glucose (ml/dl)   78.4 ± 4.7
Fasting Insulin (µl/ml)     4.6 ± 1.4
GDR (mg/kgFFM/min)   14.7 ± 4.1
FFA (mmol)     0.4 ± 0.1
Body Fat (%)   16.2 ± 3.2
FCS (µl)   0.93 ± 0.2
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Change in overnight fasting blood parameters after a 50% high fat diet at energy 
balance and fixed activity level. Values are presented as sample means + SEM.  BL = baseline, 
HFD = high fat diet (50%fat). Repeated measures ANOVA was used to test for time effects; P = 
0.847, 0.130, 0.047 for glucose, insulin and FFA, respectively.  When post-hoc comparisons of 
each HFD day vs. average of the two baseline values were significant (p < 0.05; Dunnetts 
adjustment) these values are marked with an asterisk. 
 
identified using oligonucleotide microarrays and analyzed by sequential analysis that included 
LOWESS normalization, gene shaving, bootstrapping and ANOVA.  A cluster analysis grouped 
Variable BL1 BL2 HFD day 1 HFD day 2 HFD day 3 
Glucose (mg/dl)   88.60 ± 7.38 89.77 ± 8.74 89.00 ± 9.76 89.40 ± 7.29 90.40 ± 9.03
Insulin (mIU/ml)    6.81 ± 3.02   6.98 ± 2.86   6.65 ± 3.00      6.07 ± 2.98 *   6.89 ± 2.67
FFAs (mmol)    0.26 ± 0.08   0.28 ± 0.10   0.22 ± 0.08   0.25 ± 0.08   0.27 ± 0.10
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 the regulated genes into five clusters based on three principal components (Figure 3.1).  The 
three-day isoenergetic high fat diet significantly changed the expression of 298 genes 
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Figure 3.1 Cluster analysis of changes in gene expression with high-fat diet. In a cohort of 
healthy insulin-sensitive males (n=10), effect of a three-day isoenergetic high-fat diet (50% fat 
vs. 35% fat) reduced the expression of 298 genes in skeletal muscle. The 298 microarray ‘hits’ 
are divided among five clusters of co-regulated genes.  Clustering was performed using the k-
means technique. Differentially expressed genes were identified based on a Bonferroni adjusted 
p-value <0.001. The majority of the oxidative phosphorylation genes ‘hits’ were in cluster # 5.  
 
(p < 0.001; Appendix A.2).  163 genes were upregulated and 135 were downregulated by the 
high fat diet.  Of those genes, six were known to be involved in oxidative phosphorylation by 
visual inspection or through gene ontogeny analysis (p < 0.001; Table 3.3).  All of the oxidative 
phosphorylation genes were downregulated and none were upregulated.  Three of these genes are 
components of complex I and one is a component of complex II.  The remaining regulated gene 
is involved in mitochondrial solute transport. 
We then sought to confirm the expression of these six oxidative phosphorylation genes 
by quantitative real time RT-PCR (Appendix A.1).  Of the six ‘hits’ from the microarray all 
displayed the same downward trend with RT-PCR as by microarray, and three genes were 
‘confirmed’ (Figure 3.2.A):  NDUFB5 (3.19 ± 0.26 to 2.12 ± 0.20AU, p < 0.01), SDHB 
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 (0.26 ± 0.02 to 0.19 ± 0.02AU, p < 0.05), NDUFS1 (0.28 ± 0.03 to 0.21 ± 0.02AU, p=0.05), 
SLC25A12 (0.29 ± 0.04 to 0.19 ± 0.02AU, p=0.08), NDUFB3 (0.39 ± 0.05 to 0.26 ± 0.034AU, 
p=0.14) and NDUFV1 (0.36 ± 0.05 to 0.30 ± 0.04AU, p=0.32).  The magnitudes of these 
Table 3.3 Microarray hits - oxidative phosphorylation. By microarray analysis, 298 genes 
were up- or downregulated after a HFD. Of those 298, 6 are known to be involved in oxidative 
phosphorylation or mitochondrial function. NDUFB3, NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 3; NDUFB5, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; 
SDHB, succinate dehydrogenase complex, subunit B; SLC25A12, solute carrier family 25 
(mitochondrial carrier); NDUFV1, NADH dehydrogenase (ubiquinone) flavoprotein 1; 
NDUFS1, NADH dehydrogenase (ubiquinone) Fe-S protein 1. 
 
 Gene Fold Change p-value 
NDUFB3 ↓ 1.4 <0.01 
NDUFB5 ↓ 1.9 <0.01 
SDHB ↓ 2.4 <0.01 
SLC25A12 ↓ 1.8 <0.01 
NDUFV1 ↓ 1.9 <0.01 
NDUFS1 ↓ 2.4 <0.01 
 
 
 
 
 
 
changes (~ 20-30%) are strikingly similar to the decreases demonstrated by microarray analysis 
of reduced skeletal muscle oxidative phosphorylation gene expression found by Patti and Mootha 
in diabetic subjects (83; 84).  As a subsequent step in elucidating the effects of the diet 
intervention on the expression of genes involved in mitochondrial function, we examined the 
mRNA for genes in complex III and complex IV using qRT-PCR (Figure 3.2.A).  Cytochrome C 
(complex III) and Surfeit 1 (complex IV) expression levels were reduced (1.13 ± 0.07 to 0.85 ± 
0.05AU, p < 0.01 and 1.10 ± 0.05 to 0.90 ± 0.05 AU, p < 0.01).  Because expression levels of 
genes involved in mitochondrial function decreased, we examined gene expression of those 
involved in mitochondrial biogenesis.  We observed a 20% and a 25% reduction in mRNA levels 
in PGC1α and PGC1β, respectively (Figure 3.3.A); PGC1α (1.44 ± 0.08 to 1.13 ± 0.06 AU,  
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 Figure 3.2.A HFD decreases mRNA for genes involved in oxidative phosphorylation in 
healthy young men. Effect of a three day isoenergetic high fat diet (50% fat vs. 35% fat) in a 
cohort of healthy insulin-sensitive males (n=10) at baseline and after intervention on the 
expression of genes in complex I (NDUFB3, NDUFB5, NDUFV1, NDUFS1) complex II 
(SDHB), complex III (CYC1), complex IV (SURF1) and a mitochondrial carrier protein 
(SLC25A12).  mRNA was quantified by qRT-PCR. Data are shown as means ± SE and corrected 
for the expression of 18S and RPLP0. NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 3; NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; NDUFV1 
NADH dehydrogenase (ubiquinone) flavoprotein 1; NDUFS1 NADH dehydrogenase 
(ubiquinone) Fe-S protein 1); SDHB succinate dehydrogenase complex, subunit B; SLC25A12 
solute carrier family 25 (mitochondrial carrier); CYC1 cytochrome c-1; SURF1 surfeit 1; 18S 
18S ribosomal RNA; RPLP0 ribosomal protein, large, P0.  
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 Figure 3.2.B HFD decreases mRNA for genes involved in oxidative phosphorylation in 
mice. Effect of a 21 day high fat diet (45% fat vs. 10% fat) in a cohort of C57Bl/6J mice 
(control, n=6; HFD, n=7) on genes in Complex I (NDUFB3 AND NDUFB5) Complex II 
(SDHB), Complex III (CYC1), Complex IV (SURF1) and a mitochondrial carrier protein 
(SLC25A12).  Data are shown as means ± SE and corrected for the expression of Cyclophilin B. 
mm mus musculus; mmNDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3; 
mmNDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; mmSLC25A12 solute 
carrier family 25 (mitochondrial carrier); mmSDHB  succinate dehydrogenase complex, subunit 
B; mmCYC1 cytochrome c-1; mmSURF1 surfeit 1; mmCycB peptidylprolyl isomerase B 
(cyclophilin B). 
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 p<0.01) and PGC1β (2.12 ± 0.16 to 1.59 ± 0.18 AU, p<0.05).  Mitochondrial transcription factor 
A (TFAM), a key activator of mitochondrial transcription and its genome replication, was not 
significantly changed (2.00 ± 0.19 to 1.79 ± 0.19 AU, p=0.38), nor was nuclear respiratory factor 
1, NRF1 (1.89 ± 0.13 to 1.56 ± 0.16AU, p=0.14) (Figure 3.3.A).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
igure 3.3.A HFD decreases expression of transcriptional cofactors involved in the 
egulation of oxidative phosphorylation gene expression and mitochondrial biogenesis in 
ealthy young men. Effect of a three day isoenergetic high fat diet (50% fat vs. 35% fat) in a 
ohort of healthy insulin-sensitive males (n=10) at baseline and after intervention on the 
xpression of genes involved in mitochondrial biogenesis.  Data are shown as means ± SE and 
orrected for the expression of RPLP0. PGC1α peroxisome proliferative activated receptor, 
amma, coactivator 1, alpha; PGC1β peroxisome proliferative activated receptor, gamma, 
oactivator 1, beta; TFAM transcription factor A, mitochondrial; NRF1 nuclear respiratory 
ctor-1; RPLP0 ribosomal protein, large, P0. 
We next tested whether the changes in gene expression we found in the clinic were 
resent in a murine model of high fat diet-induced obesity.  We fed C57Bl/6J mice either a 10% 
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 experiments.  Decline in gene expression was of greater magnitude than that seen in the human 
xperiments.  As measured by real time qRT-PCR, each of these genes was downregulated in 
± 
3.58 to 
 ± 
In parallel to the human experiment, we measured both PGC1α and PGC1β mRNA in 
these sa
n range 
 
3.3 Dis
r mRNAs encoding genes involved in mitochondrial oxidative 
phosph  
e
high fat fed mice as compared to their controls (Figure 3.2.B):  NDUFB5 (24.05 ± 7.89 to 2.10 
0.44AU, p < 0.01), NDUFB3 (19.02 ± 6.25 to 1.82 ± 0.29AU, p < 0.01), SDHB (10.84 ± 
1.05 ± 0.20AU, p < 0.01) SLC25A12 (6.14 ± 1.99 to 0.45 ± 0.11AU, p < 0.01), CYC1 (10.41
3.40 to 0.79 ± 0.13 AU,p<0.01), and SURF1 (175.50 ± 57.35 to 13.81 ± 3.20 AU, p<0.01). 
me mice.  We found a 90% reduction in mRNA levels for both PGC1α and PGC1β 
(Figure 3.3.B):  PGC1α (34.63 ± 12.57 to 2.67 ± 0.31 AU, p<0.01) and PGC1β (25.75 ± 9.03 to 
1.85 ± 0.30 AU, p<0.01). 
It has been shown that the half-life of a mitochondrion in a mammalian cell ca
from about three days up to ten days, depending on the measurement technique 
(132).  Given that the expression of both PGC1α and PGC1β were decreased, we hypothesized
that skeletal muscle mitochondrial DNA copy number might be decreased by the high fat diet; 
however, we found no differences between animals fed a high fat diet when compared to those 
fed a low fat diet (Figure 3.3.B); mitochondrial DNA in low fat animals 1166 ± 112.50 and in 
high fat animals 1127 ± 70.28 AU, p=0.78. 
cussion 
Numerous studies have implicated reduced mitochondrial biogenesis and oxidative 
phosphorylation in the pathogenesis of insulin resistance and Type 2 diabetes (133).  Reductions 
in the expression of nuclea
orylation have been reported in individuals with a family history of Type 2 diabetes and
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 in individuals affected by Type 2 diabetes (83; 84).  These studies complement earlier anatomic
and physiologic studies documenting alterations in mitochondrial number, mitochondrial enzym
 
e  
 
Figure 3.3.B HFD decreases expression of transcriptional cofactors involved in the 
regulation of oxidative phosphorylation gene expression and mitochondrial biogenesis in 
mice. Effect of a 21 day high fat diet (45% fat vs. 10% fat) in a cohort of C57Bl/6J mice 
(control, n=6; HFD, n=7) involved in mitochondrial biogenesis and mitochondrial DNA copy 
number per nuclear DNA copy number.  Data are shown as means ± SE and corrected for the 
expression of Cyclophilin B. mmPGC1α peroxisome proliferative activated receptor, gamma, 
coactivator 1, alpha; mmPGC1β peroxisome proliferative activated receptor, gamma, coactivator 
1, beta; mmCOXII cytochrome c oxidase II, mitochondrial; mmUCP2 uncoupling protein 2; 
mmCycB peptidylprolyl isomerase B (cyclophilin B). 
 
activities and oxidative vs. glycolytic fiber type in skeletal muscle (123).  Importantly, functional 
studies of skeletal muscle energy metabolism in situ demonstrate that ATP synthesis is reduced 
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 in aging and the offspring of insulin resistant individuals (85; 86).  The latter authors
that lipid flux is not involved in the reduction in expression of OXPHOS genes because fasting 
PGC1α), may be identified.  Overall, an acute HFD elicits a coordinated downregulation o
genes involved in oxidative phosphorylation within the electron transport chain.  Moreover, the 
expression of PGC1β is also decreased.      
Our results support the hypothesis that high fat diets and/or high fat flux through the 
 suggested 
plasm
lly, 
m
f 
itochondria reduce the expression of nuclear genes encoding mitochondrial proteins and 
a NEFAs were similar in insulin-resistant and insulin-sensitive individuals, and glycerol  
turnover studies did not demonstrate an increase in lipolysis.  However, our data suggest that 
dietary fat, or increased fat utilization in skeletal muscle, is an important factor in the  
observed reduction in OXPHOS genes in insulin resistant states.  Microarray analysis and 
 quantitative real time RT-PCR results revealed a downregulation of OXPHOS genes after eating 
the HFD, as well as transcription factors and cofactors, in our human experiments.  Additiona
we have shown that the reductions in genes involved in oxidative phosphorylation and 
itochondrial biogenesis were recapitulated in an animal model of dietary-induced obesity and 
insulin resistance (134) and were of a much greater magnitude in mice as compared to man.   
Through the combined use of microarray technology, advanced bioinformatics and 
confirmation of the microarray results with qRT-PCR, we were able to identify subtle (20-30%) 
changes in OXPHOS gene expression without a priori grouping of genes based on known 
function (83).  The advantage of this approach is genes that do not exhibit large changes in 
transcription, but that are clearly important in carbohydrate and energy metabolism (e.g. 
m
transcription factors involved in mitochondrial biogenesis.  Both PGC1α and PGC1β were 
decreased by about 20% and were accompanied by a 20% reduction in OXPHOS gene 
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 expression.  Previous studies suggest a link between the downregulation of PGC1 and 
dysregulation of OXPHOS genes.  Our results are consistent with this sequence of events, and 
deed three of our OXPHOS genes found by microarray analysis were also present in the 
analyses of Mootha and Patti (83; 84).  Therefore, our findings expand the view beyond the 
relationship between PGC1 and OXPHOS genes.  We move upstream to show that increased 
fatty acid flux through the mitochondria decreases PGC1 expression and is associated with a 
downregulation of expression of genes involved in oxidative phosphorylation.  Highly 
homologous to one another, PGC1α and PGC1β both alter mitochondrial metabolism but 
ultimately retain different physiological functions (135).  Puigserver and Spiegelman (124) 
demonstrated that PGC1α is a master regulator of mitochondrial biogenesis and OXPHOS gene 
expression (136).  PGC1α co-activation of NRF1-mediated transcription leads to transcription 
and subsequent translocation of TFAM to the mitochondrion, thus increasing mtDNA 
transcription (137; 138).  In these studies, both coactivators PGC1α and PGC1β were 
downregulated; however, we saw no significant change in two downstream targets, NRF1 and 
TFAM (Figure 3.3.A).    
Although an increase in free fatty acid concentrations was not seen in this cohort, fatty 
acid flux through the muscle is by necessity increased in these subjects as demonstrated by an 
increase in fat oxidation to match fat intake in this experimental paradigm (90).  Another 
explanation for the reduction in the expression of these genes is that HFD decreases insulin-
stimulated gene expression.  Fatty acids decrease insulin signaling both in vivo and in vitro.  
Recent microarray studies demonstrate an upregulation of OXPHOS genes after a short-term 
insulin infusion (139).  A reduction in insulin signaling might reduce expression of these same 
genes.  Our studies do not identify the exact mechanism of the reduction in PGC1α, PGC1β or 
in
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id flux has 
drial 
e 
btle changes in mitochondrial number or function with an acute HFD.    
ingly, 
wnstream targets.  Rather these studies point toward dietary fat, or increased lipolysis
a potential source of the previously reported reduction in mitochondrial oxidative 
phosphorylation and subsequent mitochondrial dysfunction. 
Importantly, mice fed a HFD for three weeks showed a similar pattern of change
expression as in the shorter (three day) human experiments.  The magnitude of the chan
gene expression was much larger in mice than in man.  In light of the fact that three days of HF
is not long enough to cause changes in mtDNA copy number as mitochondrial turnover is 
relatively slow (132), we next tested the hypothesis that the changes in the transcriptional 
cofactors (e.g. PGC1α and PGC1β) would decrease mitochondrial number in mice fed a HFD 
three weeks.  We found large changes in PGC1α and PGC1β, but mtDNA remained unchange
after three weeks of HFD in mice.   
In some ways our inability to find changes in mitochondrial DNA copy number are
inconsistent with recent studies demonstrating a reduction in mitochondrial number in diabe
and insulin resistance (116; 123) but similar to studies showing a decrease in OXPHOS gene 
expression (83; 84).  One possibility is that ‘chronic’ versus ‘acute’ effects of high fat flux 
through mitochondria are different.  In the prediabetic and diabetic states, increased lip
been maintained for a longer period of time.  Therefore, additional studies of mitochon
number and function, including electron transport chain activity and electron microscopy, will b
needed to fully rule out su
Our studies reveal a key question: “why would increased fatty acid flux decrease the 
expression of genes needed to oxidize these same fatty acids?”.  Fasting is another ‘normal’ 
physiological condition where fatty acid flux through skeletal muscle is increased.  Surpris
fasting produces changes in gene expression that are strikingly similar to the pattern of fat-
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 induced changes observed in our studies of high fat diets.  For example, Jagoe et al found that
CASQ2 (calsequestrin 2), NDUFS1, glycogen synthase and PDK4 (pyruvate dehydrogenase 
kinase isoenzyme 4), four genes found on our microarray ‘hit’ list (Appendix A.2) and confirme
by qRT-PCR (data not shown), were similarly regulated by fasting in rodents (140).  This may 
explain the paradoxical decrease in systems needed to oxidize fatty acids (nuclear genes 
encoding mitochondrial proteins, PGC1α) when fat flux is increased during a high 
other words, the parallel results between fasting and high fat 
 
d 
fat diet.  In 
diets suggest that fat flux through 
the ske
n our 
es encoding mitochondrial proteins (e.g. mitochondrial 
carrier 
 
letal muscle might be interpreted as a signal of fasting/starvation by the muscle cell itself.  
Signaling systems normally reserved for responding to energy deprivation (fasting) may be co-
opted when dietary fat is increased.  This hypothesis is also consistent with the observed changes 
in the transcription of genes involved in non-oxidative metabolism (e.g. glycolysis) found o
microarray ‘hit’ list (Appendix A.2).   
In conclusion, high fat diets in both insulin-sensitive humans and in mice were associated 
with a reduction in the expression of genes involved in oxidative capacity (e.g. genes of the 
electron transport chain), nuclear gen
proteins) and those involved in mitochondrial biogenesis (e.g. PGC1α and PGC1ß).  
These studies support the novel hypothesis that high fat diets or high fat flux explain the 
reduction in OXPHOS genes seen in aging, the prediabetic state and in overt diabetes.  
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TER 4:  GLUCOSE METABOLISM VIA A LONG-TERM TRANSCRIPTION
 
4.1 Introduction 
Type 2 diabetes affects over 110 million people worldwide, and Type 2 diabetes 
associated with obesity is reaching epidemic proportions (1, 2).  Many pathophysiological 
processes have been implicated in diabetes, such as pancreatic β cell dysfunction, as well as 
defects in insulin signaling, carbohydrate utilization and mitochondrial metabolism (3, 4). The 
earliest detectable abnormality in people at risk for Type 2 diabetes is insulin resistance in 
skeletal muscle.  The ability of insulin to activate signal transduction events, alter gene 
expression of selected genes (5) and stimulate muscle glycogen synthesis is an integral part of 
the body’s response to macronutrient intake. 
The physiologic purpose of alterations in fuel selection is to channel energy to and from 
the appropriate storage compartments under all circumstances that may confront the organism.  
An obligate need exists to regulate glycogen within a relatively narrow window.  Studies 
conducted in subjects with Type 2 diabetes and in healthy subjects to determine the fate of 
glucose after it is taken up by muscle c
ycolysis, is an important pathway in skeletal muscle glucose metabolism (6).  Muscle 
cells adjust the fuels they oxidize in order to match substrate supply, signals from the endocr
and neural systems and the ATP required for contraction.   
 
* published as Metabolism: Clinical and Experimental 55: 1457-1463, 2006, with permis
from Metabolism. 
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 The supply of substrate to muscle tissue depends upon several factors including the 
dietary macronutrient content, the storage of nutrients in liver and fat, capillary recruitment and 
transport, and in the case of triglycerides, the release of free fatty acids by the enzymatic activity of 
lipoprotein lipase (LPL) at the surface of the cell.  The adjustment of substrate oxidation to the 
local nutrient concentrations occurs through at least three mechanisms: minute-to-minute 
c
the activation of signaling pathways such as PKC (8) and NFκB (9) and through long-term 
transcription and hence the cellular machinery 
driving .e. insulin 
avel 
 
 
 
 young, healthy volunteers (10).  The purpose of 
this res
 
hanges in the activity of enzymes that direct carbohydrate and fat into oxidation or storage (6), 
regulatory systems that involve changes in gene 
 the first two processes.  The ability of insulin to regulate glucose homeostasis, i
sensitivity, is closely related to these regulatory pathways, justifying further attempts to unr
the details of these regulatory systems.  Strong experimental evidence exists for each of these
pathways, particularly for the regulation of substrate utilization and insulin sensitivity through 
enzyme activity (7) and signaling pathways (8).  Less data is available to implicate 
transcriptional pathways as key components of this autoregulatory loop.  We previously
described the effects of a short-term HFD to reduce the expression of genes related to oxidative
phosphorylation within the skeletal muscle of
earch was to expand that investigation and to identify the transcriptional responses for 
other metabolic systems such as carbohydrate oxidation and storage, as well as fatty acid 
oxidation. 
4.2 Results 
 Participants presented to the Pennington Biomedical Research Center inpatient unit 
(Figure 4.1) on day -4 at 07:00 PM.  The characteristics of the study population are presented
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 in Table 4.1.  Fasting glucose, insulin and free fatty acids were unchanged as the diet was 
switched from ‘standard’ fat : carbohydrate content (35% : 49%) to high fat : low  
 
 
carbohydrate, 16% protein) followed by a euglycemic-hyperinsulinemic (EH) clamp and a 
te, 
16% protein) and placed in metabolic chamber for a total of 4 days where fatty acid oxidation 
biopsy on Day4. 
 163 genes 
further 
metabolism by visual inspection or through gene ontogeny analysis (Table 4.2).  Of the  
-1
 
CONTROL DIET HF / LC DIET
 
 
 
Figure 4.1 ADAPT study design. Subjects consumed a prescribed control diet (35% fat, 49% 
muscle biopsy.  They were switched to a prescribed HF/LC diet (50% fat, 34% carbohydra
was measured by respiratory quotient (RQ) at Day0 and Day4.  They finished with a muscle 
 
carbohydrate content (50% : 34%; data not shown).  Intra-subject changes in skeletal muscle 
gene expression before versus after three days eating the high fat/low carbohydrate diet were 
identified using oligonucleotide microarrays according to low laser analysis previously 
described (10). 
 The three-day isoenergetic high fat/low carbohydrate diet significantly changed the 
expression of 298 genes according to the low laser ‘hit’ list (p < 0.01; Appendix A.2). 
were upregulated and 135 were downregulated by the high fat/low carbohydrate diet.  A 
analysis of the low laser dataset revealed an additional 72 genes regulated by the intervention (p 
> 0.01 < 0.05; Appendix A.4). 
From these analyses, seven of those genes were known to be involved in glucose 
Muscle Biopsy
EH Clamp
Day -4 2 4-2 3
in metabolic chamber
0 1-3
24h RQ 0.87 ± 0.01 0.82 ± 0.01
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glucose metabolism genes five were downregulated and two were upregulated.  Fructose-2,6-
biphosphatase 3 (PFKFB3) and pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) increased 
4.1 ate 
iet. T h 
e 
rotein kinase kinase 3 (MAP2K3) and UDP-glucose pyrophosphorylase 2 (UGP2) decreased in 
 initial 
is (p < 0.01).  Within this cohort of insulin-sensitive males, although circulating 
strate 
 
Subject Characteristics Mean ± SD Range
Table Characteristics of the study population before high fat/low carbohydr
d en male subjects were chosen from the larger study population based on a hig
aerobic capacity and insulin sensitivity. BMI, body mass index; GDR, glucose disposal 
rate; CHO, carbohydrate; FFA, free fatty acids.  
 
  Age (y) 23.0 ± 3.1 18.0 – 28.0
 
 
 
 
 
 
Height (cm) 179.7 ± 6.3 170.6 – 189.5
Weight (kg)     78.9 ± 13.2 61.7 – 104.8
BMI (kg/m²) 24.3 ± 3.0 21.0 – 30.7
WHR (au)   0.88 ± 0.1 0.8 – 1.0
RQ (au)     0.87 ± 0.02   0.85 – 0.90
VO2max (ml/kg/min) 49.4 ± 4.0 45.5 – 56.1
Fasting Glucose (mg/dl) 78.4 ± 4.7 70.0 – 86.0
Fasting Insulin (µU/ml) 4.6 ± 1.4 2.6 – 7.6
GDR (mg/kgFFM/min) 14.7 ± 4.1 9.9 – 24.5
Cumulative CHO Balance     139.9 ± 163.9 -208.8 – 297.5
FFA (mmol) 0.4 ± 0.1 0.07 – 0.50
 
at the RNA expression level, while glycogen synthase 1, muscle (GYS1), galactose-1-phosphat
uridyltransferase (GALT), pyruvate dehydrogenase, beta subunit (PDHB), mitogen-activated 
Body Fat (%) 16.2 ± 3.2 11.5 – 20.4
 
p
expression. 
All of the genes are involved in the oxidation and storage of glucose, or glucose 
transporter expression (18).  All qRT-PCR results are based on the seven genes from the
low laser analys
free fatty acid (FFA) concentrations did not increase (Figure 4.2.A), we were able to demon
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an increase in fatty acid oxidation on the HF / LCD as measured by a significant decrease in their 
respiratory quotient (RQ) during their four-day stay in the metabolic chamber (Figure 4.2.B):  
(0.87 ± 0.01 to 0.82 ± 0.01AU, p < 0.01).  Due to phenotypic changes in the subjects as 
Table 4.2 Microarray hits in glucose metabolism pathways. By microarray analysis, a total of 
nvolved 
in glucose metabolism. PFKFB3, fructose-2,6-biphosphatase 3; PDK4, pyruvate dehydrogenase 
inase, isoenzyme 4; GYS1, glycogen synthase 1 (muscle); GALT, galactose-1-phosphate 
 
te balance subsequent 
 genes by 
real tim croarray list (p < 0.01), 
 
re 
 
370 genes were up- or downregulated after a HF/LCD. Of those 370, 7 are known to be i
k
uridyltransferase; PDHB, pyruvate dehydrogenase, beta subunit; MAP2K3, mitogen-activated 
protein kinase kinase 3; UGP2, UDP-glucose pyrophosphorylase 2. 
 
 
 
 
Gene Fold Change p-value
PFKFB3 ↑ 3.3 < 0.01
PDK4 ↑ 1.7 < 0.01
 
 
 
evidenced by a decrease in RQ, as well as displaying a positive carbohydra
to intervention, we then sought to confirm the expression of these glucose metabolism
e qRT-PCR (Appendix A.3).  Of the ‘hits’ from the low laser mi
three genes were confirmed (Figure 4.3.A): PDK4 (0.09 ± 0.01 to 0.16 ± 0.03AU, p < 0.01), 
PFKFB3 (1.61 ± 0.26 to 3.28 ± 0.52AU, p < 0.01) and GYS1 (2.17 ± 0.17 to 1.71 ± 0.16AU, p <
GYS1 ↓ 1.7 < 0.01
GALT ↓ 1.6 < 0.01
PDHB ↓ 1.7 < 0.01
MAP2K3 ↓ 2.0 < 0.01
UGP2 ↓ 2.0 < 0.01
 
0.01).   
We next tested whether the changes in gene expression that we found in the clinic we
present in a murine model of high fat/low carbohydrate diet-induced obesity.  We fed 
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 C57Bl/  weeks.  
 
ay 
 fat/low carbohydrate diet 
0% : 34% fat) in a ensitive males (n=10) on fatty acid oxidation as 
measured by tabolic chamber. 
 
storage from the hum  expression were in the same direction, 
but of a greater magn  As measured by real time 
qRT-PCR the results in rodents m n (Figure 4.3.B): PDK4 (0.31 ± 0.03 to 1.05 
8 ± 0.17AU, p < 0.01), GYS1 (3.60 ± 0.66 to 
 0.01). 
4.3 Discussion 
During insulin stimulation the skeletal muscle is the major site for glucose disposal (19), 
to be responsive to the macronutrient composition of the diet.  Since Randle s proposal in 1963 
m
m
ol
)
baseline day 4
p = 0.20
6J mice either a 10% : 70% or 45% : 35% high fat/low carbohydrate diet for three
We chose two murine genes involved in glucose oxidation and two genes involved in glucose 
A           B 
 
Figure 4.2 HF/LCD shifts substrate utilization toward fatty acid oxidation. (A) Effect of a 
three-day isoenergetic high fat/low carbohydrate diet (50% : 34% fat) in a cohort of healthy
insulin-sensitive males (n=10) on circulating free fatty acid (FFA) concentrations during their st
in the metabolic chamber. (B) Effect of a three-day isoenergetic high
(5  cohort of healthy insulin-s
 respiratory quotient (RQ) during their stay in the me
an experiments.  The changes in gene
itude than those seen in the human experiments. 
atched those in ma
± 0.07AU, p < 0.01), PFKFB3 (0.65 ± 0.04 to 1.0
0.66 ± 0.06AU, p < 0.01) and GALT (4.37 ± 0.89 to 0.81 ± 0.07AU, p <
 
thus defects in insulin-mediated glucose uptake and in its metabolic fate in this tissue are thought 
’
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 (7) of a glucose-fatty acid cycle that embodies direct competition between substrates for 
mitochondrial oxidation, a plethora of mechanisms have been put forward to explain how fuel 
 
 
 
 
 
 
 
 
 cohort of healthy insulin-sensitive males (n=10) at baseline and after HF/LCD intervention on 
the expression of genes involved in glucose oxidation (PFKFB3 and PDK4) and glucose storage 
nase 
Although an increase in free fatty acid concentrations was not seen in this cohort (Figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.A HF/LCD regulates mRNA for genes involved in glucose metabolism in healthy 
young men. Effect of a three-day isoenergetic high fat/low carbohydrate diet (50% : 34% fat) in 
a
(GYS1). mRNA was quantified by qRT-PCR. Data are shown as means ± SE and corrected for 
the expression of RPLP0. PFKFB3 fructose-2,6-biphosphatase 3; PDK4 pyruvate dehydroge
kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); RPLP0 ribosomal protein, large, P0.  
 
Substrates could interfere with glucose disposal in skeletal muscle (20-22).  In vivo, release 
and/or intermediate products of lipid fuels (fatty acids and ketone bodies, respectively) released 
into the circulation (e.g. in starvation or diabetes) may inhibit the catabolism of glucose in 
muscle, as well as its storage (8, 23). 
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 4.2.A), fatty acid flux through the muscle is by necessity increased in these subjects as 
demonstrated by a decrease in 24h respiratory quotient (RQ; Figure 4.2.B) to match the fat 
 
 
ffect of a 21–day ad libitum feeding of a high fat/low carbohydrate diet (45% : 35%) in a 
ohort of C57Bl/6J mice (control, n=6; HF/LCD, n=7) on genes involved in glucose oxidation 
FKFB3 and PDK4) and glucose storage (GYS1 and GALT).  Data are shown as means ± SE 
nd corrected for the expression of Cyclophilin B. PFKFB3 fructose-2,6-biphosphatase 3; PDK4 
yruvate dehydrogenase kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); GALT 
alactose-1-phosphate uridyltransferase. 
take in this experimental paradigm (11).  Therefore, substrate utilization is shifting more 
ward oxidation of fatty acids by reducing the oxidation of glucose; the uptake and utilization of 
lucose should consequently be reduced.  A negative carbohydrate balance occurs immediately 
 
 
 
 
 
 
 
 
Figure 4.3.B HF/LCD regulates mRNA for genes involved in glucose metabolism in mice. 
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after consumption (one to two days) of a HF/LCD indicating a continued glucose oxidation and  
glycogen depletion as fat oxidation takes days to catch up to fat intake (31, 36).  A positive  
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 carbohydrate (CHO) balance was observed at the end of the three-day HF/LCD in this cohort of 
healthy young males, thus indicating a decrease in glucose oxidation (Table 4.1).  We also 
 
 
 
 
 
 
igure 4.4 Transcriptional regulation of glucose flux. Upon entry into the muscle cell, glucose 
e TCA cycle or it can be stored as glycogen and 
alactose via non-oxidative glucose metabolism.  The 9 genes that were altered by a three-day 
F/LCD in human skeletal muscle according to low laser microarray analysis are marked blue if 
downregulated and red if upregulated. PFKFB3 fructose-2,6-biphosphatase 3; PDK4 pyruvate 
ehydrogenase kinase, isoenzyme 4; GYS1 glycogen synthase 1 (muscle); GALT galactose-1-
phosphate uridyltransferase; PDHB pyruvate dehydrogenase, beta subunit; UGP2 UDP-glucose 
yrophosphorylase 3; MAP2K3 mitogen-activated protein kinase kinase 3; FBP1 fructose-1,6-
biphosphatase; HK hexokinase; PFK phosphofructokinase. 
bserved a decrease in the messenger RNA levels of a number of genes involved in the 
tive, glucose metabolism.  Even more striking is the matching 
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oxidative, as well as the non-oxida
murine data showing a greater magnitude of change with a longer exposure to a high fat/low 
carbohydrate diet (three days versus three weeks).  The extent of the effects of high fat/low 
carbohydrate dietary intake on muscle glucose metabolism reflects the length of each model’s 
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 exposure to the diet.  For example, the human cohort responded with about a 30% change in 
ene expression after three days of high fat/low carbohydrate diet; whereas, the murine model had 
e 
A variety of model systems have largely confirmed the validity of Randle’s experiments 
depicting the mechanism of substrate competition through changes in enzymatic activity as a 
result of product feedback inhibition, at least in terms of the acute effects of fatty acids on muscle 
e
take is increased and carbohydrate intake is decreased.  Our findings relate to changes in 
RNA expression only, and we acknowledge that many of the enzymes involved in glycolysis 
nd glycogen synthesis are regulated allosterically, and through covalent modification.  
ranscriptional regulation (Figure 4.4) may enhance the Randle cycle or changes in the 
ctivation of signaling molecules / pathways such as PKC or ceramides (8, 21).   
Through the use of bioinformatics and microarrays, we expand the view of the glucose-
tty acid cycle beyond enzymatic activity to the level of gene transcription.  In  
ur analyses of the low laser microarray data set (Appendix A.2 and Appendix A.4), we found 
g
about a 70% change in gene expression with three weeks of exposure.  These results indicat
that the effects of the HF/LCD are not transient.  Even more compelling is the concurrent 
change in phenotype, such as decreased RQ (Figure 4.2.B), positive CHO balance (Table 4.1) 
and the changes in the genes controlling glucose metabolism in response to the perturbation of 
this diet (Table 4.2). 
glucose metabolism and storage (24, 25).  Our results supplement those of Randle by 
d monstrating a downregulation of genes involved in glucose oxidation and storage when fat 
in
m
a
T
a
fa
o
over 300 genes regulated by a three-day high fat/low carbohydrate diet in our human subjects.  
Four of our glucose metabolism genes (PFKFB3, PDK4, PDHB and GALT) were found in the 
analyses, and two of the four genes were confirmed by qRT-PCR.  This is consistent with the 
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 noise inherent to current microarray technologies (26, 27).  After reporting changes in 
expression of the genes in the glucose metabolism gene cluster, we are left with the question of 
how the macronutrient composition of the diet affects other genes.  The HF/LCD significantly 
metabolism and various other genes known and unknown (Appendix A.2 and Appendix A.4). 
in OXPHOS genes and the carbohydrate metabolism genes described herein are involved in a 
m 
remains unknown.  It has been suggested that PGC1α plays a pivotal role as a link between a 
high fat diet and oxidative phosphorylation (87).  Furthermore, the implication that both 
OXPHOS and carbohydrate metabolism genes are regulated at the transcriptional level is 
important for two reasons: (1) the unidentified transcriptional control system may be a ‘master 
regulator’ of energy homeostasis for both glucose and mitochondria and (2) strategies to identify 
the key regulators of this system should include both subsets of these genes. 
Consonant with recent evidence by Pehleman et al (28) demonstrating the enzymatic 
regulation of glucose disposal in human skeletal muscle after a high fat/low carbohydrate diet, 
our results expand this view to a transcriptional co-regulation of glucose metabolism in this same 
tissue, as well as murine skeletal muscle after a high fat/low carbohydrate diet.  Pehleman et al 
found a dramatic decrease in the activity of pyruvate dehydrogenase (PDH) with a concomitant 
increase in the enzymatic activity of PDH kinase (PDK) in response to a 56h eucaloric high 
fat/low carbohydrate diet (73% : 5%) within a healthy human cohort of insulin-sensitive males.  
While our results are not as dramatic, probably due to difference in dietary fat/carbohydrate 
regulated the expression of many OXPHOS genes, a few genes involved in fatty acid 
Recent studies suggest that both acute and chronic increases in fatty acids downregulate 
oxidative phosphorylation in skeletal muscle (10, 23).  Cluster analysis suggests that the changes 
long-term transcriptional loop; however, the identity of the overall transcriptional control syste
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 content (50% : 34% vs. 73% : 5%), we do show the same effects on PDK at the level of 
transcription.  Together, our results identify both enzymatic activity and gene expression as 
targets 
 kinase 4 
on 
s 
ic 
2, 35, 
(2) inhi
his 
lar 
ch to regulate 
of the transcriptional regulation.  
Several studies over the past decade have shown pyruvate dehydrogenase
(PDK4) message, protein and activity decrease as a result of increased free fatty acids, starvati
and diabetes (30-32).  More recently, PDK4 has become the target of diabetic drug investigation
(33, 34).  PDK4 promotes gluconeogenesis and suppresses glucose oxidation and maintains 
glucose levels in starvation.  Although prior studies bolster the credibility of PDK4 as a diabet
drug target, our result argues against this view.  We demonstrate that while glucose oxidation is 
suppressed, the transcription of genes before and after PDK4 is downregulated by HFD.  Thus, 
the inactivation of PDK4 might not be effective in the setting of HFD / ‘lipotoxicity’. 
The original studies which formed the basis of the glucose-fatty acid cycle (7, 2
36) elucidated (1) fatty acid-induced desensitization of insulin-mediated glucose transport and 
bitory effects of increased fatty acid oxidation on glucose metabolism.  According to the 
Randle hypothesis (7, 24), an increase in lipid oxidation in muscle will decrease glucose 
oxidation by suppression of the mitochondrial pyruvate dehydrogenase complex, with a 
consequential reduction of glycolytic flux resulting in an increase in glucose-6-phosphate, 
inhibition of hexokinase activity and ultimately leading to decreased glucose uptake.  Non-
oxidative metabolism (storage) of glucose is, therefore, also predicted to be decreased.  T
mechanism has been reexamined and evolved over the past few decades (37), but the cellu
effect is consistently observed.  Differences in glucose-6-phosphate levels and mechanisms 
aside, a consistently observed effect of increased fat intake is the reduction of non-oxidative 
glucose metabolism (38).  This data provides a basis for a transcriptional swit
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 substra t 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
te utilization within the skeletal muscle in response to changes in dietary macronutrien
content.  Overall, the novel contribution of this paper is its identification of multiple regulated 
genes within the same pathway by high fat/low carbohydrate diet. 
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 CHAPTER 5:  A ROLE FOR ADIPOSE TISSUE INFLAMMATION IN METAB
 
 
OLIC 
INFLEXIBILITY 
5.1 Introduction 
A key feature of the Type 2 diabetes (T2D) is metabolic inflexibility, which is
characterized by impaired fasting fat oxidation and decreased insulin-stimulated glucose 
oxidation.  Metabolic inflexibility is defined as an inability to transition between the utilization 
of lipids (fasting) and carbohydrates (after a meal).  In obese individuals key features of 
metabolic inflexibility are (1) failure of skeletal muscle to appropriately move between use of 
lipid in the fasting state and use of carbohydrate in the insulin-stimulated state and (2) impaired 
transitioning from fatty acid efflux to storage (71).  Obesity, hyperglycemia, impaired insulin 
stimulation of skeletal muscle glucose uptake (141), impaired mitochondrial biogenesis and 
decreased capacity for oxidation of dietary fat are all involved in the state of metabolic 
inflexibility (72).  Furthermore, these physiologic characteristics are enriched in healthy young 
men with a family history of Type 2 diabetes (Ukropcova, B; in review).   
White adipose tissue (WAT) is a major site of energy storage and is important for energy 
homeostasis: it stores energy in the form of triglycerides during nutritional abundance and 
releases energy as FFAs during nutritional deprivation (142; 143).  While WAT provides a 
survival advantage in times of starvation, excess WAT and adipocyte hypertrophy are now 
linked to obesity-related health problems in the current nutritionally rich environments of 
developed countries.  Furthermore, while adipoc es are traditionally known as a fat storage 
depot, they have recently been recognized as an endocrine organ that secretes hormones and 
cytokines as a metabolic response.  Increased basal/fasted lipolysis in white adipose tissue leads 
to increased fasting FFA levels, which have been inked to insulin resistance (57).  Increased 
chemotaxis and macrophage content in WAT are hese 
yt
 l
 characteristics of the obese state.  T
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 disturbances make the dysfunctional adipocyte a potential upstream ‘causal’ factor in metabolic 
inflexibility.   
Taken together, this suggests that the quantity (body fatness) and the characteristics of the 
adipose tissue (adipocyte hypertrophy, disordered lipid metabolism, inflammation) might 
contribute to metabolic inflexibility.  To explore this hypothesis, we studied 56 healthy young 
men under carefully controlled conditions, exam ing how adipose tissue mass and quality 
influence metabolic flexibility during a euglycem ic clamp. 
5.2 Results 
Subject characteristics are liste bjects were healthy young males 
MI and percent body fat (20.1 – 34.7 kg/m2 and 8.4 – 32.3 %, respectively).  
The res mic 
 
B).  
m, 
c 
 were associated with 
a lower
in
ic-hyperinsulinem
d in Table 5.1.  All su
ranging widely in B
piratory quotient was measured before and during the euglycemic-hyperinsuline
clamp (EHC) to determine metabolic flexibility (∆RQ).  ∆RQ varied greatly ranging from
inflexible to flexible (0.03 – 0.25).  Lower ∆RQ was associated with higher percent body fat 
(ANOVA, p < 0.05; Figure 5.1.A) and larger fat cell size (ANOVA, p = 0.05; Figure 5.1.
Lower serum adiponectin levels were associated with lower ∆RQ (ANOVA, p < 0.05; Figure 
5.1.C). 
Obesity and hypertrophic adipocytes are associated with increased fasting FFAs and 
insulin-resistant adipocytes.  To determine the contribution of disturbances in lipid metabolis
we explored the relationship between fasting and insulin-suppressed FFAs and metaboli
flexibility.  ∆RQ was not related to fasting FFAs (ANOVA, p > 0.05; Figure 5.1.D); however, 
higher concentrations of insulin-suppressed FFAs after a 2h insulin infusion
 ∆RQ (ANOVA, p < 0.05; Figure 5.1.E).  Fat cell size (FCS) was positively correlated 
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 with fasting and insulin-suppressed free fatty acids (FFAs) during euglycemic-hyperinsulin
clamp (EHC) (data not shown). 
Table 5.1 Characteristics of the study population. All male subjects were chosen fro
2
BMI, body mass index; GDR, glucose disposal rate; WHR, waist to hip ratio; FFA, f
 
 
 
 
 
 
 
emic 
m the 
larger mixed gender study population. *during insulin infusion (80mIU/m BSA/min). 
ree 
fatty acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nd 
d 
on 
 
(FFAs) and metabolic flexibility (change in respiratory quotient; ∆RQ) (Table 5.2).  Insulin-
suppressed FFAs were significantly correlated with the expression of genes involved in 
Subject Characteristics Mean ± SD Range
Age (y) 22.6 ± 3.2 18.0 – 29.0
Height (cm) 176.9 ± 5.8 163.0 – 189.5
BMI (kg/m²) 26.4 ± 4.1 20.1 – 34.7
Body Fat (%) 20.3 ± 6.5 8.4 – 32.3
Visceral a
Fasting RQ (au
 
 
 
 
 
 
 
 
 
Given the relationship between adipocyte hypertrophy, disordered lipid metabolism a
metabolic inflexibility, we examined mRNA expression of candidate genes involved in lipi
metabolism (lipid synthesis, uptake, oxidation and storage, as well as lipolysis) and inflammati
(chemokines and macrophage markers) and related these to insulin-suppressed free fatty acids
Weight (kg)     82.5 ± 13.2 59.2 – 118.3
WHR (au)     0.87 ± 0.07 0.7 – 1.0
dipose tissue mass (kg) 2.1 ± 1.3 0.5 – 5.7
)     0.84 ± 0.04 0.74 – 0.95
Ste
∆RQ (au) 0.07 ± 0.15 -0.96 – 0.25
Fasting Glucose (mg/dl) 80.5 ± 5.4 66.0 – 90.0
 – 3.5
GDR (mg/kgFFM/min) 11.1 ± 4.1 4.0 – 24.5
FFA (mmol) 0.6 ± 0.2 0.07 – 0.84
Steady State* FFA (mmol) 0.05 ± 0.02 0.02 – 0.16
Fat
ady State* RQ (au)     0.93 ± 0.04 0.85 – 1.03
VO2max (ml/kg/min) 41.2 ± 7.2 23.5 – 59.2
Steady State* Glucose (mg/dl) 89.02 ± 4.5 78.0 – 102.0
Fasting Insulin (µU/ml) 8.2 ± 4.6 2.6 – 22.4
Steady State* Insulin (µU/ml)  160.1 ± 35.7 103.9 – 251.3
C-peptide (ng/ml) 1.93 ± 0.70 0.9
Fasting 
 cell size (µl) 0.6 ± 0.2 0.22 – 0.95
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) 
in healthy young men. Change in respiratory quotient (∆RQ; metabolic flexibility) was 
d before and during a euglycemic-hyperinsulinemic clamp (EHC) in the population of 56 
healthy young men.  ∆RQ was subdivided into quartiles and correlated with clinical 
measur ell 
size (B).  Lower serum adiponectin levels were associated with lower ∆RQ (C).  Lower ∆RQ 
associated with higher levels of insulin-suppressed FFAs during steady state of the EHC (E) as 
 for 
differences in biopsy and blood parameters across quartiles of metabolic flexibility (∆RQ), with 
HSD; alpha = 0.05.  Type I error rate was set a priori at p < 0.05.  Data are shown as means +
Figure 5.1 Body fatness, FFAs, and adiponectin are related to metabolic inflexibility (∆RQ
measure
ements.  Lower ∆RQ was associated with higher percent body fat (A), and larger fat c
was not related to fasting FFAs as measured by enzyme assay (D); however, lower ∆RQ was 
measured by high performance liquid chromatography (HPLC).  ANOVA was used to test
post-hoc testing by mean equality contrast between different groups using the Tukey-Kramer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SE.  All Levels not connected by same letter are significantly different. 
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 chemotaxis (MCP-1 and MIP-1α) and markers of macrophage content (CD68 and MAC- 
2) (Table 5.2).   
 Metabolic flexibility (∆RQ) was negatively correlated with MCP-1, MIP-1α, 
CD68 and MAC-2 (Table 5.2).  The expressions of these four genes were highly 
Table 5.2 Relationships between adipose tissue gene expression, glucose disposal, 
fasting free fatty acids and insulin-suppressed free fatty acids (R2). All data are 
presented as R2.  *p < 0.01, **p ≤ 0.05.  § during insulin infusion 
(80mIU/m2BSA/min). GDR, glucose disposal rate; FCS, fat cells size; FFA, free 
fatty acids; ∆RQ, delta respiratory quotient; LPL, lipoprotein lipase; FAS, fatty 
acid synthase; PCK1, phosphoenolpyruvate carboxykinase 1; SCD1, stearoyl-CoA 
desaturase; MCAD, acyl-Coenzyme A dehydrogenase C-4 to C-12 straight chain; CAP, 
cbl-associated protein; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive 
lipa ; MC -1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory 
protein 1, alpha subunit. 
 
intercorrelated with R own).  FCS was positively 
correlated with th acrophage marker  
% Fa
se P
 
Functional 
Category  
Gene 
Expression 
(mRNA)   
GDR 
CD36  0.07 -0
t FCS Fasting FFAs 
Steady 
State 
FFAs§  
∆RQ 
.02 -0.01 -0.06 0.00    0.00 Lipid Uptake  LPL  0.00  0.00 0.08 -0.03 0.00  -0.06 
FAS   0.07 -0.06 -0.05 0.00 -0.13**   0.05 
PCK1  0.08 -0.07 -0.06 -0.08 0.00  0.00 
PPAR 1   0.19* -0.05 -0.05  -0.16* -0.01  0.00 Lipid Synthesis
  
PPAR 2  -0.02  0.06  0.05 0.04 0.00  0.01 
Lipid Storage  SCD1   0.06 -0.05 -0.01 0.00 -0.06  0.06 
MCAD    0.17*   -0.08** -0.06  -0.14** -0.01  0.01 Lipid Oxidation  PPARa    0.14**  -0.10** -0.07  -0.10** -0.01  0.00 
perilipin  0.07 -0.01  0.00 -0.02 -0.01  0.00 
CAP    0.10** -0.02  0.00 -0.03 -0.03  0.01 
ATGL     0.11** -0.02 -0.02 -0.01 -0.01  0.00 Lipolysis  
HSL   0.19*  -0.08** -0.05  -0.08** -0.03  0.00 
CD68  -0.02 0.07  0.10** 0.04 0.38*    -0.10** 
MAC -2  -0.02 0.08 0.07 0.01 0.20*    -0.10** 
MCP -1  0.00 0.04 0.04 0.01 0.23*    -0.11** Inflammation   
MIP-1a    -0.10**  0.20*  0.18*  0.10** 0.20*  -0.16* 
  
2 ranging from 0.35 – 0.78 (data not sh
e chemokine MIP-1α (data not shown) and the m
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 CD68 (data not shown).  There was no relationship between fasting FFAs and the 
he okines MCP-1 and MIP-1α; however, insulin-suppressed FFAs were positively  
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Figure 5.2 Relationships between metabolic inflexibility (∆RQ) and expressions of 
chemokines and macrophage markers. The change in respiratory quotient (∆RQ) was 
divided into quartiles and correlated with gene expressions of chemokines and 
macrophage markers in adipose tissue of 56 young healthy men.  Both MCP-1 expression 
(A) and MIP-1α expression (B) were negatively correlated with ∆RQ.  Both CD68 
expression (C) and MAC-2 expression (D) were also negatively correlated with ∆RQ.  
mRNA expression data were normalized to 18S.  Delta RQ (∆RQ) was subdivided into 
quartiles.  Data are shown as means +
c m
          B 
         
            A 
 SE.  All pairs were compared using Tukey-Kramer 
HSD, alpha = 0.05.  Levels not connected by same letter are significantly different. 
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 Figure 5.3 Oxidative and non-oxidative carbohydrate (CHO) disposal are related to 
(CHO) oxidation
metabolic inflexibility (∆RQ) in healthy young men. Higher fasting carbohydrate 
 (A) was associated with lower ∆RQ.  Lower levels of insulin-
suppressed CHO oxidation (B) and storage (C) were associated with lower ∆RQ.  Delta 
 
biopsy and blood parameters across quartiles of metabolic flexibility (∆RQ), with post-
ramer 
RQ (∆RQ) was subdivided into quartiles.  ANOVA was used to test for differences in
hoc testing by mean equality contrast between different groups using the Tukey-K
HSD; alpha = 0.05.  Type I error rate was set a priori at p < 0.05.  Data are shown as 
means + SE.  All Levels not connected by same letter are significantly different. 
were positively correlated with CD68 and MAC-2 (Table 5.2).  
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 correlated with MCP-1 and MIP-1α (Table 5.2).  There was no relationship between the 
macrophage markers CD68 and MAC-2 and fasting FFAs.  Insulin-suppressed F
We divided metabolic flexibility (∆RQ) into quartiles (quartile 1 = ∆RQ < 0.06
quartile 2 = 0.06 < ∆RQ 
FAs 
; 
< 0.08; quartile 3 = 0.08 < ∆RQ < 0.11; quartile 4 = ∆RQ > 
0.11) and compared quartiles to adipose tissue inflammatory gene expression.  The 
chemokines MCP-1 and MIP-1α were higher in inflexible subjects (lower ∆RQ) 
NOVA, p < 0.05; Figure 5.2.A and ANOVA, p < 0.05; Figure 5.2.B, respectively), as 
ere the macrophage markers CD68 and MAC-2 (ANOVA, p < 0.05; Figure 5.2.C and 
NOVA, p < 0.05; Figure 5.2.D).   
Metabolic inflexibility is described as both higher fasting glucose oxidation (high 
Q) and lower insulin-stimulated glucose oxidation (low RQ).  To explore the 
ontribution of these two possibilities, we calculated fasting glucose oxidation, as well as 
xidative and non-oxidative glucose disposal.  Lower ∆RQ (metabolic inflexibility) was 
ssociated with higher fasting carbohydrate (CHO) oxidation (ANOVA, p < 0.05; Figure 
.3.A), while lower insulin-suppressed CHO oxidation was associated with lower ∆RQ 
NOVA, p < 0.05; Figure 5.3.B).  Lower non-oxidative CHO disposal (CHO storage) 
as associated with lower ∆RQ (ANOVA, p < 0.05; Figure 5.3.C).  Upon insulin 
imulation, CHO storage was significantly greater than CHO oxidation for both flexible 
igher ∆RQ) and inflexible subjects (lower ∆RQ) (0.57 ± 0.06 vs. 0.22 ± 0.02 g/min and 
.43 ± 0.05 vs. 0.20 ± 0.01 g/min, respectively; data not shown). 
.3 Discussion 
Increased body fatness, coupled with adipocyte hypertrophy, is a determinant of 
etabolic inflexibility.  While metabolic flexibility varied greatly (0.03 – 0.25) across the 
(A
w
A
R
c
o
a
5
(A
w
st
(h
0
5
m
 65
 cohort of 56 healthy young males, those with a higher percentage of body fat and larger 
ssociated with increased free fatty acids (FFAs) and insulin-resistant adipocytes.  In the 
resent study, lower serum adiponectin levels were associated with metabolic 
flexibility.  Fat cell size (FCS) was positively correlated with fasting and insulin-
ppressed FFAs, which are essentially free fatty acid levels upon insulin stimulation 
uring steady state of a euglycemic-hyperinsulinemic clamp (EHC); however, metabolic 
flexibility was not related to fasting FFAs.  In fact, the novel finding we describe is a 
lationship between 
etabolism.  Our results revealed that higher insulin-suppressed FFAs were associated 
ith higher gene expressions of certain macrophage markers (CD68 and MAC-2) and 
hemokines (MCP-1 and MIP-1α); however, fasting FFAs were not related to any of the 
flammatory gene expressions.  Fat cell size was positively correlated with the 
acrophage CD68 and the chemokine MIP-1α.  The expressions of these mRNAs 
ggest a presence of macrophages and chemokines, as in the inflammatory state.  
urthermore, their increased expression as insulin-suppressed free fatty levels increase 
pports a relationship between macrophage infiltration and chemotaxis and a reduced 
bility of the adipose tissue to respond to insulin’s signal of lipolysis suppression.  Even  
ore striking was that mRNA expression of both the macrophage markers and the 
hemokines coordinately increased, suggesting an interdependent, and perhaps causal, 
lationship between the two groups.  Our results also revealed that metabolically 
ssions of both macrophage markers (CD68 and 
 
fat cells were more inflexible (lower ∆RQ).  Obesity and hypertrophic adipocytes are 
a
p
in
su
d
in
re metabolic inflexibility and insulin-suppressed FFAs.   
Adipocyte hypertrophy and metabolic inflexibility are also related to disordered lipid 
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inflexible subjects had higher gene expre
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 Figure 5.4 Metabolic flexibility was affected by body fatness, adipocyte 
leads to increased body fatness (%) and hypertrophic adipocytes.  Hypertrophic 
hypertrophy, chemokines and macrophage content and adiponectin. Energy excess 
adipocytes secrete chemokines and lead to macrophage infiltration.  The macrophage-
infiltra s 
well as decrease adiponectin secretion.  Elevated levels of FFAs during steady state 
ion 
of insulin-stimulated glucose uptake and oxidation in skeletal muscle and a decreased 
 
 
 
 
 
 
 
ted hypertrophic adipocytes decrease insulin stimulated suppression of lipolysis, a
(insulin infusion), coupled with decreased serum adiponectin levels, lead to an inhibit
capacity for fat oxidation.  
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 MAC-2), as well as both chemokines (MCP-1 and MIP-1α).  These relationships 
implicate adipocyte hypertrophy, increased chemokines and macrophage infiltrat
causes of an impaired insulin suppression of FFAs and metabolic inflexibility.  The 
expression of genes involved in chemotaxis and macrophage content are higher in obesity
and related metabolic disord
ion as 
 
ers (144-149).  Metabolic inflexibility is classically described 
oxidation in skeletal muscle (Figure 5.4).  This model and experimental data are 
consistent with a growing body of literature.  
For example, FFAs suppress insulin-stimulated glucose disposal.  Boden et al 
showed that FFA infusion during a clamp leads to proportional inhibitions of insulin-
stimulated glucose uptake and of intracellular glucose utilization (150).  Heilbronn et al 
has shown that administration of recombinant adiponectin in rodents increases glucose 
uptake and fat oxidation in muscle and improves whole body insulin resistance (151).  
as both higher fasting glucose oxidation (high RQ) and lower insulin-stimulated glucose 
oxidation (low RQ).  Metabolically inflexible subjects had higher fasting carbohydrate 
(CHO) oxidation and both lower insulin-stimulated CHO oxidation and storage.   
 Metabolic flexibility is affected by body fatness, adipocyte hypertrophy, 
chemokines and macrophage content.  This data is consistent with a model where energy 
excess increases body fat and adipocytes become hypertrophic.  Hypertrophic adipocytes 
secrete chemokines, such as MCP-1, that recruit macrophages, leading to macrophage 
infiltration of adipose tissue.  The macrophage-infiltrated hypertrophic adipocytes secrete 
cytokines that decrease adipocyte insulin sensitivity leading to impaired suppression of 
FFAs.  Taken together, these disturbances in adipocyte functioning lead to decreased 
insulin-stimulated glucose uptake and oxidation, as well as a decreased capacity for fat 
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 Additionally, recent studies by Civitarese et al demonstrated that low adiponectin levels 
are associated with low mitochondrial DNA (mtDNA) copy number, as well as decreased 
flammatory pathway can be a mechanism for certain obesity-related metabolic 
isorders, such as Type 2 diabetes (28).  Consequently, while there is no question that the 
flammatory pathway becomes activated in adipose tissue in various obese states, and 
at this negatively impacts insulin action in adipocytes, the total contribution of adipose 
ssue as a source of these cytokines and/or chemokines is still unclear.  In this respect, 
cent attention has focused on the potential role of macrophages in this process (153).  
eisberg et al. and Xu et al. have shown that in obesity, adipose tissue contains an 
creased number of resident macrophages and that, in some circumstances, macrophages 
an constitute up to almost half of the cell population within an adipose tissue depot (22; 
3).  Macrophages have been shown to be a potential source of secreted proinflammatory 
ctors, and these data have led to the concept that macrophages can directly influence 
dipocyte biology and ultimately lead to a state of insulin resistance.  
munohistochemical analysis from Weisberg et al. of human subcutaneous adipose 
tissue revealed that the percentage of cells expressing the macrophage antigen CD68 was 
significantly and positively correlated with both adipocyte size and body mass (22).   
Enlarged adipocytes are associated with metabolic inflexibility and are an 
independent predictor of Type 2 diabetes.  To understand the molecular link between 
these diseases and adipocyte hypertrophy, Jernas, et al. developed a technique to separate 
human adipocytes from an adipose tissue sample into populations of small cells and large 
mitochondrial functions (152).   
To date, the accepted idea has emerged that chronic activation of the 
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 cells.  They identified genes with markedly higher expression in large, compared w
small, human adipocytes, and they concluded that these genes may link hypertrophic 
obesity to Type 2 diabetes (154).  This transcriptional link between adipocyte 
hypertrophy and insulin resistance is complementary to our data showing a physiological 
link between adipocyte hypertrophy and impaired insulin suppression of lipolysis, which 
leads to metabolic inflexibility.  The risk of metabolic complication is increased not only 
by
ith 
  the amount and location of adipose tissue, but also by the size of the fat cells.  Human
fat cells can change 20-fold in diameter and several thousand-fold in volume.  Lipid 
obiliz  In 
y 
at 
ulin action in response to a 7-day reduction 
of plas y 
m ation and glucose metabolism are increased in enlarged adipocytes (155). 
contrast, the stimulating effect of insulin on the rate of glucose metabolism is inversely 
related to the size of the fat cell (156; 157).  Cytokine release within adipose tissue also 
appears to be correlated with adipocyte size (158-161), and hypertrophic adipocytes ma
contribute to lipotoxicity (162).  Thus, adipocyte hypertrophy leads to macrophage 
infiltration and chemotaxis, ultimately resulting in an impaired insulin suppression of free 
fatty acids. 
FFA levels are pivotal in complex disease states such as T2D, as well as those th
precede it, such as metabolic inflexibility.  Recent studies by Bajaj et al. (163) 
demonstrate an improvement in peripheral ins
ma FFAs in Type 2 diabetics.  Experiments by Hickner et al. (164) in which the
used a microdialysis technique to determine suppression of whole body and regional 
lipolysis by insulin in sedentary pre-menopausal women revealed a resistance to the 
suppression of lipolysis by insulin in obesity.  Correlated with intraabdominal fat mass, 
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 this impaired insulin suppression of lipolysis leads to an increase in FFA availability 
primarily in the liver and muscle, as well as other organs.   
Past studies have shown that fat infusions (163) inhibit carbohydrate metabolism.  
An imp atty acids.  
 
 as the culprit in 
r, to 
inflamm te 
aired insulin suppression of lipolysis leads to excess circulating free f
Accumulation of excess fatty acids in the form of triacylglycerol (TAG) in skeletal 
muscle and in liver is associated with metabolic inflexibility (70; 165; 166).  This 
increase in fat flux leads to ‘metabolic inflexibility’ whereby the skeletal muscle is 
unable to switch substrates from fat to carbohydrate.  The link between adipose tissue and
metabolic flexibility emphasizes the important role of adipose tissue in buffering the 
daily influx of dietary fat entering the circulation and preventing excessive exposure of 
other tissues to this fat influx.   
Body fatness, chemotaxis, macrophage infiltration and impaired insulin 
suppression of FFAs combine to contribute to a diminished capacity of substrate 
switching from that of fat oxidation to carbohydrate oxidation as measured by the change 
in respiratory quotient when infused with insulin.  Currently, the literature points the 
finger at inflammation, particularly macrophage infiltration (167-172),
obesity that eventually leads to metabolic disorders such as Type 2 diabetes.  Howeve
date no one has determined the cause.  Our study has implicated a middle man between 
metabolic disorders related to obesity, such as metabolic inflexibility and the state of 
ation—blunted insulin suppression of lipolysis, which stems from adipocy
hypertrophy. 
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 CHAPTER 6:  SUMMARY AND CONCLUSIONS 
 
6.1 Summary 
Studies have suggested that defects in the ability to switch substrate oxidation 
from fat to carbohydrate during insulin stimulation might contribute to development of 
obesity and/or the metabolic sequelae of obesity (173).  Metabolism involves the 
adaptation to both the supply and demand of energy, and this adaptability requires ‘a 
clear capacity to utilize lipid and carbohydrate fuels and to transition between them’ 
(123).  In the healthy state, this transitioning between substrates is termed ‘metabolic 
flexibility’.  However, as it always is according to the laws of the universe, this state of 
flexibility has a counterpart characterized by the body’s inability to switch substrate 
utilization under appropriate conditions.  This state is termed ‘metabolic inflexibility’.  
Increasing evidence points to metabolic inflexibility as a key dysfunction of the cluster of 
disease states that contribute to the metabolic syndrome, such as Type 2 diabetes.  Two 
main features of metabolic inflexibility are:  (1) failure of skeletal muscle to 
appropriately switch between the use of lipid in the fasting state and use of carbohydrate 
upon insulin stimulation and (2) an impaired transition from fatty acid efflux to storage in 
response to a meal.  The reduced ability to metabolize fuel, such as oxidative 
phosphorylation in the electron transport chain in skeletal muscle, is indicated by reduced 
mitochondrial size and function, and it is characteristic of metabolic inflexibility (70; 
123).  
Our studies on the effects of an acute high fat diet (HFD) in a population of young 
healthy males and mice demonstrated that substrate switching in skeletal muscle occurs 
via classic endocrine/physiologic systems, as well as at the transcriptional level.  
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 Importantly, there were no changes in fasting glucose, insulin and free fatty acids afte
the diet intervention, fatty acid oxidation did increase as me
r 
asured by a decrease in 
respirat
 real 
ll as 
ly, 
of 
to man. 
ion of the 
 
 
 in 
, glucose metabolism.  Furthermore, the analogous murine experiment 
howed a similar effect (albeit with a greater magnitude of change). 
ory quotient (RQ).  Using oligonucleotide microarray technology, we found that 
about 300 genes were regulated by the three-day high fat diet in the skeletal muscle of 
healthy young men.  The first part of the microarray analysis, along with quantitative
time RT-PCR, revealed a downregulation of OXPHOS genes after the HFD, as we
transcription factors and cofactors involved in mitochondrial biogenesis.  Additional
we observed that the reductions in the expression of genes involved in oxidative 
phosphorylation and mitochondrial biogenesis were recapitulated in an animal model 
dietary-induced obesity and insulin resistance (134) and were of a much greater 
magnitude in mice as compared 
In the second part of the microarray analysis, we expanded the investigat
effects of an acute high fat/low carbohydrate diet (HF/LCD) to the transcriptional
responses for other metabolic systems such as carbohydrate oxidation and storage, as 
well as fatty acid oxidation.  Muscle cells adjust the fuels they oxidize and match 
substrate supply to demand.  Fuel selection shifts toward the oxidation of fatty acids and
reduces the oxidation of glucose at the transcriptional level.  A positive carbohydrate 
balance was observed at the end of the three-day HF/LCD in the cohort of the healthy 
young males, indicating a decrease in glucose oxidation.  We also observed a decrease
the messenger RNA levels of a number of genes involved in the oxidative, as well as 
non-oxidative
s
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 Increased se states such as 
Type 2 diabetes (T2D).  It has recently been shown in obesity and other complex disease 
states that there exists a resistance to suppression of lipolysis by insulin.  This trait is 
correlated with intraabdominal fat mass; furthermore, the impaired insulin suppression of 
lipolysis leads to an increase in FFA availability at the liver and muscle.  Leanness, 
insulin sensitivity and fat cell size determine metabolic flexibility, and are subsequently 
related to fasting free fatty acid (FFA) levels, as well as FFAs upon insulin infusion.  Our 
experiments revealed impaired insulin suppression of free fatty acids in a cohort of 
healthy young men during a euglycemic-hyperinsulinemic clamp (EHC).  Fat cell size 
was positively correlated with fasting and insulin-suppressed FFAs, as well as expression 
of macrophage markers and chemokines.  Gene expression of macrophage markers 
(CD68 and MAC-2) and chemokines (MCP-1 and MIP-1α) was positively correlated 
with insulin-suppressed FFAs.  Even more striking was that the expression of both the 
macrophage markers and the chemokines was coordinately increased.  One novel aspect 
of this work was the negative correlation between insulin-suppressed FFAs and glucose 
disposal rate (GDR), as well as fat cell size, chemokines and markers of macrophage 
content.  Interestingly, we observed a consistent negative correlation between “metabolic 
flexibility” as measured by the change in respiratory quotient (RQ) and several adipose 
tissue parameters such as percent body fat, fat cell size, insulin suppression of FFAs and 
expression of chemokines and macrophage markers.  Not only did we demonstrate the 
expected relationships among adipocyte hypertrophy and glucose disposal, but we 
revealed a consequence of adipocyte hypertrophy, increased expression of macrophage 
markers and chemokines and subsequent impaired insulin suppression of lipolysis. 
 free fatty acid (FFA) levels are pivotal in complex disea
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 6.2 Conclusions 
 The link between obesity and insulin resistance has been recognized for man
years.  In the past several years, evidence that a disturbance in muscle lipid oxidative 
capacity results in the accumulation of the lipid intermediates that interfere with insulin
signaling and ultimately inhibit insulin-mediated glucose uptake and subsequent 
metabolism.  Underlying mechanisms for disturbed fatty acid handling may relate to 
impaired adipose tissue lipolysis and a reduced ability to oxidize fat.  Many of these 
abnormalities have been reported both in the obese and Type 2 diabetics (174-176
Increased free fatty acid (FFA) flux from adipose tissue to non-adipose tissue is at the 
heart of many metabolic disturbances characteristic of insulin resistance and Typ
diabetes. 
y 
 
).  
e 2 
ins and 
and the 
 
ovel 
ity that is seen in 
aging, obesity, insulin resistance and Type 2 diabetes. 
It has been purported that high fat diets and/or high fat flux through the 
mitochondria reduce the expression of nuclear genes encoding mitochondrial prote
transcription factors involved in mitochondrial biogenesis.  Our data support this 
hypothesis.  Previous studies suggest a link between the downregulation of PGC1 
dysregulation of OXPHOS genes.  Our results are consistent with this sequence of events,
and indeed three of our OXPHOS genes were also present in analyses by Patti and 
Mootha (83; 84).  We also move our view upstream, beyond the relationship between 
PGC1 and OXPHOS genes.  We showed an increased fatty acid flux through the 
mitochondria decreases PGC1 expression and is associated with a downregulation of 
expression of genes involved in oxidative phosphorylation.  Our studies support the n
hypothesis that high fat diets explain the reduction in oxidative capac
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 The acute effects of fatty acids on glucose metabolism and storage have been 
shown enzymatically; however, our studies supplement these effects by demonstrating a 
downregulation of genes involved in glucose oxidation and storage when fat intake is 
increased and carbohydrate intake is decreased.  Therefore, we expand the view of the 
‘glucose-fatty acid cycle’ beyond enzymatic activity to the transcriptional level.  Ove
our identification of multiple regulated genes within the same pathway by a high fat/low 
carbohydrate diet is novel. 
Adipose tissue in obesity becomes noncompliant to suppression of fat 
mobilization, i.e. lipolysis, by insulin, and also to the normal insulin-stimulated fat 
storage by activation of lipoprotein lipase.  The net effect is “full” adipocytes that are 
unable to store more fat; thus, in the post-prandial state after a meal, there is an exce
flux of lipid that would normally have been absorbed by the adipose tissue.  This 
situation leads to fat deposition in other tissues.  Accumulation of triacylglycerol in 
skeletal muscle and in liver is associated with insulin resistance.  Furthermore, this 
increase in fat flux leads to ‘metabolic inflexibility’ in whereby the skeletal muscle is 
unable to switch substrates from fat to carbohydrate.  The link between adipose tissue
insulin resistance and metabolic flexibility emphasizes the important role of adipose 
tissue in buffering the daily influx of dietary fat entering the circulation and preventing 
excessive exposure of other tissues to this influx.  Our studies have demonstrated a 
physiological relationship among adipocyte hypertrophy, impaired insulin suppression o
adipose tissue lipolysis and glucose disposal in skeletal muscle.  We also revealed a
transcriptional level an increase in macrophage markers and chemokines.  These data 
rall, 
ss 
 and 
f 
t the 
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 suggest an infiltration of macrophages and chemotaxis leads to the state of inflammation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
present in obesity and its related metabolic disorders, such as metabolic inflexibility. 
 
  
 
 78
 LITERATURE CITED 
1. Obesity and overweight.  
http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/. World Health 
urtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence 
 the United States, 1999-2004. Jama 295:1549-1555, 2006 
4. Campbell BC, Cajigal A: Diabetes: energetics, development and human evolution. 
5. Hales CN, Barker DJ: Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty 
 in 
es 
8. Klein S: The case of visceral fat: argument for the defense. J Clin Invest 113:1530-
9. Armstrong EJ, Morrow DA, Sabatine MS: Inflammatory biomarkers in acute coronary 
11. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis 
factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993 
Organization, 2006 
2. Finkelstein EA, Fiebelkorn IC, Wang G: National medical spending attributable to 
overweight and obesity: how much, and who's paying? Health Aff (Millwood) Suppl Web 
Exclusives:W3-219-226, 2003 
3. Ogden CL, Carroll MD, C
of overweight and obesity in
Med Hypotheses 57:64-67, 2001 
phenotype hypothesis. Diabetologia 35:595-601, 1992 
6. Weyer C, Vozarova B, Ravussin E, Tataranni PA: Changes in energy metabolism
response to 48 h of overfeeding and fasting in Caucasians and Pima Indians. Int J Ob
Relat Metab Disord 25:593-600, 2001 
7. Kissebah AH: Insulin resistance in visceral obesity. Int J Obes 15 Suppl 2:109-115, 
1991 
1532, 2004 
syndromes: part I: introduction and cytokines. Circulation 113:e72-75, 2006 
10. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose 
tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. 
J Clin Invest 95:2409-2415, 1995 
 79
 12. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor 
J Physiol Endocrinol Metab 280:E745-751, 2001 
necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am 
13. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor alpha: a key component of 
etes link. Diabetes 43:1271-1278, 1994 
4. Pat n JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, 
Grunfeld C: Interferons and tumor necrosis factors have similar catabolic effects on 3T3 
L1 cells. Proc Natl Acad Sci U S A 83:8313-8317, 1986 
15. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-
induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614, 
1997 
16. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein 
similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995 
17. Pajvani UB, Scherer PE: Adiponectin: systemic contributor to insulin sensitivity. 
Curr Diab Rep 3:207-213, 2003 
18. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, 
Brownlee M, Scherer PE: Structure-function studies of the adipocyte-secreted hormone 
Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 
278:9073-9085, 2003 
19. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, 
Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino 
Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced 
insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002 
20. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, 
Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa 
K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: 
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic 
patient Arterioscler Thromb Vasc Biol 20:1595-1599, 2000 
21. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G: Adiponectin 
expression from human adipose tissue: relation to obesity, insulin resistance, and tumor 
necrosis factor-alpha expression. Diabetes 52:1779-1785, 2003 
the obesity-diab
1 to
s. 
 80
 22. Weisberg SP, McCann D, D ibel RL, Ferrante AW, Jr.: 
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 
23. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, 
Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the 
nduced inflammatory changes in adipose 
tissue. J Clin Invest 112:1785-1788, 2003 
25. Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349-
356, 2001 
, Chung YJ, Penner KM, Pestka JJ, North CM, 
Claycombe KJ: Expression of interleukin-6 is greater in preadipocytes than in adipocytes 
27. Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, 
sulin resistance, and reduction by pioglitazone. 
Diabetes 54:2305-2313, 2005 
ellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 
115:1111-1119, 2005 
o RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of 
insulin on the disposal of intravenous glucose. Results from indirect calorimetry and 
30. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, 
31. Lithell H, Lindgarde F, Hellsing K, Lundqvist G, Nygaard E, Vessby B, Saltin B: 
esai M, Rosenbaum M, Le
112:1796-1808, 2003 
development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003 
24. Wellen KE, Hotamisligil GS: Obesity-i
26. Harkins JM, Moustaid-Moussa N
of 3T3-L1 cells and C57BL/6J and ob/ob mice. J Nutr 134:2673-2677, 2004 
Ranganathan G, Peterson CA, McGehee RE, Kern PA: Expression of CD68 and 
macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: 
association with cytokine expression, in
28. W
29. DeFronz
hepatic and femoral venous catheterization. Diabetes 30:1000-1007, 1981 
Christin L, Secomb TW, Bogardus C: Skeletal muscle capillary density and fiber type are 
possible determinants of in vivo insulin resistance in man. J Clin Invest 80:415-424, 1987 
Body weight, skeletal muscle morphology, and enzyme activities in relation to fasting 
serum insulin concentration and glucose tolerance in 48-year-old men. Diabetes 30:19-
25, 1981 
 81
 32. Simoneau JA, Colberg SR, Thaete FL, Kelley DE: Skeletal muscle glycolytic and
oxidative enzyme capacities are determinants of insulin sensitivity and muscle 
composition in obese women. Faseb J 9:273-278, 
 
1995 
l Physiol 83:166-171, 1997 
ibution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930-934, 
2005 
Diabetes 37:1595-1607, 1988 
cations of NMR spectroscopy to study muscle glycogen 
metabolism in man. Annu Rev Med 50:277-290, 1999 
39. Felig P, Marliss E, Cahill GF, Jr.: Plasma amino acid levels and insulin secretion in 
Biden TJ, Kraegen EW: 
Muscle lipid accumulation and protein kinase C activation in the insulin-resistant 
33. Simoneau JA, Kelley DE: Altered glycolytic and oxidative capacities of skeletal 
muscle contribute to insulin resistance in NIDDM. J App
34. Kern PA, Simsolo RB, Fournier M: Effect of weight loss on muscle fiber type, fiber 
size, capillarity, and succinate dehydrogenase activity in humans. J Clin Endocrinol 
Metab 84:4185-4190, 1999 
35. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA: 
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and 
redistr
36. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. 
37. Roden M, Shulman GI: Appli
38. Felber JP, Golay A: Pathways from obesity to diabetes. Int J Obes Relat Metab 
Disord 26 Suppl 2:S39-45, 2002 
obesity. N Engl J Med 281:811-816, 1969 
40. Krebs M, Roden M: Nutrient-induced insulin resistance in human skeletal muscle. 
Curr Med Chem 11:901-908, 2004 
41. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW: The role of intramuscular 
lipid in insulin resistance. Acta Physiol Scand 178:373-383, 2003 
42. Laybutt DR, Schmitz-Peiffer C, Saha AK, Ruderman NB, 
chronically glucose-infused rat. Am J Physiol 277:E1070-1076, 1999 
 82
 43. Richter EA, Hansen BF, Hansen SA: Glucose-induced insulin resistance of skeleta
muscle glucose transport and uptake. Biochem J 252:733-737, 1988 
l-
44. Krebs HA: Metabolism of amino-acids: Deamination of amino-acids. Biochem J 
45. Waters ET FJ, Mirsky IA: Relation between carbohydrate and 3-hydroxybutyrate 
utilization by heart lung preparations. Am J Physiol 122:542-546, 1938 
 of fatty acids, ketone bodies, diabetes 
and starvation on pyruvate metabolism in rat heart and diaphragm muscle. Nature 
47. Newsholme EA, Randle PJ, Manchester KL: Inhibition of the phosphofructokinase 
. 
48. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its 
et 
e physiological role of insulin. Recent Prog Horm Res 
22:1-48, 1966 
50. Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose 
fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283, 1998 
c 
 
29:1620-1644, 1935 
46. Garland PB, Newsholme EA, Randle PJ: Effect
195:381-383, 1962 
reaction in perfused rat heart by respiration of ketone bodies, fatty acids and pyruvate
Nature 193:270-271, 1962 
role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lanc
1:785-789, 1963 
49. Randle PJ, Garland PB, Hales CN, Newsholme EA, Denton RM, Pogson CI: 
Interactions of metabolism and th
51. Frayn KN: The glucose-fatty acid cycle: a physiological perspective. Biochem So
Trans 31:1115-1119, 2003 
52. Alam N, Saggerson ED: Malonyl-CoA and the regulation of fatty acid oxidation in 
soleus muscle. Biochem J 334 ( Pt 1):233-241, 1998 
53. Kelpe CL, Moore PC, Parazzoli SD, Wicksteed B, Rhodes CJ, Poitout V: Palmitate
inhibition of insulin gene expression is mediated at the transcriptional level via ceramide 
synthesis. J Biol Chem 278:30015-30021, 2003 
 83
 54. Boden G, Chen X, Ruiz J, White JV, Rossetti L: Mechanisms of fatty acid-induced
inhibition of glucose uptake. J Clin Invest 93:2438-2446, 1994 
 
55. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA: Effect of fatty acids on glucose 
56. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ: Interaction between glucose and 
obesity and type 2 diabetes: defining their 
role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 
cGarry JD: Glucose-fatty acid interactions in health and disease.  
J Clin Invest 60:265-270, 1977 
ty acids by rat-liver microsomes. 
 106:280-290, 1965 
 J Biol Chem 265:1502-1509, 1990 
carboxylase-beta and its unique features. Proc Natl Acad Sci U S A 93:11466-11470, 
1996 
 W, Hsu M, Abu-Elheiga L, Chirala SS, 
Wakil SJ: Human fatty acid synthase: properties and molecular cloning. Proc Natl Acad 
64. Guillet-Deniau I, Pichard AL, Kone A, Esnous C, Nieruchalski M, Girard J, Prip-
l-
44, 
production and utilization in man. J Clin Invest 72:1737-1747, 1983 
free fatty acid metabolism in human skeletal muscle. J Clin Invest 92:91-98, 1993 
57. Boden G, Shulman GI: Free fatty acids in 
32 Suppl 3:14-23, 2002 
58. M Am J Clin Nutr
67:500S-504S, 1998 
59. McGarry JD, Mannaerts GP, Foster DW: A possible role for malonyl-CoA in the 
regulation of hepatic fatty acid oxidation and ketogenesis. 
60. Nugteren DH: The enzymic chain elongation of fat
Biochim Biophys Acta
61. Bianchi A, Evans JL, Iverson AJ, Nordlund AC, Watts TD, Witters LA: Identification 
of an isozymic form of acetyl-CoA carboxylase.
62. Ha J, Lee JK, Kim KS, Witters LA, Kim KH: Cloning of human acetyl-CoA 
63. Jayakumar A, Tai MH, Huang WY, al-Feel
Sci U S A 92:8695-8699, 1995 
Buus C: Glucose induces de novo lipogenesis in rat muscle satellite cells through a stero
regulatory-element-binding-protein-1c-dependent pathway. J Cell Sci 117:1937-19
2004 
 84
 65. Henriksson J: Muscle fuel selection: effect of exercise and training. Proc Nutr Soc 
54:125-138, 1995 
66. Flatt JP: Body composition, respiratory quotient, and weight maintenance. Am J C
Nutr 62:1107S-1117S
lin 
, 1995 
Am 
69. Andres R, Cader G, Zierler KL: The quantitatively minor role of carbohydrate in 
of 
6 
71. Storlien L, Oakes ND, Kelley DE: Metabolic flexibility. Proc Nutr Soc 63:363-368, 
ith SR: 
Dynamic changes in fat oxidation in human primary myocytes mirror metabolic 
73. DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A 
74. Lillioja S, Bogardus C, Mott DM, Kennedy AL, Knowler WC, Howard BV: 
67. Flatt JP: McCollum Award Lecture, 1995: diet, lifestyle, and weight maintenance. 
J Clin Nutr 62:820-836, 1995 
68. Flatt JP: Use and storage of carbohydrate and fat. Am J Clin Nutr 61:952S-959S, 
1995 
oxidative metabolism by skeletal muscle in intact man in the basal state; measurements 
oxygen and glucose uptake and carbon dioxide and lactate production in the forearm. J 
Clin Invest 35:671-682, 195
70. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin 
resistance: a reexamination. Diabetes 49:677-683, 2000 
2004 
72. Ukropcova B, McNeil M, Sereda O, de Jonge L, Xie H, Bray GA, Sm
characteristics of the donor. J Clin Invest 115:1934-1941, 2005 
collusion responsible for NIDDM. Diabetes 37:667-687, 1988 
Relationship between insulin-mediated glucose disposal and lipid metabolism in man. J 
Clin Invest 75:1106-1115, 1985 
75. Kelley DE, Reilly JP, Veneman T, Mandarino LJ: Effects of insulin on skeletal 
muscle glucose storage, oxidation, and glycolysis in humans. Am J Physiol 258:E923-
929, 1990 
 85
 76. Colberg SR, Simoneau JA, Thaete FL, Kelley DE: Skeletal muscle utilization of free
fatty acids in women with visceral obesity. J Clin Invest 95:1846
 
-1853, 1995 
 1994 
52:2191-2197, 2003 
scle of postobese women. Am J Physiol 275:E487-494, 1998 
 
keletal muscle: relation to insulin resistance and obesity and effects 
of weight loss. Faseb J 13:2051-2060, 1999 
metabolism in nondiabetic control and NIDDM subjects. Comparison using human 
Diabetes
82. Gaster M, Rustan AC, Aas V, Beck-Nielsen H: Reduced lipid oxidation in skeletal 
, 
er 
op LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are 
coordinately downregulated in human diabetes. Nat Genet 34:267-273, 2003 
 
aker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, 
Kahn CR, Mandarino LJ: Coordinated reduction of genes of oxidative metabolism in 
tersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, 
Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin 
resistance. Science 300:1140-1142, 2003 
77. Kelley DE, Simoneau JA: Impaired free fatty acid utilization by skeletal muscle in 
non-insulin-dependent diabetes mellitus. J Clin Invest 94:2349-2356,
78. Goodpaster BH, Katsiaras A, Kelley DE: Enhanced fat oxidation through physical 
activity is associated with improvements in insulin sensitivity in obesity. Diabetes 
79. Raben A, Mygind E, Astrup A: Lower activity of oxidative key enzymes and smaller 
fiber areas in skeletal mu
80. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE: Markers of capacity to utilize
fatty acids in human s
81. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP: Insulin action and glucose 
skeletal muscle cell cultures.  44:936-946, 1995 
muscle from type 2 diabetic subjects may be of genetic origin: evidence from cultured 
myotubes. Diabetes 53:542-548, 2004 
83. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, 
Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N
Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshul
D, Gro
84. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane
I, Costello M, Saccone R, Land
humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl 
Acad Sci U S A 100:8466-8471, 2003 
85. Pe
 86
 86. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial 
activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 
350:664-671, 2004 
 RA, Mynatt RL, Hulver MW, Bray G, Smith SR: A 
High-Fat Diet Coordinately Downregulates Genes Required for Mitochondrial 
. Diabetes : , 
88. Wisloff U, Najjar SM, Ellingsen O, Haram PM, Swoap S, Al-Share Q, Fernstrom M, 
 
90. Smith SR, de Jonge L, Zachwieja JJ, Roy H, Nguyen T, Rood J, Windhauser M, 
91. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW an 
d 
S A 93:10614-10619, 1996 
f 
98 
93. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, 
nts]. Nat Med 4:844-847, 
1998 
n CJ, Shoulders CC, Graf D, St. Lezin E, Kurtz TW, 
Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J: Identification of 
95. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, 
Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, 
87. Sparks LM, Xie H, Koza
Oxidative Phosphorylation in Skeletal Muscle 54 1926-1933 2005 
Rezaei K, Lee SJ, Koch LG, Britton SL: Cardiovascular risk factors emerge after 
artificial selection for low aerobic capacity. Science 307:418-420, 2005 
89. Zurlo F, Nemeth PM, Choksi RM, Sesodia S, Ravussin E: Whole-body energy 
metabolism and skeletal muscle biochemical characteristics. Metabolism 43:481-486,
1994 
Volaufova J, Bray GA: Concurrent physical activity increases fat oxidation during the 
shift to a high-fat diet. Am J Clin Nutr 72:131-138, 2000 
: Parallel hum
genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Aca
Sci U 
92. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display o
genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 19
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-
throughput molecular profiling of tumor specimens [see comme
94. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-
Majali KM, Trembling PM, Man
Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose 
metabolism in hypertensive rats [see comments]. Nat Genet 21:76-83, 1999 
 87
 Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, 
Armitage JO, Warnke R, Staudt LM, et al.: Distinct types of diffuse large B-cell 
lymphoma identified by gene expression profiling [see comments]. Nature 403:503-511, 
96. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Jr., 
Haussler D: Knowledge-based analysis of microarray gene expression data by using 
97. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JCF, Trent JM, Staudt LM, 
, 1999 
 
g 
 
array 
102. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, 
 L, Albu JB, Kelley DE, Ravussin E, Smith SR: 
Relationship between serum resistin concentrations and insulin resistance in nonobese, 
obese, and obese diabetic subjects. J Clin Endocrinol Metab 89:1844-1848, 2004 
2000 
support vector machines. Proc Natl Acad Sci U S A 97:262-267, 2000 
Hudson J, Jr., Boguski MS, Lashkari D, Shalon D, Botstein D, Brown PO: The 
transcriptional program in the response of human fibroblasts to serum [see comments]. 
Science 283:83-87, 1999 
98. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, 
Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes 
using cDNA microarrays. Nat Genet 23:41-46
99. Srivastava M, Eidelman O, Pollard HB: Pharmacogenomics of the cystic fibrosis
transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX usin
genome microarray analysis. Mol Med 5:753-767, 1999 
100. Diehn M, Eisen MB, Botstein D, Brown PO: Large-scale identification of secreted
and membrane-associated gene products using DNA microarrays. Nat Genet 25:58-62, 
2000 
101. Lee ML, Kuo FC, Whitmore GA, Sklar J: Importance of replication in micro
gene expression studies: statistical methods and evidence from repetitive cDNA 
hybridizations. Proc Natl Acad Sci U S A 97:9834-9839, 2000 
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, 
Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human 
breast tumours. Nature 406:747-752, 2000 
103. Heilbronn LK, Rood J, Janderova
 88
 104. Carter H, Jones AM, Barstow TJ, Burnley M, Williams CA, Doust JH: Oxygen 
uptake kinetics in treadmill running and cycle ergometry: a comparison. J Appl Physiol 
89:899-907, 2000 
105. Smith SR, Lovejoy JC, Greenway F, Ryan D, Dejonge L, De La Bretonne J, 
Volafova J, Bray GA: Contributions of total body fat, abdominal subcutaneous adipos
tissue compartments, and visceral adipose tissue to the metabolic complications of 
e 
obesity. Metabolism 50:425-435., 2001 
:99-
 for 
108. Smith SR, Xie H, Baghian S, Needham A, McNeil M, Bogacka I, Bray GA: 
 
109. Quackenbush J: Microarray data normalization and transformation. Nat Genet 32 
lizadeh A, Levy R, Staudt L, Chan WC, 
Botstein D, Brown P: 'Gene shaving' as a method for identifying distinct sets of genes 
111. Kerr MK, Churchill GA: Bootstrapping cluster analysis: assessing the reliability of 
5, 2001 
 18:207-208, 2002 
nscription 
polymerase chain reaction assays. J Mol Endocrinol 25:169-193., 2000 
106. Livesey G, Elia M: Food energy values of artificial feeds for man. Clin Nutr 4
111, 1985 
107. Miles JM, Ellman MG, McClean KL, Jensen MD: Validation of a new method
determination of free fatty acid turnover. Am J Physiol 252:E431-438, 1987 
Pioglitazone chnages the distribution of adipocyte size in type 2 diabetics. Adipocytes
2:11-22, 2006 
Suppl:496-501, 2002 
110. Hastie T, Tibshirani R, Eisen MB, A
with similar expression patterns. Genome Biol 1:RESEARCH0003, 2000 
conclusions from microarray experiments. Proc Natl Acad Sci U S A 98:8961-896
112. Sturn A, Quackenbush J, Trajanoski Z: Genesis: cluster analysis of microarray data. 
Bioinformatics
113. Kerr MK, Martin M, Churchill GA: Analysis of variance for gene expression 
microarray data. J Comput Biol 7:819-837, 2000 
114. Bustin SA: Absolute quantification of mRNA using real-time reverse tra
 89
 115. Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is th
cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19:399
116. He L, Chinnery PF, Durham
e 
8, 1991 
 SE, Blakely EL, Wardell TM, Borthwick GM, Taylor 
RW, Turnbull DM: Detection and quantification of mitochondrial DNA deletions in 
muscle types at the level of enzymatic organization. Eur J Biochem 10:198-206, 1969 
l 9:221-233, 1970 
 
121. Zimmet P: Globalization, coca-colonization and the chronic disease epidemic: can 
ccili D: Lilly lecture 2003: the struggle for mastery in insulin action: from 
triumvirate to republic. Diabetes 53:1633-1642, 2004 
n 
50, 2002 
 
individual cells by real-time PCR. Nucleic Acids Res 30:e68, 2002 
117. Bass A, Brdiczka D, Eyer P, Hofer S, Pette D: Metabolic differentiation of distinct 
118. Srere PA: An eclectic view of metabolic regulation: control of citrate synthase 
activity. Adv Enzyme Regu
119. Ritov VB, Menshikova EV, Kelley DE: High-performance liquid chromatography-
based methods of enzymatic analysis: electron transport chain activity in mitochondria 
from human skeletal muscle. Anal Biochem 333:27-38, 2004 
120. Shaw JE, Zimmet PZ, McCarty D, de Courten M: Type 2 diabetes worldwide 
according to the new classification and criteria. Diabetes Care 23 Suppl 2:B5-10, 2000
the Doomsday scenario be averted? J Intern Med 247:301-310, 2000 
122. A
123. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria i
human skeletal muscle in type 2 diabetes. Diabetes 51:2944-29
124. Puigserver P, Spiegelman BM: Peroxisome proliferator-activated receptor-gamma
coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. 
Endocr Rev 24:78-90, 2003 
125. Scarpulla RC: Nuclear activators and coactivators in mammalian mitochondrial 
biogenesis. Biochim Biophys Acta 1576:1-14, 2002 
 90
 126. Spiegelman BM, Puigserver P, Wu Z: Regulation of adipogenesis and energy 
balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 24 Suppl 4:S8-10, 
2000 
127. Meirhaeghe A, Crowley V, Lenaghan C, Lelliott C, Green K, Stewart A, Hart
Schinner S, Sethi JK, Yeo G, Brand MD, Cortright RN, O'Rahilly S, Montague C, Vidal-
Puig AJ: Characterization of the human, mouse and rat PGC1 beta (peroxisome-
proliferator-activated receptor-gamma co
 K, 
-activator 1 beta) gene in vitro and in vivo. 
Biochem J 373:155-165, 2003 
mar R, Halvatsiotis P, Schimke JC, Nair KS: Gene expression profile in 
skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51:1913-
1920, 2002 
129. McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the 
 Ravussin E: Emerging paradigms for understanding fatness and diabetes 
risk. Curr Diab Rep 2:223-230, 2002 
 BM: Dietary fat intake does affect obesity! Am J Clin Nutr 
68:1157-1173., 1998 
carbonate 
incorporation. J Biol Chem 256:8652-8657, 1981 
in human muscle. Trends Endocrinol Metab 14:393-394, 2003 
in J, Sutherland A, Petro AE, Opara EC, Kuhn CM, 
Rebuffe-Scrive M: Differential effects of fat and sucrose on the development of obesity 
Metabolism
135. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, Newgard CB, Spiegelman BM: 
128. Sreeku
etiology of type 2 diabetes. Diabetes 51:7-18, 2002 
130. Smith SR,
131. Bray GA, Popkin
132. Lipsky NG, Pedersen PL: Mitochondrial turnover in animal cells. Half-lives of 
mitochondria and mitochondrial subfractions of rat liver based on [14C]bi
133. Boirie Y: Insulin regulation of mitochondrial proteins and oxidative phosphorylation 
134. Surwit RS, Feinglos MN, Rod
and diabetes in C57BL/6J and A/J mice.  44:645-651, 1995 
Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 
1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem 278:26597-
26603, 2003 
 91
 136. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, Sihag S, Yang W, Altsh
D, Puigserver P, Patterson N, Willy PJ, Schulman IG, Heyman RA, Lander ES, 
uler 
Spiegelman BM: Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative 
137. Evans MJ, Scarpulla RC: NRF-1: a trans-activator of nuclear-encoded respiratory 
138. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti 
124, 
clamp. J Biol Chem 
278:18063-18068, 2003 
atrophying skeletal muscles: response to food deprivation. Faseb J 16:1697-1712, 2002 
metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 
142. Kahn CR: Triglycerides and toggling the tummy. Nat Genet 25:6-7, 2000 
nce. Cell 
104:531-543, 2001 
rophage infiltration in adipose tissue but not in skeletal 
muscle in severely obese subjects. Am J Physiol Endocrinol Metab 290:E961-967, 2006 
 the fire? J Clin Invest 116:33-35, 
2006 
phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U 
S A 101:6570-6575, 2004 
genes in animal cells. Genes Dev 4:1023-1034, 1990 
S, Lowell B, Scarpulla RC, Spiegelman BM: Mechanisms controlling mitochondrial 
biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115-
1999 
139. Rome S, Clement K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, Riou JP, 
Laville M, Vidal H: Microarray profiling of human skeletal muscle reveals that insulin 
regulates approximately 800 genes during a hyperinsulinemic 
140. Jagoe RT, Lecker SH, Gomes M, Goldberg AL: Patterns of gene expression in 
141. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid 
277:E1130-1141, 1999 
143. Spiegelman BM, Flier JS: Obesity and the regulation of energy bala
144. Bruun JM, Helge JW, Richelsen B, Stallknecht B: Diet and exercise reduce low-
grade inflammation and mac
145. Neels JG, Olefsky JM: Inflamed fat: what starts
 92
 146. Neels JG, Pandey M, Hotamisligil GS, Samad F: Autoamplification of tumor 
necrosis factor-alpha: a potential mechanism for the maintenance of elevated tumor 
necrosis factor-alpha in male but not female obese mice. Am J Pathol 168:435-444, 2006 
Eckel J: Monocyte chemotactic protein-1 is a 
potential player in the negative cross-talk between adipose tissue and skeletal muscle. 
149. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, 
Leibel RL, Ferrante AW, Jr.: CCR2 modulates inflammatory and metabolic effects of 
150. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with 
151. Heilbronn LK, Smith SR, Ravussin E: The insulin-sensitizing role of the fat derived 
152. Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, 
ell 
153. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R: Role of 
n 
pression. Faseb J 
20:1540-1542, 2006 
 
147. Sell H, Dietze-Schroeder D, Eckardt K, Eckel J: Cytokine secretion by human 
adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem 
Biophys Res Commun 343:700-706, 2006 
148. Sell H, Dietze-Schroeder D, Kaiser U, 
Endocrinology 147:2458-2467, 2006 
high-fat feeding. J Clin Invest 116:115-124, 2006 
non-insulin-dependent diabetes. J Clin Invest 96:1261-1268, 1995 
hormone adiponectin. Curr Pharm Des 9:1411-1418, 2003 
Ravussin E, Smith SR: Role of adiponectin in human skeletal muscle bioenergetics. C
Metab 4:75-87, 2006 
macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 
8:347-354, 2005 
154. Jernas M, Palming J, Sjoholm K, Jennische E, Svensson PA, Gabrielsson BG, Levi
M, Sjogren A, Rudemo M, Lystig TC, Carlsson B, Carlsson LM, Lonn M: Separation of 
human adipocytes by size: hypertrophic fat cells display distinct gene ex
155. Smith U: Studies of human adipose tissue in culture. I. Incorporation of glucose and
release of glycerol. Anat Rec 172:597-602, 1972 
 93
 156. Salans LB, Knittle JL, Hirsch J: The role of adipose cell size and adipose tissue 
insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Inves
165, 1968 
t 47:153-
157. Salans LB, Zarnowski MJ, Segal R: Effect of insulin upon the cellular character of 
rat adipose tissue. J Lipid Res 13:616-623, 1972 
arstedt A, Schmelz M, Yang X, 
Jansson PA, Smith U: High local concentrations and effects on differentiation implicate 
an Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, 
Arner P: Leptin secretion from subcutaneous and visceral adipose tissue in women. 
Diabetes 47:913-917, 1998 
Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral 
adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum 
003 
161. Zhang Y, Guo KY, Diaz PA, Heo M, Leibel RL: Determinants of leptin gene 
162. Lelliott C, Vidal-Puig AJ: Lipotoxicity, an imbalance between lipogenesis de novo 
4 
I, 
t of a sustained reduction in plasma free fatty acid concentration on 
intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. 
Diabetes
body and regional lipolysis by insulin: effects of obesity and exercise. J Clin Endocrinol 
165. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk 
ML, Potts JL, Hockaday TD: Adipose tissue metabolism in obesity: lipase action in vivo 
before and after a mixed meal. Metabolism 41:264-272, 1992 
158. Sopasakis VR, Sandqvist M, Gustafson B, Hamm
interleukin-6 as a paracrine regulator. Obes Res 12:454-460, 2004 
159. V
160. Winkler G, Kiss S, Keszthelyi L, Sapi Z, Ory I, Salamon F, Kovacs M, Vargha P, 
Szekeres O, Speer G, Karadi I, Sikter M, Kaszas E, Dworak O, Gero G, Cseh K: 
TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 149:129-135, 2
expression in fat depots of lean mice. Am J Physiol Regul Integr Comp Physiol 
282:R226-234, 2002 
and fatty acid oxidation. Int J Obes Relat Metab Disord 28 Suppl 4:S22-28, 200
163. Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman G
DeFronzo RA: Effec
 54:3148-3153, 2005 
164. Hickner RC, Racette SB, Binder EF, Fisher JS, Kohrt WM: Suppression of whole 
Metab 84:3886-3895, 1999 
 94
 166. Kelley DE, Goodpaster BH: Skeletal muscle triglyceride. An aspect of regiona
adiposity and insulin resistance. Diabetes Care 24:933-941, 2001 
l 
167. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, 
n of 
561, 2006 
ns are independent of type 2 diabetes or 
parameters of obesity: results from the Cooperative Health Research in the Region of 
Augsburg Survey S4 (KORA S4). Eur J Endocrinol 154:311-317, 2006 
sa K, Kitazawa R, Kitazawa S, 
Miyachi H, Maeda S, Egashira K, Kasuga M: MCP-1 contributes to macrophage 
170. Permana PA, Menge C, Reaven PD: Macrophage-secreted factors induce adipocyte 
172. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, 
Greenberg AS, Obin MS: Adipocyte death defines macrophage localization and function 
173. Zurlo F, Lillioja S, Esposito-Del Puente A, Nyomba BL, Raz I, Saad MF, Swinburn 
 disturbances in skeletal muscle fatty acid metabolism in obesity and 
type 2 diabetes mellitus. Proc Nutr Soc 63:323-330, 2004 
ation, mitochondrial 
function and fat oxidation results in ectopic fat storage, insulin resistance and type II 
diabetes mellitus. Int J Obes Relat Metab Disord 28 Suppl 4:S12-21, 2004 
Basdevant A, Hen AB, Bedossa P, Guerre-Millo M, Clement K: Increased infiltratio
macrophages in omental adipose tissue is associated with marked hepatic lesions in 
morbid human obesity. Diabetes 55:1554-1
168. Herder C, Muller-Scholze S, Rating P, Koenig W, Thorand B, Haastert B, Holle R, 
Illig T, Rathmann W, Seissler J, Wichmann HE, Kolb H: Systemic monocyte 
chemoattractant protein-1 concentratio
169. Kanda H, Tateya S, Tamori Y, Kotani K, Hia
infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin 
Invest 116:1494-1505, 2006 
inflammation and insulin resistance. Biochem Biophys Res Commun 341:507-514, 2006 
171. Virmani R, Burke AP, Kolodgie F: Morphological characteristics of coronary 
atherosclerosis in diabetes mellitus. Can J Cardiol 22 Suppl B:81B-84B, 2006 
in adipose tissue of obese mice and humans. J Lipid Res 46:2347-2355, 2005 
BA, Knowler WC, Bogardus C, Ravussin E: Low ratio of fat to carbohydrate oxidation as 
predictor of weight gain: study of 24-h RQ. Am J Physiol 259:E650-657, 1990 
174. Blaak EE: Basic
175. Heilbronn L, Smith SR, Ravussin E: Failure of fat cell prolifer
 95
 176. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 
23:201-229, 2002 
  
 96
APPENDIX A:  SUPPLEMENTAL TABLES 
 
Gene Accession number Forward primer Probe Reverse primer 
NDUFB3  NM_002491 TCAGATTGCTGTCAGACATGG Sybr Green I detection TGGTGTCCCTTCTATCTTCCA 
NDUFB5 NM_002492 TTCGACACAGTGGAGACCAT Sybr Green I detection TTCAGCTTGACCAATGAATACA 
NDUFV1 NM_007103 CTGATCCCCAAGTCTGTGTGTGAGA Sybr Green I detection GATGTCCGTCGAGCGGTCCAT 
NDUFS1 NM_005006 GAATGTGATCTGCAGGACCAGTC Sybr Green I detection GTCTTTACCAATGGCCCAATGT 
SDHB   
  
 
    
    
    
 
   
   
   
    
    
   
  
    
    
    
   
   
   
   
NM_003000 AAATGTGGCCCCATGGTATTG Sybr Green I detection AGAGCCACAGATGCCTTCTCTG
SLC25A12
 
NM_003705 AGCACTCTAGCTGGCACAAGGAA Sybr Green I detection AGTCAAGCGCCCTGAAGCATTATAT 
18S NM_000979 GATATGCTCATGTGGTGTTGA Sybr Green I detection ACGTTCCACCTCATCCTCA 
CYC1 NM_001916 TGGCCCCTCCCATCTACAC AGAGTTTGACGATGGCACCCCAGCTA ATCCTTGGCTATCTGGGACATG
SURF1 NM_003172 CCTATGTGGTCACTCCCTTCCA TGGTGACTCCCAGGTCGGTGCA TGGGAACGAACCCTCTATTTACC
PGC1α NM_015062 AGGTGAAAGTGTAATACTGTTGGTTGA
 
TGCTGAAGAGGGAAAGTGAGCGATTAGTTGA
 
CATGTAGAATTGGCAGGTGGAA
 PGC1β NM_133263 CAGCCACTCGAAGGAACTTCA CTGAACACGGCCCTCTGCTCTCACA CGGATGCTTGGCGTTCTG
TFAM NM_009360 CCCAGATGCAAAAACTACAGAACTAA CGCAGTCACAACACTTACAAGCCAAAC
 
TCCGCCCTATAAGCATCTTGA
NRF1 NM_005011 CGTTGCCCAAGTGAATTATTCTG TTGTTCCACCTCTCCATCAGCCA CCCTGTAACGTGGCCCAAT
RPLP0 NM_001002 CCATTCTATCATCAACGGGTACAA TCTCCACAGACAAGGCCAGGACTCG AGCAAGTGGGAAGGTGTAATCC 
mmNDUFB3 NM_025597 TGGCCATGGTAAAATGGAACT CAGATTACAGACAGTGGAAAATTGAAGGGACG AAGCTTCTTCTGCACCGTTTCT
mmNDUFB5 NM_025316 GCATCCGATATCAAGATGGATCG
 
CTGAAAAGAACTACGAGAAAACCCTGGCTATCCT
 
CTTTAACCGTAACTCAGCCTTTTCA
mmSLC25A12
 
NM_172436 CACCACAGGACCGAGAGTCA
 
TGCTTCAGGACCTGGGACTTTTCGG GGCTTTGGCACCCTTGTACA
mmSDHB NM_023374 CCCAGGAGGGCAAGCAA AGTATCTGCAGTCCATCGAGGACCGG GTACAGCCCGTCCAGCTTCT
mmCYC1 NM_025567 CAGCTACCCATGGTCTCATCGT TCCGAATGCTGGTGTGGTCCAAGGA CACCTGCTTGTATACCTGGAAACC
mmSURF1 NM_013677 AAGTGAATCCTGAGACCAGACAGA AGGCCAGGTTCTGGGAGAAGTAGACC TGTGAGCCTCACTATGCCAACT
mmPGC1α NM_008904 CATTTGATGCACTGACAGATGGA
 
CCGTGACCACTGACAACGAGGCC CCGTCAGGCATGGAGGAA
mmPGC1β NM_133249 AGGAAGCGGCGGGAAA AGAGATTTCGAATGTATACCACACGGCCTTCA
 
CTACAATCTCACCGAACACCTCAA
mmCOXII NC_005089 TTTTCAGGCTTCACCCTAGATGA CATGAGCAAAAGCCCACTTCGCCA GAAGAATGTTATGTTTACTCCTACGAATATG
 mmUCP2 NM_011671 GCGTTCTGGGTACCATCCTAAC CGCACTGAGGGTCCACGCAGC GCGACCAGCCCATTGTAGA
mmCycB NM_011149 GGTGGAGAGCACCAAGACAGA ATCCTTCAGTGGCTTGTCCCGGCT GCCGGAGTCGACAATGATG
 
A.1 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. For all assays performed using SYBR Green I detection, 
18S was used as the internal control, and for all assays performed using Taqman primers and probe, RPLP0, which is the human 
equivalent of the murine gene 36B4, was used as the internal control.  Cyclophilin B was used as the internal control for all murine 
assays. NDUFB3, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3; NDUFB5, NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 5; NDUFV1, NADH dehydrogenase (ubiquinone) flavoprotein 1; NDUFS1, NADH dehydrogenase (ubiquinone) Fe-S 
protein 1); SDHB, succinate dehydrogenase complex, subunit B; SLC25A12, solute carrier family 25 (mitochondrial carrier); 18S, 
18S ribosomal RNA; CYC1, cytochrome c-1; SURF1, surfeit 1; PGC1α, peroxisome proliferative activated receptor, gamma, 
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coactivator 1, alpha; PGC1β, peroxisome proliferative activated receptor, gamma, coactivator 1, beta; TFAM, transcription factor A, 
mitochondrial; NRF1, nuclear respiratory factor-1; RPLP0, ribosomal protein, large, P0; mm, mus musculus; mmNDUFB3, NADH 
dehydrogenase (ubiquinone) 1 beta subcomplex, 3; mmNDUFB5, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5; 
mmSLC25A12, solute carrier family 25 (mitochondrial carrier); mmSDHB,  succinate dehydrogenase complex, subunit B;  
mmCYC1, cytochrome c-1; mmSURF1, surfeit 1; mmPGC1α, peroxisome proliferative activated receptor, gamma, coactivator 1, 
alpha; mmPGC1β, peroxisome proliferative activated receptor, gamma, coactivator 1, beta; mmCOXII, cytochrome c oxidase II, 
mitochondrial; mmUCP2, uncoupling protein 2; mmCycB, peptidylprolyl isomerase B (cyclophilin B). 
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CLUSTER ACCESSION GENE DESCRIPTION FOLD CHANGE DIRECTION FUNCTION
BONFERONNI P-
VALUE
1 AB028968 Homo sapiens mRNA for KIAA1045 protein, partial cds 1.5 down biological process unknown 0.002999056
1 AB037743 Homo sapiens mRNA for KIAA1322 protein, partial cds 1.4 down developmental processes 0.003082866
1 AB039903 Homo sapiens ifp1 mRNA for interferon-responsive finger protein 1 long form, complete cds 2 down pathogenesis 0.000120886
1 AB046796 Homo sapiens mRNA for KIAA1576 protein, partial cds 1.4 down ethanol oxidation 0.000091228
1 AF052087 Homo sapiens clone 23604 mRNA sequence 1.1 down DNA packaging 3.34674E-06
1 AF060169 Homo sapiens AS11 protein mRNA, partial cds 1.8 down transcription regulation 0.001436171
1 AF086156 Homo sapiens full length insert cDNA clone ZB55H12 1.1 down biological process unknown 0.002373667
1 AF086350 Homo sapiens full length insert cDNA clone ZD62G08 2.2 down biological process unknown 0.008001914
1 AF090102 Homo sapiens clone IMAGE 21785 2.1 down biological process unknown 0.002811766
1 AK000032 Homo sapiens cDNA FLJ20025 fis, clone ADSE01840 1.8 down biological process unknown 0.00025246
1 AK000789 Homo sapiens cDNA FLJ20782 fis, clone COL03841 2.6 down biological process unknown 1.42117E-09
1 AK021462 Homo sapiens cDNA FLJ11400 fis, clone HEMBA1000673 2.4 down biological process unknown 1.37972E-05
1 AK022297 Homo sapiens cDNA FLJ12235 fis, clone MAMMA1001243 1.7 down biological process unknown 0.000513922
1 AK026037 Homo sapiens cDNA: FLJ22384 fis, clone HRC07594 1.4 down biological process unknown 0.004993469
1 AL117653 Homo sapiens mRNA; cDNA DKFZp586C0224 (from clone DKFZp586C0224) 2.2 down biological process unknown 0.000065843
1 AL137363 Homo sapiens mRNA; cDNA DKFZp434D1026 (from clone DKFZp434D1026) 1.4 down biological process unknown 0.003665174
1 AL137597 Homo sapiens mRNA; cDNA DKFZp434B2411 (from clone DKFZp434B2411) 2.2 down biological process unknown 0.00010901
1 AL157476 Homo sapiens mRNA; cDNA DKFZp761C082 (from clone DKFZp761C082) 1.7 down cell adhesion 0.008059978
1 D87292 Homo sapiens mRNA for rhodanese, complete cds 1.9 down cyanate catabolism 0.00610911
1 L19362 Human (clone xip1) mRNA sequence 1.5 down biological process unknown 0.000444252
1 NM_000155 Homo sapiens galactose-1-phosphate uridylyltransferase (GALT) mRNA 1.6 down galactose metabolism 0.009046843
1 NM_000476 Homo sapiens adenylate kinase 1 (AK1), nuclear gene encoding mitochondrial protein, mRNA 1.5 down nucleic acid metabolism 0.000990824
1 NM_000532 H.sapiens propionyl Coenzyme A carboxylase, beta polypeptide (PCCB), mRNA 1.6 down fatty acid catabolism 2.98029E-06
1 NM_000666 Homo sapiens aminoacylase 1 (ACY1), mRNA 1.6 down proteolysis and peptidolysis 0.000398322
1 NM_001297 Homo sapiens cyclic nucleotide gated channel beta 1 (CNGB1) mRNA, and translated products 1.7 down vision 2.01462E-09
1 NM_001412 Homo sapiens eukaryotic translation initiation factor 1A (EIF1A) mRNA 2 down protein synthesis initiation 0.001449064
1 NM_002487 Homo sapiens necdin (mouse) homolog (NDN) mRNA 1.2 down neurogenesis 0.001234221
1 NM_002491 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3 (12kD, B12) (NDUFB3) mRNA 1.4 down complex I (NADH to ubiquinone) 0.007275987
1 NM_003974 Homo sapiens docking protein 2, 56kD (DOK2) mRNA 1.4 down signal transduction (cell surface receptor) 0.005136911
1 NM_004236 Homo sapiens thyroid receptor interacting protein 15 (TRIP15) mRNA 1.9 down signal transduction 0.00960494
1 NM_007126 Homo sapiens valosin-containing protein (VCP), mRNA 2 down intracellular protein traffic 0.000413305
1 NM_014056 Homo sapiens DKFZP564K247 protein (DKFZP564K247), mRNA 1.7 down mitochondrial processing 1.14425E-07
1 NM_016417 Homo sapiens clone FLB4739 (LOC51218), mRNA 1.5 down biological process unknown 0.001473864
1 NM_016599 Homo sapiens muscle-specific protein (LOC51778), mRNA 2.1 down biological process unknown 0.000000
1 X78938 H.sapiens SRI mRNA 1.6 down biological process unknown 0.00688159
1 AL049471 Homo sapiens mRNA; cDNA DKFZp586N012 (from clone DKFZp586N012) 1.7 up biological process unknown 2.22666E-06
1 L08902 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 9.4576E-08
1 L09070 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L09071 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L09078 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 9.4576E-08
1 L09080 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L09081 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L09086 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L09089 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 9.4576E-08
1 L09092 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L09095 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L09097 Homo sapiens mRNA fragment 1.8 up proteolysis and peptidolysis 9.4576E-08
1 L09098 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 9.4576E-08
1 L09099 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L09100 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L09102 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L10140 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L10141 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
99
1 L10146 Homo sapiens mRNA fragment 1.8 up blood coagulation 9.4576E-08
1 L10147 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L10148 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L10151 Homo sapiens mRNA fragment 1.8 up chymotrypsin 9.4576E-08
1 L23867 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L23869 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L23870 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L43345 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L43347 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L43349 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 L43350 Homo sapiens mRNA fragment 1.8 up biological process unknown 9.4576E-08
1 NM_000067 Homo sapiens carbonic anhydrase II (CA2) mRNA 1 up protein targeting 0.002923499
1 NM_000954 Homo sapiens prostaglandin D2 synthase (21kD, brain) (PTGDS), mRNA 1.9 up prostaglandin metabolism 4.78094E-06
1 NM_001492 Homo sapiens growth differentiation factor 1 (GDF1), mRNA 1.4 up membrane targeting 3.26237E-07
1 NM_001963 Homo sapiens epidermal growth factor (beta-urogastrone) (EGF) mRNA 1.7 up signal transduction 0.001798554
1 NM_003234 Homo sapiens transferrin receptor (p90, CD71) (TFRC) mRNA 1.5 up iron transport 0.009
1 NM_005655 Homo sapiens TGFB inducible early growth response (TIEG), mRNA 1.9 up cell proliferation 1.3307E-09
1 NM_016485 Homo sapiens hypothetical protein (HSPC228), mRNA 1.6 up cell wall integrity 1.50129E-09
1 NM_017659 Homo sapiens hypothetical protein FLJ20084 (FLJ20084), mRNA 1.3 up protein modification 0.006886306
1 NM_018593 Homo sapiens hypothetical protein PRO0813 (PRO0813), mRNA 1.7 up biological process unknown 0.000337473
1 U81380 Human interleukin-13 receptor soluble form mRNA, complete cds 1.2 up signal transduction (cell surface receptor) 0.000180734
1 X04236 Human small cellular 7 SK mRNA 1.2 up biological process unknown 0.001137583
1 Z36789 H.sapiens (xs138) mRNA, 250bp 1.9 up blood coagulation 2.33058E-06
2 AF055030 Homo sapiens clone 24538 mRNA sequence 1.5 down transcription regulation 0.005462657
2 AF070565 Homo sapiens clone 24425 mRNA sequence 2 down biological process unknown 2.38024E-08
2 AF086264 Homo sapiens full length insert cDNA clone ZD43A10 1.1 down biological process unknown 0.000105155
2 AF147426 Homo sapiens full length insert cDNA clone YP79H10 1.3 down biological process unknown 3.36945E-09
2 AK001906 Homo sapiens cDNA FLJ11044 fis, clone PLACE1004451 1.4 down biological process unknown 0.002560693
2 AK025657 Homo sapiens cDNA: FLJ22004 fis, clone HEP06871 2.1 down sensory perception 3.78602E-08
2 AL049361 Homo sapiens mRNA; cDNA DKFZp566H243 (from clone DKFZp566H243) 1.6 down biological process unknown 2.13573E-05
2 AL050148 Homo sapiens mRNA; cDNA DKFZp586G1520 (from clone DKFZp586G1520) 1.6 down biological process unknown 9.92366E-05
2 AL390169 Homo sapiens mRNA; cDNA DKFZp547D064 (from clone DKFZp547D064) 1.8 down biological process unknown 0.000091741
2 NM_000083 Homo sapiens chloride channel 1 , skeletal muscle (CLCN1), mRNA 1.8 down chloride transport 2.58873E-07
2 NM_000717 Homo sapiens carbonic anhydrase IV (CA4), mRNA 1.5 down protein targeting 0.0061872
2 NM_001829 Homo sapiens chloride channel 3 (CLCN3) mRNA 1.4 down chloride transport 0.004788336
2 NM_003167 Homo sapiens sulfotransferase family 2A, dehydroepiandrosterone (DHEA) -preferring, member 1 (SULT2A1) mRNA 1.3 down steroid metabolism 0.008640503
2 NM_003344 Homo sapiens ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H) mRNA 1.4 down proteolysis and peptidolysis 6.68648E-06
2 NM_003665 Homo sapiens ficolin (collagen/fibrinogen domain-containing) 3 (Hakata antigen) (FCN3), mRNA 1.6 down opsinization 0.000932942
2 NM_004170 Homo sapiens solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter), member 1 (SLC1A1), mRNA 1.3 down glutamate transport 0.000186263
2 NM_014709 Homo sapiens KIAA0570 gene product (KIAA0570), mRNA 1.2 down spermatogenesis 0.000871745
2 NM_014752 Homo sapiens KIAA0102 gene product (KIAA0102), mRNA 1.2 down steroid metabolism 0.00045674
2 NM_014845 Homo sapiens KIAA0274 gene product (KIAA0274), mRNA 1.6 down synaptic vesicle endocytosis 4.30869E-09
2 NM_017781 Homo sapiens hypothetical protein FLJ20359 (FLJ20359), mRNA 1.4 down electron transport 0.002432844
2 NM_018467 Homo sapiens uncharacterized hematopoietic stem/progenitor cells protein MDS032 (MDS032), mRNA 1.8 down immune response 0.000685921
2 AB011152 Homo sapiens mRNA for KIAA0580 protein, partial cds 1.4 up cytoskeleton integrity 2.58635E-05
2 AB018310 Homo sapiens mRNA for KIAA0767 protein, partial cds 1.4 up steroid metabolism 0.000210553
2 AB033102 Homo sapiens mRNA for KIAA1276 protein, partial cds 1.5 up muscle contraction 2.87647E-07
2 AF082657 Homo sapiens Era GTPase A protein (HERA-A) mRNA, partial cds 1.5 up transport 0.00500205
2 AF085351 Homo sapiens ELISC-1 mRNA, partial cds 1.2 up biological process unknown 7.24137E-09
2 AF291181 Homo sapiens LHX5 protein mRNA, complete cds 1.3 up transcription regulation 0.00044144
2 AJ224166 Homo sapiens mRNA containing U19H snoRNA; mRNA 1 1.2 up cell growth and maintenance 5.90463E-05
2 AK022872 Homo sapiens cDNA FLJ12810 fis, clone NT2RP2002464, weakly similar to DNA repair protein PSO2/SNM1 1.6 up DNA repair 3.07146E-07
2 AK023610 Homo sapiens cDNA FLJ13548 fis, clone PLACE1007068 1.4 up biological process unknown 0.005040947
2 AK023683 Homo sapiens cDNA FLJ13621 fis, clone PLACE1010954 1.1 up cytoskeleton integrity 0.002260697
2 AK024927 Homo sapiens cDNA: FLJ21274 fis, clone COL01781 1.5 up biological process unknown 0.003126244
100
2 AK026679 Homo sapiens cDNA: FLJ23026 fis, clone LNG01738 2.1 up biological process unknown 0.005879573
2 AL161991 Homo sapiens mRNA; cDNA DKFZp761C169 (from clone DKFZp761C169); partial cds 1.4 up biological process unknown 6.62599E-08
2 L08902 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 0.001922163
2 L09070 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L09071 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L09078 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 0.001922163
2 L09080 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L09081 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L09086 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L09089 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 0.001922163
2 L09092 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L09095 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L09097 Homo sapiens mRNA fragment 1.8 up proteolysis and peptidolysis 0.001922163
2 L09098 Homo sapiens mRNA fragment 1.8 up humoral defense mechanism 0.001922163
2 L09099 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L09100 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L09102 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L10140 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L10141 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L10146 Homo sapiens mRNA fragment 1.8 up blood coagulation 0.001922163
2 L10147 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L10148 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L10151 Homo sapiens mRNA fragment 1.8 up chymotrypsin 0.001922163
2 L23867 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L23869 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L23870 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L25080 Homo sapiens GTP-binding protein (rhoA) mRNA, complete cds 1.6 up cell growth and maintenance 0.002526602
2 L43345 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L43347 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L43349 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 L43350 Homo sapiens mRNA fragment 1.8 up biological process unknown 0.001922163
2 M20699 Human terminal deoxynucleotidyltransferase gene, exon 7 1.4 up DNA replication 5.20357E-09
2 M55536 Human glucose transporter pseudogene 1.4 up biological process unknown 4.658E-12
2 NM_000367 Homo sapiens thiopurine S-methyltransferase (TPMT) mRNA 1.3 up nucleic acid metabolism 0.000455608
2 NM_001714 Homo sapiens Bicaudal D (Drosophila) homolog 1 (BICD1) mRNA 1.5 up embryogenesis and morphogenesis 1.56169E-06
2 NM_002864 Homo sapiens pregnancy-zone protein (PZP) mRNA 1.6 up intracellular protein traffic 0.005691476
2 NM_002907 Homo sapiens RecQ protein-like (DNA helicase Q1-like) (RECQL) mRNA 1.5 up DNA repair 0.000516067
2 NM_003375 Homo sapiens voltage-dependent anion channel 2 (VDAC2), nuclear gene encoding mitochondrial protein, mRNA 1.5 up anion transport 2.28422E-06
2 NM_004259 Homo sapiens RecQ protein 5 (RECQ5) mRNA 1.4 up DNA repair 1.43416E-06
2 NM_005531 Homo sapiens interferon, gamma-inducible protein 16 (IFI16) mRNA 1.7 up transcription regulation 9.65381E-07
2 NM_006598 Homo sapiens solute carrier family 12 (potassium/chloride transporters), member 7 (SLC12A7), mRNA 2.8 up transport 0.000156565
2 NM_007016 Homo sapiens protein similar to E.coli yhdg and R. capsulatus nifR3 (PP35), mRNA 1.4 up `de novo` pyrimidine biosynthesis 0.000204868
2 NM_014590 Homo sapiens endogenous retroviral family W, env(C7), member 1 (syncytin) (ERVWE1), mRNA 1.2 up embryogenesis and morphogenesis 2.40867E-06
2 NM_014873 Homo sapiens KIAA0205 gene product (KIAA0205), mRNA 1.7 up phosphatidic acid biosynthesis 0.003616239
2 NM_015975 Homo sapiens neuronal cell death-related protein (LOC51616), mRNA 1.5 up nucleic acid metabolism 3.86252E-05
2 NM_016360 Homo sapiens clone HQ0477 PRO0477p (LOC51204), mRNA 1.5 up nucleotide-excision repair 3.44637E-05
2 NM_018183 Homo sapiens hypothetical protein FLJ10701 (FLJ10701), mRNA 1 up DNA repair 0.003742495
2 NM_020367 Homo sapiens MIB006 (C12orf6), mRNA 1.1 up cytoskeleton integrity 0.000435746
2 U10511 Human clone 2D12 Cri-du-chat critical region mRNA, partial sequence 1.9 up biological process unknown 1.57562E-06
2 X74804 H.sapiens D54 mRNA 1.6 up biological process unknown 0.003756293
2 X78712 H.sapiens mRNA for glycerol kinase testis specific 2 1.5 up glycerol metabolism 0.000155077
3 AF009265 Homo sapiens clone FB2C5 Cri-du-chat region mRNA 1.4 down biological process unknown 0.000445326
3 AF088018 Homo sapiens full length insert cDNA clone YY88A05 1.3 down biological process unknown 4.72428E-05
3 AF131855 Homo sapiens clone 25056 mRNA sequence 1.5 down biological process unknown 2.84387E-07
3 AF147343 Homo sapiens full length insert cDNA clone YB31B05 1.9 down biological process unknown 5.47705E-06
101
3 AF147369 Homo sapiens full length insert cDNA clone YB64E02 1.4 down biological process unknown 0.00341564
3 AK001228 Homo sapiens cDNA FLJ10366 fis, clone NT2RM2001420 1.8 down biological process unknown 2.26217E-05
3 AK002109 Homo sapiens cDNA FLJ11247 fis, clone PLACE1008693 1.4 down biological process unknown 0.001115375
3 AK002150 Homo sapiens cDNA FLJ11288 fis, clone PLACE1009607 1.8 down biological process unknown 0.000234275
3 AK002173 Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102 1.4 down biological process unknown 0.006648993
3 AK022850 Homo sapiens cDNA FLJ12788 fis, clone NT2RP2001946 1.4 down biological process unknown 1.53982E-07
3 AK023600 Homo sapiens cDNA FLJ13538 fis, clone PLACE1006617 1.5 down biological process unknown 0.008859778
3 AK026099 Homo sapiens cDNA: FLJ22446 fis, clone HRC09457 2.2 down biological process unknown 0.009163995
3 AK026571 Homo sapiens cDNA: FLJ22918 fis, clone KAT06627 1.4 down biological process unknown 0.002059913
3 AL049342 Homo sapiens mRNA; cDNA DKFZp566A193 (from clone DKFZp566A193) 1.5 down biological process unknown 0.000592814
3 AL109715 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 430268 1.4 down biological process unknown 0.000185708
3 AL109818 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 191017 1.3 down biological process unknown 0.000423743
3 AL137313 Homo sapiens mRNA; cDNA DKFZp761M10121 (from clone DKFZp761M10121) 1.4 down biological process unknown 0.007227646
3 AL137703 Homo sapiens mRNA; cDNA DKFZp564P1772 (from clone DKFZp564P1772) 1.2 down DNA packaging 0.002187628
3 AL162065 Homo sapiens mRNA; cDNA DKFZp762K135 (from clone DKFZp762K135) 1.5 down transcription regulation 0.000696087
3 AL359056 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 328974 1.3 down biological process unknown 0.003624825
3 D28446 Human mRNA for cytokeratin 8, 5'UTR (sequence from the 5'cap to the start codon) 1.8 down biological process unknown 0.004367359
3 L39924 Homo sapiens (clone HPL14E8) mRNA, partial EST 1.4 down biological process unknown 2.23848E-05
3 NM_000143 Homo sapiens fumarate hydratase (FH) mRNA 1.8 down fumarate metabolism 0.000064016
3 NM_002048 Homo sapiens growth arrest-specific 1 (GAS1) mRNA 1.7 down cell cycle arrest 0.000240229
3 NM_002413 Homo sapiens microsomal glutathione S-transferase 2 (MGST2) mRNA, and translated products 1.7 down leukotriene metabolism 0.000741744
3 NM_003705 Homo sapiens solute carrier family 25 (mitochondrial carrier, Aralar), member 12 (SLC25A12) mRNA 1.8 down mitochondrial transport 4.58982E-09
3 NM_004837 Homo sapiens geranylgeranyl diphosphate synthase 1 (GGPS1), mRNA 1.4 down lipid metabolism 0.001170041
3 NM_006550 Homo sapiens fibrinogen silencer binding protein (FSBP) mRNA 1.8 down developmental processes 0.008701064
3 NM_014028 Homo sapiens HSPC019 protein (HSPC019), mRNA 1.2 down biological process unknown 1.26357E-08
3 NM_014118 Homo sapiens PRO0159 protein (PRO0159), mRNA 1.9 down biological process unknown 4.29652E-05
3 NM_014157 Homo sapiens HSPC065 protein (HSPC065), mRNA 1.4 down biological process unknown 0.000726736
3 NM_018394 Homo sapiens hypothetical protein FLJ11342 (FLJ11342), mRNA 2 down nitrogen metabolism 0.002850132
3 NM_019845 Homo sapiens candidate mediator of the p53-dependent G2 arrest (REPRIMO), mRNA 1.3 down cell cycle arrest 0.005328642
3 U00960 Human clone KDBB1.2 (CAC)n/(GTG)n repeat-containing mRNA 1.6 down biological process unknown 8.63988E-10
3 AB029396 Homo sapiens hu-GlcAT-P mRNA for glucuronyltransferase, complete cds 1.2 up carbohydrate metabolism 0.005055305
3 AB037770 Homo sapiens mRNA for KIAA1349 protein, partial cds 1.3 up transcription regulation 3.68379E-05
3 AB040672 Homo sapiens GalNAc-T9 mRNA for UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, complete cds 1.1 up carbohydrate metabolism 2.60519E-06
3 AF052115 Homo sapiens clone 23688 mRNA sequence 1.3 up biological process unknown 0.000309023
3 AF086535 Homo sapiens full length insert cDNA clone ZE07G05 1.7 up biological process unknown 5.46007E-05
3 AF088035 Homo sapiens full length insert cDNA clone ZC26G04 1.5 up biological process unknown 0.001835077
3 AF090920 Homo sapiens clone HQ0352 PRO0352 mRNA, partial cds 1.2 up biological process unknown 0.001037299
3 AF147349 Homo sapiens full length insert cDNA clone YB40C09 1.1 up biological process unknown 6.10882E-05
3 AF320908 Homo sapiens MAGE-D4 (MAGED4) mRNA, partial cds 1.4 up neurogenesis 1.9466E-11
3 AK023060 Homo sapiens cDNA FLJ12998 fis, clone NT2RP3000267 1.6 up energy pathways 0.000269399
3 AK024244 Homo sapiens cDNA FLJ14182 fis, clone NT2RP2004675 2.1 up biological process unknown 1.01781E-07
3 AK025686 Homo sapiens cDNA: FLJ22033 fis, clone HEP08810, highly similar to HSU43374 Human normal keratinocyte mRNA 1.6 up biological process unknown 0.000105142
3 AL049679 Human gene from PAC 97K10, chromosome X, similar to heparan-sulphate 6-sulfotransferase 1.3 up heparin sulfate biosynthesis 1.3547E-09
3 AL137519 Homo sapiens mRNA; cDNA DKFZp434A1518 (from clone DKFZp434A1518); partial cds 1.9 up microtubule-based movement 0
3 D63487 Human mRNA for KIAA0153 gene, partial cds 1.2 up cytoskeleton integrity 8E-15
3 L19778 Homo sapiens histone H2A.1b mRNA, complete cds 1.8 up nucleosome assembly 8.01858E-06
3 L23544 Human (clone z159) retinal mRNA 1.1 up biological process unknown 1.68491E-08
3 NM_001075 Homo sapiens UDP glycosyltransferase 2 family, polypeptide B10 (UGT2B10) mRNA 1.9 up metabolism 1.01363E-05
3 NM_001718 Homo sapiens bone morphogenetic protein 6 (BMP6) mRNA 1.1 up cell growth and maintenance 0.004084709
3 NM_002232 Homo sapiens potassium voltage-gated channel, shaker-related subfamily, member 3 (KCNA3) mRNA 1.5 up potassium transport 0.00010528
3 NM_002416 Homo sapiens monokine induced by gamma interferon (MIG), mRNA 1.2 up immune response 0.003447458
3 NM_006332 Homo sapiens interferon, gamma-inducible protein 30 (IFI30) mRNA 1.7 up immune response 8.38588E-06
3 NM_006581 Homo sapiens fucosyltransferase 9 (alpha (1,3) fucosyltransferase) (FUT9) mRNA 1.2 up carbohydrate metabolism 0.002088679
3 NM_006782 Homo sapiens zinc-finger protein in MEN1 region (MCG4), mRNA 1.6 up cell growth and maintenance 0.000808155
3 NM_006925 Homo sapiens splicing factor, arginine/serine-rich 5 (SFRS5), mRNA 1.4 up mRNA processing 4.88143E-05
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3 NM_013363 Homo sapiens procollagen C-endopeptidase enhancer 2 (PCOLCE2), mRNA 1.5 up cell growth and maintenance 0.00114394
3 NM_014470 Homo sapiens GTP-binding protein (RHO6), mRNA 1.7 up cell growth and maintenance 0.001556582
3 NM_017721 Homo sapiens hypothetical protein FLJ20241 (FLJ20241), mRNA 1.5 up cytoskeleton integrity 2.11999E-05
3 NM_017912 Homo sapiens hypothetical protein FLJ20637 (FLJ20637), mRNA 1.4 up ubiquitination 4.50622E-06
3 NM_018224 Homo sapiens hypothetical protein FLJ10803 (FLJ10803), mRNA 1.6 up biological process unknown 6.82061E-07
4 AF086084 Homo sapiens full length insert cDNA clone YZ84C01 1.3 down biological process unknown 0.000937429
4 AK000165 Homo sapiens cDNA FLJ20158 fis, clone COL08935 1.2 down biological process unknown 0.007709425
4 AK001125 Homo sapiens cDNA FLJ10263 fis, clone HEMBB1000991 1.3 down biological process unknown 0.00420537
4 AK021722 Homo sapiens cDNA FLJ11660 fis, clone HEMBA1004610 1.5 down biological process unknown 0.00033026
4 AK023224 Homo sapiens cDNA FLJ13162 fis, clone NT2RP3003625 1.4 down biological process unknown 0.00060531
4 L07383 Homo sapiens E2 small nucleolar RNA 1.8 down biological process unknown 0.000200539
4 NM_002133 Homo sapiens heme oxygenase (decycling) 1 (HMOX1), mRNA 2.8 down C21-steroid hormone biosynthesis 1.74019E-07
4 NM_002563 Homo sapiens purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) mRNA 1.2 down G-protein signaling, activates PLC 0.001918707
4 NM_014664 Homo sapiens KIAA0615 gene product (KIAA0615), mRNA 1.6 down proteolysis and peptidolysis 0.00172726
4 U00925 Human clone C4E 1.61 (CAC)n/(GTG)n repeat-containing mRNA 1.4 down biological process unknown 2.82531E-06
4 U79249 Human clone 23839 mRNA sequence 2.2 down biological process unknown 0.004528961
4 U80770 Human EST clone 251800 mariner transposon Hsmar1 sequence 1.7 down chromatin binding 0.001639818
4 AF091033 Homo sapiens GTP-binding protein RAB19B (RAB19B) mRNA, partial cds 1.8 up intracellular protein traffic 0.001388839
4 AK024067 Homo sapiens cDNA FLJ14005 fis, clone Y79AA1002361, similar to Rattus norvegicus mRNA for protein phosphatase 1 1.7 up glycogen metabolism 2.59537E-10
4 AL137724 Homo sapiens mRNA; cDNA DKFZp434D1319 (from clone DKFZp434D1319); partial cds 1.3 up cell growth and maintenance 0.000010435
4 NM_002871 Homo sapiens RAB interacting factor (RABIF) mRNA 1.5 up non-selective vesicle transport 0.000179949
4 NM_004113 Homo sapiens fibroblast growth factor 12B (FGF12B) mRNA 1.6 up signal transduction 0.004340852
4 NM_006765 Homo sapiens Putative prostate cancer tumor suppressor (N33), mRNA 1.1 up protein-nucleus import 9.01884E-05
4 NM_012200 Homo sapiens beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) (B3GAT3), mRNA 1.5 up carbohydrate metabolism 0.000264031
4 NM_016109 Homo sapiens PPAR(gamma) angiopoietin related protein (PGAR), mRNA 1.3 up cell growth and maintenance 1.86227E-08
4 NM_017737 Homo sapiens hypothetical protein FLJ20275 (FLJ20275), mRNA 1.6 up cell growth and maintenance 0.009220201
4 U79242 Human clone 23560 mRNA sequence 1.7 up biological process unknown 0.000772738
4 U92017 Human clone 199288 defective mariner transposon Hsmar2 mRNA sequence 1.4 up biological process unknown 9.44859E-07
5 AF084362 Homo sapiens lipoate-protein ligase B mRNA, partial cds 1.3 down cell cycle 0.000224514
5 AF086220 Homo sapiens full length insert cDNA clone ZC66B10 1.6 down biological process unknown 4.01705E-05
5 AF147395 Homo sapiens full length insert cDNA clone YI62C12 1.5 down biological process unknown 0.001884459
5 AF207831 Homo sapiens guanine nucleotide exchange factor (ARHGEF6) mRNA, 5' UTR and partial cds 2.1 down biological process unknown 1.18416E-09
5 AK026728 Homo sapiens cDNA: FLJ23075 fis, clone LNG05768 1.6 down biological process unknown 0.001440961
5 AL050182 Homo sapiens mRNA; cDNA DKFZp586A1923 (from clone DKFZp586A1923) 1.9 down microtubule-based process 0.004033682
5 AL137511 Homo sapiens mRNA; cDNA DKFZp761M222 (from clone DKFZp761M222) 1.3 down electron transport 0.001218442
5 AL137631 Homo sapiens mRNA; cDNA DKFZp434B205 (from clone DKFZp434B205); partial cds 1.6 down intracellular protein traffic 0.009583668
5 M11948 Human promyelocytic leukemia cell mRNA, clones pHH58 and pHH81 1.5 down biological process unknown 0.000240291
5 NM_000016 H.sapiens acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM), mRNA 2.3 down fatty acid beta-oxidation 0.00124041
5 NM_000925 Homo sapiens pyruvate dehydrogenase (lipoamide) beta (PDHB) mRNA 1.7 down glucose metabolism 0.000125179
5 NM_001232 Homo sapiens calsequestrin 2, cardiac muscle (CASQ2), mRNA 1.8 down striated muscle contraction 3.21972E-10
5 NM_001359 Homo sapiens 2,4-dienoyl CoA reductase 1, mitochondrial (DECR1), mRNA 1.8 down fatty acid beta-oxidation 0.001979939
5 NM_001995 Homo sapiens fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1), nuclear gene encoding mitochondrial protein, mRNA 2 down fatty acid metabolism 6E-15
5 NM_002079 Homo sapiens glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) (GOT1) mRNA 1.7 down aspartate catabolism 0.004712809
5 NM_002103 Homo sapiens glycogen synthase 1 (muscle) (GYS1) mRNA 1.7 down glycogen metabolism 0.00081699
5 NM_002218 Homo sapiens inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4) mRNA 1.2 down proteolysis and peptidolysis 0.003586815
5 NM_002492 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 (16kD, SGDH) (NDUFB5) mRNA 1.9 down complex I (NADH to ubiquinone) 2.09703E-05
5 NM_002493 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 (17kD, B17) (NDUFB6) mRNA 1.4 down complex I (NADH to ubiquinone) 0.000392787
5 NM_002756 Homo sapiens mitogen-activated protein kinase kinase 3 (MAP2K3), mRNA 2 down signal transduction 5.21806E-08
5 NM_003000 Homo sapiens succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB), mRNA 2.4 down electron transport 0.000318155
5 NM_003754 Homo sapiens eukaryotic translation initiation factor 3, subunit 5 (epsilon, 47kD) (EIF3S5) mRNA 1.8 down translational regulation, initiation 0.004751168
5 NM_005006 H.sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 1 (75kD) (NADH-coenzyme Q reductase) (NDUFS1) mRNA 2.4 down complex I (NADH to ubiquinone) 0.001563059
5 NM_006759 Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2), mRNA 2 down UDP-glucose metabolism 1.03084E-07
5 NM_007079 Homo sapiens protein tyrosine phosphatase type IVA, member 3 (PTP4A3), mRNA 1.7 down DNA replication 1.15352E-05
5 NM_007103 Homo sapiens NADH dehydrogenase (ubiquinone) flavoprotein 1 (51kD) (NDUFV1), mRNA 1.9 down energy pathways 0.000114478
5 NM_015831 Homo sapiens acetylcholinesterase (YT blood group) (ACHE), transcript variant E4-E5, mRNA 1.9 down synaptic transmission 4.33511E-07
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5 NM_018464 Homo sapiens uncharacterized hematopoietic stem/progenitor cells protein MDS029 (MDS029), mRNA 1.9 down microtubule-based process 3.07654E-10
5 NM_018533 Homo sapiens hypothetical protein PRO2706 (PRO2706), mRNA 1.8 down biological process unknown 9.05355E-07
5 S74678 heterogeneous nuclear ribonucleoprotein complex K [human, mRNA, 2302 nt] 2.2 down RNA processing 2.462E-12
5 U00942 Human clone A9A2BR17 (CAC)n/(GTG)n repeat-containing mRNA 1.7 down biological process unknown 0.00089146
5 U56725 Human heat shock protein mRNA, complete cds 1.4 down spermatid development 0.000542513
5 X03168 Human mRNA for S-protein 1.9 down cell adhesion 0.001129344
5 Y12235 H.sapiens mRNA for fructose-1,6-biphosphatase, alternative 5'UTR 1.4 down biological process unknown 0.001089767
5 AJ001904 Homo sapiens cDNA selection product, DCR1-24.0 1.2 up biological process unknown 0.001378771
5 AK022090 Homo sapiens cDNA FLJ12028 fis, clone HEMBB1001850 1.4 up biological process unknown 0.002103195
5 AK022282 Homo sapiens cDNA FLJ12220 fis, clone MAMMA1001082 1.9 up biological process unknown 1.02208E-08
5 AK022343 Homo sapiens cDNA FLJ12281 fis, clone MAMMA1001745 1.4 up biological process unknown 0.002352396
5 AK024532 Homo sapiens cDNA: FLJ20879 fis, clone ADKA03124 1.1 up biological process unknown 0.007801208
5 D16875 Human HepG2 3' region cDNA, clone hmd1f06 1.4 up biological process unknown 0.000715273
5 NM_000596 Homo sapiens insulin-like growth factor binding protein 1 (IGFBP1), mRNA 1.9 up signal transduction 2.1353E-11
5 NM_001647 Homo sapiens apolipoprotein D (APOD) mRNA 1.7 up transport 0.002302229
5 NM_002612 Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) mRNA 1.7 up glucose metabolism 0.000173786
5 NM_003492 Homo sapiens ITBA1 gene (ITBA1), mRNA 1.8 up biological process unknown 0.000131711
5 NM_004566 Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) mRNA 3.3 up fructose metabolism 2E-14
5 NM_004906 Homo sapiens gene predicted from cDNA with a complete coding sequence (KIAA0105) mRNA 1.8 up cell cycle 7.90062E-08
5 NM_005920 Homo sapiens MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) (MEF2D) mRNA 1.4 up transcription regulation 0.009663229
5 NM_020162 Homo sapiens hypothetical protein DKFZp762F2011 (DKFZp762F2011), mRNA 2.1 up developmental processes 6.83262E-07
5 NM_020193 Homo sapiens GL002 protein (GL002), mRNA 1.9 up cytoskeleton integrity 5.20558E-05
5 U21072 Human tandem repeat region from facioscapulohumeral muscular dystrophy-associated mRNA clone cDNAdelta4 1.3 up biological process unknown 1.35132E-06
5 U52832 Homo sapiens Cri-du-chat region mRNA, clone CSC3 1.6 up biological process unknown 0.000895676
Appendix A.2 Microarray low laser hit list (p < 0.01). By microarray analysis, 298 genes were up- or downregulated 
after a HFD. Of those 298, 6 are known to be involved in oxidative phosphorylation or mitochondrial function.  
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Gene Accession number Forward primer Probe Reverse primer 
PDK4    NM_002612 TTTCCAGACCAACCAATTCACA AGCATATGATGGAGGTGAGAAGGAACATACACG CGCATTGCATTCTTAAATAGTTCAA
PFKFB3 
  
   
   
 
    
   
  
   
  
NM_004566 ACTACTAGAGAGAGGAGACACATGATCCT
 
 AACGCCTTAAAGTCATTTTCTTTGGCAAAATG
 
 CGCACACCGACTCGATGA 
GYS1 NM_002103 GAGAACGCAGTGCTCTTCGAA
 
TGCCACCCACCTTGTTAGCCACCT TCGTCTGCAGCACCGTGTAG
GALT NM_000155 ACGCCGCAGCAGCAA TGCTGATGGTCGTTTGCCCGG CATCCTGCAGCGGGTTGTA
RPLP0 NM_001002 CCATTCTATCATCAACGGGTACAA TCTCCACAGACAAGGCCAGGACTCG AGCAAGTGGGAAGGTGTAATCC 
PDHB NM_000925 GAAGGAGGCTGGCCACAGT Sybr Green I detection TTGAACGCAGGACCTTCCAT 
MAP2K3 NM_002756 CTACATGGCCCCTGAGAGGAT Sybr Green I detection TCCAGACG TCGGACTTGACA 
UGP2 NM_006759 AATCAACCCACCCAATGGAA Sybr Green I detection GTGAGTGTCCCGCCCTTTAC 
18S NM_022551 GATATGCTCATGTGGTGTTGA Sybr Green I detection ACGTTCCACCTCATCCTCA 
mmPDK4 NM_013743 TTCCATGAGAAGAGCCCAGAA CCCTGTCAGAGTTTGTAGACACGCTGGTCA GCCATTGTAGGGACCACATTATG
 mmPFKFB3
 
NM_133232 TGCAGAGGAGATGCCATACCT TCAGTTTCAGGACAGTGTGGAGCGGA ACCCGGCACCCATATGC
mmGALT NM_016658 GCCATGATGGGCTGTTCTAAC TGCTAGCCCAAACCTGGCAGTGG GGGCGATATCTGGCAGGAA 
mmGYS1 NM_030678 CCGGCTTTGGCTGCTTTA TAAATGCCGTAAGCTGAGGGATCTGCGAT
 
CGGAACCTCCGATCCAGAAT 
mmCycB NM_011149 GGTGGAGAGCACCAAGACAGA ATCCTTCAGTGGCTTGTCCCGGCT GCCGGAGTCGACAATGATG
 
Appendix A.3 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. For all assays performed using Taqman 
primers and probe, RPLP0, which is the human equivalent of the murine gene 36B4, was used as the internal control.  For all assays 
performed using SYBR Green I detection, 18S was used.  Cyclophilin B was used as the internal control for all murine assays.  PDK4, 
pyruvate dehydrogenase kinase, isoenzyme 4; PFKFB3, fructose-2,6-biphosphatase 3; GYS1, glycogen synthase 1 (muscle); GALT, 
galactose-1-phosphate uridyltransferase; RPLP0, ribosomal protein, large, P0; PDHB, pyruvate dehydrogenase (lipoamide) beta;  
MAP2K3, mitogen-activated protein kinase kinase 3; UGP2, UDP-glucose pyrophosphorylase 2; 18S, ribosomal protein S18; mm, 
mus musculus; mmPDK4, pyruvate dehydrogenase kinase, isoenzyme 4; mmPFKFB3, fructose-2,6-biphosphatase 3; mmGALT, 
galactose-1-phosphate uridylyltransferase; mmGYS1, glycogen synthase 1 (muscle); mmCycB, peptidylprolyl isomerase B 
(cyclophilin B).  
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CLUSTER ACCESSION GENE DESCRIPTION FOLD CHANGE DIRECTION FUNCTION
BONFERONNI P-
VALUE
1 AF075006 Homo sapiens full length insert cDNA YH98F07 2.2 down biological process unknown 0.018577505
1 AJ227908 Homo sapiens partial mRNA; ID ED70-2A 2.9 down biological process unknown 0.011717709
1 AK025950 Homo sapiens cDNA: FLJ22297 fis, clone HRC04521 1.8 down cell cycle 0.048899404
1 AK026675 Homo sapiens cDNA: FLJ23022 fis, clone LNG01117 2.3 down biological process unknown 0.035757495
1 AL359586 Homo sapiens mRNA; cDNA DKFZp762H185 (from clone DKFZp762H185) 1.8 down biological process unknown 0.028866444
1 NM_004793 Homo sapiens protease, serine, 15 (PRSS15), mRNA 2.0 down proteolysis and peptidolysis 0.025259937
1 NM_006335 Homo sapiens translocase of inner mitochondrial membrane 17 (yeast) homolog A (TIM17), mRNA 2.0 down mitochondrial translocation 0.017267625
1 X74606 H.sapiens XAP-1 mRNA 1.6 down biological process unknown 0.014891916
1 AK000689 Homo sapiens cDNA FLJ20682 fis, clone KAIA3543, highly similar to AF131826 H.sapiens clone 24945 mRNA 1.7 up transcription 0.035494872
1 AK021789 Homo sapiens cDNA FLJ11727 fis, clone HEMBA1005374 2.3 up biological process unknown 0.021014007
1 AK021815 Homo sapiens cDNA FLJ11753 fis, clone HEMBA1005583 1.6 up glycogen biosynthesis 0.029970463
1 AK026764 Homo sapiens cDNA: FLJ23111 fis, clone LNG07835 2.2 up biological process unknown 0.017174109
1 NM_002319 Homo sapiens leucine-rich neuronal protein (LRN) mRNA, complete sequence 2.1 up biological process unknown 0.036158241
1 NM_006145 Homo sapiens heat shock 40kD protein 1 (HSPF1) mRNA 1.8 up protein folding 0.024477331
1 X98115 H.sapiens mRNA for cardiac titin, clone ZisL 2.2 up cytoskeletal anchoring 0.014638631
2 AB031038 Homo sapiens mRNA for hTbr2, complete cds 2.2 down embryogenesis / morphogenesis 0.046379407
2 AF086452 Homo sapiens full length insert cDNA clone ZD83B06 2.6 down biological process unknown 0.017967876
2 AK023814 Homo sapiens cDNA FLJ13752 fis, clone PLACE3000352 1.6 down biological process unknown 0.046664747
2 NM_001486 Homo sapiens glucokinase (hexokinase 4) regulatory protein (GCKR) mRNA 1.8 down nitrogen metabolism 0.012285037
2 NM_005691 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 9 (ABCC9), mRNA 1.9 down biological process unknown 0.014468696
2 NM_006033 Homo sapiens lipase, endothelial (LIPG), mRNA 1.5 down lipid metabolism 0.014177713
2 NM_013356 Homo sapiens monocarboxylate transporter 3 (SLC16A8), mRNA 1.6 down transport 0.049486595
2 NM_014632 Homo sapiens KIAA0750 gene product (KIAA0750), mRNA 3.4 down cell motility 0.010994883
2 NM_018366 Homo sapiens hypothetical protein FLJ11230 (FLJ11230), mRNA 1.6 down biological process unknown 0.014768323
2 AF009290 Homo sapiens clone HEC5 Cri-du-chat region mRNA 1.3 up biological process unknown 0.029964519
2 AF097645 Homo sapiens candidate tumor suppressor protein DICE1 mRNA, complete cds 1.5 up cell growth and/or maintenance 0.011826773
2 AK026339 Homo sapiens cDNA: FLJ22686 fis, clone HSI10987 1.5 up cytoskeleton organization / biogenesis 0.011832297
2 AL050125 Homo sapiens mRNA; cDNA DKFZp586F071 (from clone DKFZp586F071) 1.6 up biological process unknown 0.048827711
2 AL353951 Homo sapiens mRNA; cDNA DKFZp761A0423 (from clone DKFZp761A0423) 1.2 up biological process unknown 0.020453577
2 M33197 Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, complete cds 1.6 up biological process unknown 0.02396184
2 NM_003948 Homo sapiens cyclin-dependent kinase-like 2 (CDC2-related kinase) (CDKL2), mRNA 1.8 up biological process unknown 0.0294794
2 NM_004293 Homo sapiens guanine deaminase (GDA), mRNA 1.7 up nucleic acid metabolism 0.029360338
2 NM_006249 Homo sapiens proline-rich protein BstNI subfamily 3 (PRB3), mRNA 1.7 up cytoskeleton organization / biogenesis 0.015708017
2 NM_006268 Homo sapiens requiem, apoptosis response zinc finger gene (REQ) mRNA 1.4 up transcription regulation 0.032503592
2 NM_014684 Homo sapiens KIAA0373 gene product (KIAA0373), mRNA 1.8 up muscle contraction 0.042243882
2 NM_016098 Homo sapiens HSPC040 protein (LOC51660), mRNA 1.5 up porphyrin biosynthesis 0.016111001
2 NM_016616 Homo sapiens NM23-H8 (LOC51314), mRNA 1.7 up nucleic acid metabolism 0.024200036
3 AF056418 Homo sapiens clone FBA4 Cri-du-chat critical region mRNA 1.5 down biological process unknown 0.031744664
3 AF131745 Homo sapiens clone 25110 mRNA sequence 1.9 down ubiquinone biosynthesis 0.013476411
3 AF147315 Homo sapiens full length insert cDNA clone YA85A01 1.3 down biological process unknown 0.010894018
3 AK021970 Homo sapiens cDNA FLJ11908 fis, clone HEMBB1000089 2.0 down biological process unknown 0.041219865
3 L07033 Human hydroxymethylglutaryl-CoA lyase mRNA, complete cds 1.7 down leucine metabolism 0.037290172
3 NM_000329 Homo sapiens retinal pigment epithelium-specific protein (65kD) (RPE65) mRNA 1.5 down vision 0.044554398
3 NM_004045 Homo sapiens ATX1 (antioxidant protein 1, yeast) homolog 1 (ATOX1), mRNA 1.5 down copper ion transport 0.014124624
3 NM_014425 Homo sapiens inversin (INVS), mRNA 1.8 down vesicle transport 0.027775891
3 NM_015044 Homo sapiens KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2, mRNA 1.5 down intracellular protein traffic 0.032004408
3 NM_018077 Homo sapiens hypothetical protein FLJ10377 (FLJ10377), mRNA 1.4 down RNA processing 0.012490038
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3 NM_018139 Homo sapiens hypothetical protein FLJ10563 (FLJ10563), mRNA 1.8 down biological process unknown 0.042805641
3 AB046836 Homo sapiens mRNA for KIAA1616 protein, partial cds 1.4 up cell growth and/or maintenance 0.014551636
3 M37190 Human ras inhibitor mRNA, 3' end 1.5 up cell growth and/or maintenance 0.021971274
3 X66087 H.sapiens a-myb mRNA 1.6 up transcription regulation 0.017827478
4 AK000257 Homo sapiens cDNA FLJ20250 fis, clone COLF6635 1.6 down biological process unknown 0.023477455
4 AL117636 Homo sapiens mRNA; cDNA DKFZp434H205 (from clone DKFZp434H205) 1.4 down biological process unknown 0.013849179
4 AL359559 Homo sapiens mRNA; cDNA DKFZp762O2215 (from clone DKFZp762O2215) 1.6 down biological process unknown 0.012576309
4 AL390145 Homo sapiens mRNA; cDNA DKFZp762C115 (from clone DKFZp762C115) 1.6 down biological process unknown 0.047102089
4 NM_020154 Homo sapiens chromosome 11 hypothetical protein ORF3 (LOC56851), mRNA 1.7 down cell motility 0.040716234
4 X97303 H.sapiens mRNA for Ptg-12 protein 2.1 down transcription regulation 0.026556997
4 AF085932 Homo sapiens full length insert cDNA clone YR56G07 1.6 up biological process unknown 0.014081919
4 NM_004590 Homo sapiens small inducible cytokine subfamily A (Cys-Cys), member 16 (SCYA16), mRNA 1.5 up immune response 0.011291698
4 NM_018247 Homo sapiens hypothetical protein FLJ10856 (FLJ10856), mRNA 1.5 up mitochondrial processing 0.024924348
5 AF085899 Homo sapiens full length insert cDNA clone YQ15A02 1.6 down biological process unknown 0.027363645
5 AF104921 Homo sapiens succinyl-CoA synthetase alpha subunit (SUCLA1) mRNA, complete cds 2.1 down succinyl-CoA metabolism 0.028777168
5 AK000903 Homo sapiens cDNA FLJ10041 fis, clone HEMBA1001022 1.6 down biological process unknown 0.031533837
5 NM_001151 Homo sapiens solute carrier family 25, member 4 (SLC25A4), nuclear gene encoding mitochondrial protein, mRNA 2.4 down energy pathways 0.035615153
5 NM_012409 Homo sapiens prion gene complex, downstream (PRND), mRNA 1.9 down biological process unknown 0.033394452
5 NM_012447 Homo sapiens stromal antigen 3 (STAG3), mRNA 1.8 down male meiosis sister chromatid cohesion 0.029586542
5 NM_016497 Homo sapiens hypothetical protein (LOC51258), mRNA 1.9 down biological process unknown 0.04049059
5 AK022226 Homo sapiens cDNA FLJ12164 fis, clone MAMMA1000605 2.5 up biological process unknown 0.036196808
5 AL080113 Homo sapiens mRNA; cDNA DKFZp586K2322 (from clone DKFZp586K2322) 1.7 up biological process unknown 0.010343509
5 NM_004887 Homo sapiens CXC chemokine in breast and kidney (BRAK) mRNA 1.5 up immune response 0.011983042
5 NM_014012 Homo sapiens REM protein (REM), mRNA 1.2 up cell surface receptor signal transduction 0.035096741
5 NM_014827 Homo sapiens KIAA0663 gene product (KIAA0663), mRNA 1.8 up cytoskeleton organization / biogenesis 0.013963907
Appendix A.4 Microarray low laser hit list (p < 0.05). By microarray analysis, 72 genes were up- or downregulated 
after a HF/LCD. Of those 72, 7 are known to be involved in glucose metabolism.
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Official Gene 
Symbol 
Common 
Gene Name 
Accession 
number Forward primer Probe Reverse primer 
PPARGC1A PGC1α NM_0013261    AGGTGAAAGTGTAATACTGTTGGTTGA TGCTGAAGAGGGAAAGTGAGCGATTAGTTGA CATGTAGAATTGGCAGGTGGAA
ND1   
   
     
     
     
   
     
     
    
   
     
    
     
    
    
     
    
     
  
   
AF346985 CCCTAAAACCCGCCACATCT CCATCACCCTCTACATCACCGCCC GAGCGATGGTGAGAGCTAAGGT
genomicLPL mtDNA NC_000008 CGAGTCGTCTTTCTCCTGATGAT ACATTCACCAGAGGGTC TTCTGGATTCCAATGCTTCGA 
CD36 CD36 NM_000072 AGTCACTGCGACATGATTAATGGT CAGATGCAGCCTCATTTCCACCTTTTG CTGCAATACCTGGCTTTTCTC
LPL LPL NM_000237 TATCCGCGTGATTGCAGAGA CTAGCTGGTCCACATCTCCAAGTCCT AGAGAGTCGATGAAGAGATGAATGG
FAS FAS NM_000043 TATGCTTCTTCGTGCAGCAGTT AGCGCCTCCAGCACCCTGTTGT GCTGCCACACGCTCCTCTAG
PCK1 PCK1 NM_002591 CAGGCGGCTGAAGAAGTATGA AACTGCTGGTTGGCTCTCACTGACCC AACCGTCTTGCTTTCGATCCT 
SCD SCD1 NM_005063 TGGCATTCCAGAATGATGTCTATG CGTGACCACCGTGCCCACCACA GGAATTATGAGGATCAGCATGTGT
ACADM MCAD NM_000016 TGCCCTGGAAAGGAAAACTTT TGTAGAGCACCAAGCAATATCATTTATG GTTCAACTTTCATTGCCATTTCAG
PPARA PPARα NM_001001928 GCTTTGGCTTTACGGAATACCA AGCCATCTGAGCCAGGACAGCTTCCTAA
 
TGAAAGCGTGTCCGTGATGA
PLIN perilipin NM_002666 CACCGTGGCCATGTGGAT CCCCTGAGCAGCCTGGCCC GCCTGCATGGCCACTGAG
SORBS1 CAP NM_001034954 CAAATTCCCTGAACTTCCTGAAA
 
CCAGCAAACTTCCGAAGAGGACAATCC AGGAAACTGGTAGGTGGGAGTGTA
PNPLA2 ATGL NM_020376 CCACGGCGCTGGTCA TTGGCACCAGCCTCACCCAGG GGGCCTCTTTAGATACCTCAATGA
LIPE HSL NM_005357 GACTTCCTCCGGGAGTATGTC TGCATAAGGGATGCTTCTATGGCC GCGTGAACTGGAAGCCCA
PPARG PPARγ1 NM_005037 GTCAAACGAGAGTCAGCCTTTAACG AGAGATGCCATTCTGGCCCACCAACTT CCACGGAGCTGATCCCAA
PPARG PPARγ2 NM_015869 GATACACTGTCTGCAAACATATCACAA AGAGATGCCATTCTGGCCCACCAACTT CCACGGAGCTGATCCCAA
CD68 CD68 NM_001040059 GCTTCTCTCATTCCCCTATGGA CAGCTTTGGATTCATGCAGGACCTCC ATGTAGCTCAGGTAGACAACCTTCTG
CD163 MAC-2 NM_004244 TGCAGAAAACCCCACAAAAAG CACAACAGGTCGCTCATCCCGTCA CAAGGATCCCGACTGCAATAA 
CCL2 MCP-1 NM_002982 GATCTCAGTGCAGAGGCTCG AGCTATAGAAGAATCACCAGCAGCAAGTGTCCC
 
AATGGTCTTGAAGATCACAGCTTCT
 CCL3 MIP-1α NM_002983 ACAGAATTTCATAGCTGACTACTTTGAGA
 
AGTGCTCCAAGCCCGGTGTCATCTTC GCCGGCTTCGCTTGGT
RPS18 18S NM_022551 CGCCGCTAGAGGTGAAATTC ACCGGCGCAAGACGGACCAGA CATTCTTGGCAAATGCTTTCG 
 
Appendix A.5 Oligonucleotide sequences for primer/probe sets used for qRT-PCR. PGC1α, peroxisome proliferative activated receptor, 
gamma, coactivator 1, alpha; ND1, NADH dehydrogenase, subunit 1; genomicLPL, genomic lipoprotein lipase; CD36, CD36 molecule 
(thrombospondin receptor); LPL, lipoprotein lipase; FAS, fatty acid synthase; PCK1, phosphoenolpyruvate carboxykinase 1; SCD1, 
stearoyl-CoA desaturase; MCAD, acyl-Coenzyme A dehydrogenase C-4 to C-12 straight chain; PPARα, peroxisome proliferative activated 
receptor, alpha; perilipin, lipid droplet associated protein; CAP, cbl-associated protein; ATGL, adipose triglyceride lipase; HSL, hormone-
sensitive lipase; PPARγ1, peroxisome proliferative activated receptor, gamma 1; PPARγ2, peroxisome proliferative activated receptor, gamma 2; 
CD68, CD68 antigen; MAC-2, macrophage-associated antigen; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory 
protein 1, alpha subunit;18S, ribosomal protein S18.  For all assays performed using Taqman primers and probe, 18S was used as the internal 
control.                           
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